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RADIOTHERAPY RESPONSE USING INTRAVOXEL INCOHERENT MOTION
MAGNETIC RESONANCE IMAGING IN LIVER PATIENTS TREATED WITH
STEREOTACTIC BODY RADIOTHERAPY
By Benjamin Charles Lewis
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2019.
Director: Siyong Kim,
Professor, Department of Radiation Oncology
Magnetic resonance imaging is utilized as an important tool in radiation oncol-
ogy for delineation of healthy and cancerous tissues, and evaluating the functionality
of those tissues, structures, and organs. Currently, the clinical imaging protocol
at Virginia Commonwealth University includes anatomical imaging for tissue and
structure delineation, and to observe treatment induced changes. Diffusion weighted
imaging (DWI) is also acquired for calculation of apparent diffusion coefficient (ADC)
values to provide quantitative information on tissue diffusivity and microstructure.
However, anatomical images and ADC values may not display the true extent of
changes in tissue. This work seeks to further utilize the capabilities of MRI and ex-
pand its role in treatment response monitoring for liver cancer patients treated with
stereotactic body radiotherapy (SBRT). To do so, an imaging protocol and image
analysis methodology to evaluate treatment changes on pre- and post-treatment im-
age sets was developed. An extension of DWI, termed intravoxel incoherent motion
iv
(IVIM) imaging, was utilized to quantitatively assess levels of perfusion and diffusion
within the liver and tumor. Acquisition of high quality diffusion weighted images of
the liver necessitated the development of an MR safe respiratory motion management
device, which was designed, constructed and evaluated in this work. An imaging pro-
tocol was developed providing anatomical and functional images of the liver, acquired
under breath hold, utilizing the respiratory motion management device. An IVIM
parameter calculation and texture analysis workflow was developed using MATLAB,
and applied to acquired data sets from multiple studies, including past clinical cases,
investigator, healthy volunteer, and liver cancer patient. Differences in IVIM and
texture analysis parameters were investigated for healthy and diseased tissue, and
for select dose regions from pre- and post-treatment imaging sessions. Significant
differences, at a voxel level, were found between healthy and diseased tissue, and
pre- and post-treatment volumes, for multiple parameters, including apparent diffu-
sion coefficient, pure diffusion, and perfusion, as well as for various texture features.
Overall, this study showed the potential of IVIM and texture analysis to be used for
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A major barrier to effective treatment in oncology, and specifically radiation oncol-
ogy, is the ability to predict treatment outcome for individual patients. Predicting
response becomes increasingly important for more aggressive treatments, such as
stereotactic body radiotherapy (SBRT), where high doses of radiation are delivered
to the target area of the patient in five or fewer treatment sessions. Being able to
determine if a patient will respond positively to a treatment where the possibility of
radiation induced toxicity is high may prevent those with little to gain from aggressive
treatment from experiencing increased risk.
This work uses multiple diffusion weighted images of the liver acquired both
pre- and post-treatment to calculate quantitative data using an intravoxel incoher-
ent motion model (IVIM), and texture feature analysis, to investigate indicators for
efficacy of SBRT treatment. These quantitative parameters provide information on
tissue change that is not apparent on current clinical imaging protocols. This work
is the first application of the full IVIM method to radiation response of SBRT in the
liver and produces a robust and accurate image processing architecture to accurately
quantify functional data from the acquired images.
1.1 Liver Tumors
Tumors occur when cell reproductive cycles and growth checkpoints do not func-
tion normally. This unregulated cell division results in an abnormal mass of tissue,
which can impact normal organ function and spread to other parts of the body. Tu-
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mors found in the liver are identified as liver tumors and can be grouped into two
main categories: primary or secondary.
Primary liver tumors arise from multiple types of cells, including hepatocytes,
the lining of the bile duct, and the cell lining of liver blood vessels. Hepatocellular
carcinoma, starting in the hepatocytes, is the most common type of primary liver
cancer.
Secondary liver cancer refers to metastases found in the liver. These cancers do
not originate in the liver, but are the result of cancer cells separating from a primary
tumor site elsewhere in the body, being transported through the blood or lymphatic
system, and being deposited at the metastasis site. These metastatic tumors of the
liver are more common than primary liver tumors in the United States [1].
1.1.1 Primary Liver Tumors: Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy,
the leading cause of cancer-related death worldwide, and the ninth leading cause of
cancer death in the United States [2]. Risk factors associated with HCC include
chronic liver disease, cirrhosis, and diabetes. Chronic viral Hepatitis B and C (HBV
and HCV) demonstrate the highest risk of hepatocarcinogenicity, and the odds of
HCC occurrence increase 8-fold when both HBV and HCV are present [3, 4, 5]. Di-
abetes is an independent risk factor for HCC, and shows up to a 4-fold increased
risk of HCC [5, 6]. The high mortality rate is due to diagnosis of HCC at an ad-
vanced stage with severe liver impairment [7]. Screening modalities for HCC include
radiographic tests and serological marker. Ultrasound (US), computed tomography
(CT), and MRI with contrast are all current viable radiological tests, with US being
the most common [8]. However, US has poor sensitivity to small HCC nodules, less
than 2cm in diameter, and obesity can further reduce ultrasound’s ability to detect
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these small lesions [9]. Multiple treatment methods exist for HCC, including surgical
resection, liver transplant, transarterial chemoembolization, transarterial radiation,
percutaneous local ablation, microwave ablation, and focal radiation. Surgical resec-
tion retains its position as the mainstay of treatment for HCC, with a 5-year survival
of 41% to 74%. However, some tumors are not resectable due to tumor size, location,
liver function, and if the remaining liver volume will allow for resection without dras-
tic increase in morbidity and mortality [10]. Recently, advances in radiotherapy have
allowed for treatment of HCC with radiation to become more effective, especially
when focal radiation is applied at high doses, as in stereotactic body radiotherapy,
which will be described in following sections. Radiation therapy causes damage to
both diseased and healthy tissue by damaging genetic material such as DNA within
the tumor cell, limiting the cell’s ability to reproduce or resulting in mitotic progeny
which are unable to replicate [11, 12]. If a tumor cell is less able to repair DNA
damage than healthy cells, radiotherapy is a viable treatment, and the cumulative
effect of unrepaired DNA strand breaks can result in cell death of tumor cells at a
rate higher than the healthy cell death rate.
1.1.2 Secondary Liver Tumors
Liver metastasis is a result of malignant tumors elsewhere in the body. The
most common sites of primary tumor are breast, lung, and colorectal cancer [13, 14,
15, 16]. Some studies have reported hepatic metastasis in as many as 40 to 50% of
adult patients with extrahepatic primary tumors [16]. The high incidence of hepatic
metastases has been attributed to two mechanisms [16]. First, the dual blood supply
of the liver from the portal vein and systemic circulation increases the likelihood of
metastatic cell deposition in the liver. Second, the hepatic sinusoidal epithelium has
fenestrations, which enable easier penetration of the metastatic cells into the liver
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parenchyma.
1.2 Stereotactic Body Radiotherapy
1.2.1 General SBRT
Stereotactic radiosurgery (SRS) was first described in 1951 by Leksell, using a
frame based system to direct narrow beams of radiation at a target in the brain,
described by a 3D coordinate system [17]. SRS has since been vastly improved, with
implementation no longer requiring a fixed frame attached to the patient for guid-
ance, and extension of the method beyond the brain to the rest of the body with a
method called stereotactic body radiotherapy. With this expansion of methodology,
the main principles remain the same, delivery of a high dose radiation beam with
rapid dose fall-off outside of the target volume, extreme dose conformality of the
prescribed dose to the target, and extremely high repositioning accuracy [18]. The
rapid dose fall-off allows for high doses to be delivered over a few fractions, using
a hypofractionated treatment, while sparing normal tissue in close proximity to the
target volume. Treatment in typical intensity modulated radiotherapy (IMRT) plans
is delivered in 1-3Gy fractions, over 10 or more fractions, while in SBRT plans typi-
cally deliver 10-20Gy/fx, and only 1-5 fractions for the entire course of treatment [19].
To achieve normal tissue sparing, margins around the target must be reduced signif-
icantly. The increased treatment accuracy is produced by utilizing immobilization
equipment, including vacuum lock air bags, leg restraints, and head and neck masks.
Immobilization equipment alone is often not sufficient to achieve the desired tumor
localization due to respiratory motion and initial setup error. Target motion due to
respiratory motion can be significantly reduced with utilization of breath hold tech-
niques at inhale or exhale. As an example, the liver position can deviate by up to 4cm
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during regular respiratory motion in the cranio-caudal direction, and this motion can
be reduced to a reproducible position within 0.4cm using an active breathing coordi-
nator (ABC) [20]. Further target localization can be achieved using image guidance,
again allowing for reduced dose to normal tissues and improved tumor control [21].
To perform image guided radiotherapy (IGRT), the patient is imaged just prior to
treatment delivery, and corrections applied to match the planning CT or digitally
reconstructed radiographs (DRRs) [22]. On-board imaging can be performed with
a broad spectrum of imaging modalities, such as on-board cone beam CT (CBCT),
megavoltage CT (MVCT), MRI, orthogonal kilovoltage imaging, electromagnetic sys-
tems, optical systems, and ultrasound [23, 24]. Use of an appropriate IGRT system
is especially important for abdominal lesions, such as those in the liver.
1.2.2 Liver radiotherapy and motion uncertainty
As noted in previous sections, primary and metastatic liver cancer is prevalent
in the United States and around the world. Liver cancer is also distinguished by
its high mortality rates and short survival periods when compared to other cancers.
While surgical resection remains the primary treatment method, radiation treatment
is becoming more prevalent. SBRT has emerged as an effective, non-invasive option
for treatment of liver lesions [25, 26, 27]. It has been shown that there is an increase in
local control rates with increased doses; however, increased doses also result in greater
normal tissue complications. In addition to this, patients with primary liver tumors
are more likely to suffer from liver injury as a result of radiotherapy than patients
with metastatic lesions, and position of the tumor or pre-existing gastro-intestinal
(GI) conditions can significantly increase the risk of GI toxicity [28, 29]. The liver,
similar to the lungs, is an organ composed of parallel functioning tissue, meaning the
volume of the liver irradiated must be limited, even at low doses. A summary of dose
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constraints for liver radiotherapy by number of fractions can be found in Table 1. A
further complication in liver SBRT is that lesions have very low contrast with healthy
tissue on CT and CBCT images, resulting in difficulty during image guided set up
without the use of anatomical surrogates, such as the dome of the liver and vertebral
bodies.









700 mL < 15 Gy 700 mL < 21 Gy D mean < 30 Gy
Esophagus D 1 mL < 21 Gy D 5 mL < 19.5 Gy V 35 < 50%
Stomach D 1 mL < 21 Gy D 10 mL < 18 Gy D 100 < 35 Gy
Kidney D 35% < 15 Gy 200 mL < 17.5 Gy D mean < 28 Gy
Bowel and duode-
num
D 1 mL < 21 Gy D 5 mL < 18 Gy D 45 < 195 cc
Table 1. Summary of dose constraints by fractionation schedule. CTV: Clinical target
volume
An example of clinical IMRT and SBRT plans are shown in Figure 1. The IMRT
plan in the left column shows a much larger low dose wash, and a greater volume of
the liver and kidneys receiving a high dose, than the SBRT plan in the right column.
In addition to poor tissue contrast on CT, and high dosimetric risk, organ motion
in the abdominothoracic cavity can be significant. This motion can cause artifacts
in abdominal imaging, resulting in decreased analytic value of images, and geometric
miss of the defined target during radiation delivery. Suramo et al. suggested that the
liver has a movement range of 9 mm during breath hold, increasing to 25 mm during
6
Fig. 1. The left column shows a planning CT and dose volume histogram (DVH) for a
patient receiving IMRT treatment for liver cancer. The right column shows a
planning CT and DVH for a patient receiving SBRT treatment for liver cancer.
The red arrow indicates the position of the target volume. In the DVHs: purple
line is the planning target volume (purple arrows), red line is the internal target
volume or clinical target volume, brown line is the liver (brown arrows), blue
is the left kidney, and green is the right kidney.
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normal respiration, and becoming as high as 55 mm during maximum respiration
[33, 34]. Another study by Blackall et al. found that liver motion was 19±8 mm
during shallow breathing, and 37±8 mm during deep breathing [35, 36]. Danrad
et al. reported that the major component of liver motion occurs along the superior-
inferior (SI) direction with an average displacement of 10±8 mm, with a range of 7-28
mm, and the same is true for the diaphragm, which they found to move 12±7mm,
with a range of 7-28 mm [37, 38]. The motion of the liver translates to motion of the
liver tumors, with Shimizu et al. reporting a mean SI tumor displacement of 21 mm,
8 mm in the anterior-posterior (AP) direction, and 9 mm in the lateral direction [39,
40]. A further collection of live motion data can be found in Table 2. Many studies
also assume the liver as a rigid body; however, Paulsson et al. reported that the
liver frequently experiences intraorgan deformation and a study of fiducial markers
found that the rigid body estimation has an average error of 7.1 mm with a range of
1.9-11.4 mm at the periphery of the liver [41]. These deformations decreased toward
the central part of the liver, with an average error of 3.4 mm, ranging from 0.5-9.1
mm.
1.2.3 Magnetic resonance imaging for radiotherapy
Magnetic resonance imaging is a powerful tool in radiation oncology, with the
unique ability of being able to perform both anatomical and functional imaging,
while providing no ionizing radiation dose to the patient, and providing soft tissue
contrast vastly superior to CT imaging. This difference in soft tissue contrast becomes
especially stark when comparing CTsim images to MR, as in Figure 2. In addition
to improved anatomical imaging, MRI can produce functional image acquisitions
which provide detail on the tissue micro-environment. These specialized acquisition
protocols will be further discussed in Chapter 2.
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Author et al. Description AP (mm) ML
(mm)
SI (mm)
Case [42] (29 pa-
tients)








Mean (range) 4.8 (1-16) - 9.7 (3-18)
Yang [44] (14 pa-
tients)
Mean 4.5 17.5 7.1
Dhont [45] (18
patients)

























Table 2. Summary of liver motion during respiration using fluoroscopy, 4DCT, and
dynamic MRI acquisition.
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Fig. 2. Example of images acquired on a wide bore CT scanner for CT simulation (A),
and a T1w (B) and a T2w (C) image from a 3T MRI at the same position on
different days. The tumor mass is visible on all three images; however, it is
most easily delineated on the MR images.
Standard prognostic factors currently include stage, grade, histology, and patient
comorbidities; however, histology sampling is not always a possibility, and the other
factors do not provide a detailed description of the micro-environment of the tumor.
Dynamic contrast-enhanced (DCE) MRI has become a widely used tool to investigate
the perfusion and permeability of tumors [47]. DCE utilizes a contrast agent, and
rapid MR image acquisitions post injection, to follow the temporal enhancement pat-
tern of tissue as the contrast agent moves through the vascular system. The measured
signal intensity depends on the concentration of the injected paramagnetic particles,
which enter and disperse through the tissue. Pharmacokinetic analysis of the signal
intensity curves is then used to calculate Ktrans, the transfer constant for contrast
agent transport from the blood plasma into the extravascular extracellular space,
and ve, the volume fraction of the extravascular extracellular space. Previous studies
have also shown DCE-MRI to be correlated with tumor oxygenation, vascularity, and
cellular proliferation [48, 49, 50]. However, to perform DCE, contrast agents must be
administered to the patient, which often include gadolinium and other compounds
that can do significant damage to the kidneys if renal function is impaired, resulting
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in nephrogenic systemic fibrosis, and some studies have shown uptake of gadolin-
ium in the brain in patients with no history of kidney disease [51]. Damage to the
kidneys is suspected to be caused by reduction in medullary blood flow leading to
hypoxia and direct tubular damage due to the toxicity of contrast media. Measur-
ing response without contrast agents has been performed using DW imaging, fat- or
water-saturated T2 sequences, and vascular enhancement imaging using in- and out-
of-phase T1 sequences [52, 53]. Mardor et al. found that ADC of brain metastases
slightly increased one day post-treatment, with further increases over time. A 40%
increase in ADC 7 days post-treatment was associated with an 89% decrease in tumor
volume 55 days post-treatment [52]. In hepatocellular carcinoma, Oldrini et al. found
that the absence of a hyperintense region in DWI correlated with the probability of
complete response three months later on the subsequent MRI [53]. To the author's
knowledge, the only study utilizing IVIM methods for measuring tumor response
to radiotherapy is for breast cancer liver metastases undergoing radio-embolization;
however, the study uses a simplified version, utilizing only three b-values, which is
often considered insufficient for accurate quantification [54].
1.3 Radiotherapy respiratory motion management
To achieve the required position, immobilization equipment including vacuum
lock air bags, leg restraints, and hand holds are used to prevent the patient from
moving while on the table, and multiple imaging modalities are used to align the
patient to the correct position [55]. However, none of these methods succeed in
sufficiently achieving tumor localization due to respiratory motion. Multiple tech-
niques have been developed to mitigate respiratory motion, including self-enforced
breath hold, device-enforced breath hold with an active breathing coordinator unit,
compression using hard plastic plates or belts, and machine gating to the patients
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respiratory pattern [56]. These methods have all been shown to decrease respiratory
motion, but often are only implemented during CT simulation (CTsim) for treatment
planning and on the treatment machine. Further, the respiratory motion manage-
ment devices are not compatible with MRI machines. MR imaging is an integral part
of diagnosing, planning, and treatment response monitoring, but without a consis-
tent motion management mechanism across imaging platforms, it can be difficult to
register multi-modality images and assess changes to the anatomy.
1.4 Summary of complications
Within radiotherapy of the liver, and MR imaging for assessing radiotherapy
response, this work identifies three major difficulties. The first issue is the absence of
a respiratory motion management device that can be utilized across the radiotherapy
treatment process, including at the treatment machine, during CT imaging, and
during MR acquisition. A robust motion management device is required to acquire
high quality abdominal diffusion weighted images without motion artifacts, and to
correctly position the patient for treatment delivery. The second complication is what
imaging protocol to use, including number of b-values, number of signal averages,
respiratory motion management technique, and image acquisition technique. The
correct choice of protocol will allow for high quality and sufficient input data for IVIM
parameter calculation. Finally, the third complication of interest is the absence of a
standardized IVIM parameter calculation workflow for comparison of tissue types and
radiotherapy induced tissue changes. A standard protocol is vital to the application
of IVIM parameters in the clinical setting, and for extension of the protocol to other




The work in this dissertation aimed to develop an MR safe respiratory motion
management system which provides biofeedback to the subject, and investigate the
application of IVIM models and texture analysis in patients with liver cancer. The
study focuses on post-processing image analysis of the liver and cancerous liver lesions
acquired under breath hold, and the development of a software toolbox to easily and
reliably generate tissue maps of the investigated biomarkers. This work also presents
the first application of the full IVIM method to tumor response in radiotherapy to
the author’s knowledge, as previously stated.
Hypothesis: quantitative tissue parameters obtained using IVIM imaging and
analysis can provide information on tumor and liver changes for liver cancer patients
treated with SBRT, and can identify changes not visible using the current clinical
imaging protocol.
1. To develop an MR safe respiratory motion monitor and manager, which also
provides biofeedback to the patient. This system will be usable in both imaging
and treatment environments, and will introduce minimum image artifacts in
both MRI and CT acquisitions.
This aim addresses the absence of a suitable respiratory motion management
system usable across all platforms involved in radiotherapy, addressed in section
1.3.
(a) Develop a respiratory motion manager and monitor, which provides biofeed-
back to the subject, and is usable across MR and CT imaging systems, as
well as RT delivery systems.
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(b) Evaluate the reduction of respiratory motion when utilizing the system,
and introduction of imaging artifacts.
2. To develop a set of MR imaging sequences that provide anatomical and func-
tional information for the liver. This imaging protocol will include multiple
DW images to be used with the IVIM imaging method, anatomical imaging
sequences (T1w and T2w), and other quantitative or qualitative image acquisi-
tions.
3. To develop a workflow for analyzing images acquired with the imaging protocol
developed in aim 2, which produces a comparison of tissue information from
pre- and post-treatment imaging sessions for liver cancer patients treated with
SBRT.
(a) Investigate methods for improving IVIM parameter map quality utilizing
image registration and de-noising.
(b) Apply workflow to IVIM datasets and identify parameter changes from
pre- and post-treatment delivery.
In addition to development of a novel RMM device, imaging protocol, and work-
flow for IVIM analysis, a graphical user interface (GUI) was created to improve the
ease of use for the workflow, described in Chapter 7. The GUI was designed to incor-
porate each part of this work into a modular system, where the operator can decide
what image post-processing and analysis features to use. The MATLAB code for
this system is included in the Appendices of this work. Further, an initial assessment
of liver tissue change with dose region was performed for one week post-treatment
and one month post-treatment imaging data sets. Although the number of patients
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available for this study is limited, it lays the ground work for a large clinic-wide study
and can also be extended to other disease sites.
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CHAPTER 2
DIFFUSION AND PERFUSION WEIGHTED MR IMAGING
This Chapter provides background on MR imaging, and how it can be used to provide
functional details of the tissue micro-environment and micro-structure.
2.1 MR Imaging
MR imaging utilizes the physical phenomenon known as nuclear magnetic reso-
nance (NMR). NMR and the idea of nuclear spin are introduced here. Hydrogen-1,
Carbon-13, Fluorine-19, Sodium-23, and Phosphorous-31 atoms all exhibit NMR and
can be found in the human body [57]. 1H is the most common isotope in the human
body, constituting approximately 70% of the adult human body. Because of this,
protons are the most common isotope utilized for clinical MR imaging [58]. From
here on, the discussion will focus on the 1H isotope
2.1.1 NMR
NMR active nuclei are those which possess nuclear spin. Nuclear spin is a prop-
erty of nuclei containing unpaired nucleons (neutrons and protons), each of which
possess a nuclear spin of one half. The unpaired nucleon results in a non-zero spin
quantum number (I), and possesses spin angular momentum (S).
S = h̄I (2.1)
where h̄ is Planck’s constant (divided by 2π). In the case of 1H, I = 1/2,
corresponding to the single proton in the nucleus. Associated with S is a magnetic
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Table 3. Gyromagnetic ratios and relative sensitivities for NMR isotopes [57].
dipole moment µ, defined in equation (2.2).
µ = γS = γh̄I (2.2)
where γ is the gyromagnetic ratio, a known constant unique to different nuclear
species. Values for γ can be found in Table 3.
When S is defined along a given axis, it defines the number of possible spin
orientations along that axis and is defined by equation (2.3).
S = 2I + 1 (2.3)
For an 1H nucleus, this results in two possible spin states, m = +1/2 and m =
−1/2. Absent an external magnetic field, these two spin states are degenerate and
have no net magnetic moment. If these nuclei are subjected to a static magnetic field,
the interactions between µ and B0, the static magnetic field, result in a splitting of
spin states, and a net magnetization moment, M.
These two energy states are separated by ∆E, described in equation (2.4).





Fig. 3. Energy level diagram for a proton nucleus in the absence of an external mag-
netic field (B0 = 0) and spin splitting in the presence of an applied magnetic
field (B0 6= 0).
The +1/2 spin state is of less energy than the −1/2, and tends to have the
higher population; however, thermal energy is sufficiently high at room temperature
to exceed the energy separation. This results in the population ratio to be dependent






where k is the Boltzmann constant and T is the absolute temperature. At stan-
dard temperature (273.15 K) this results in an excess of 7 in 106 in the parallel state,
and a weak polarization macroscopically. In an applied field, the equilibrium nuclear





where N is the number of nuclear spins per unit volume. This shows that M0 is
proportional to the applied external magnetic field B0. It is this M0 that is manip-
ulated in MR imaging and forms the basis for all acquisition methods. The applied
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Fig. 4. Precession of a nucleus in an external magnetic field.
magnetic field also imposes a torque on the nuclear spins, resulting in a precession,







A magnetic field B1 applied in the transverse direction of the M0, with a fre-
quency equivalent to the resonant frequency of the M0 results in a transition be-
tween spin-states, and generates an NMR signal when the magnetization vector, M,
precesses orthogonally to the applied field. Under Faraday’s law of induction, an
electromotive force is induced within the receiver coil. The maximum NMR signal
is produced when the radio-frequency (RF) pulse brings the M vector parallel to the
xy transverse plane. This corresponds to an RF pulse with intensity and duration
resulting in a rotation of 90 degrees. The rotation angle is known as the tip angle or
flip angle (Θ), which is calculated using equation (2.8)
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Θ = γB1τ (2.8)
where B1 is the generated RF field and τ is the time duration of the applied pulse.
M will continue to precess about the z-axis at a precessional frequency proportional
to the applied field. Over time, M will eventually return to its equilibrium state along
the z axis, and the signal decay over time is called the free induction decay (FID).
This implies that the longitudinal component Mz must regrow, and the transverse
component Mxy must decay. The MR parameters T1 and T2 characterize this return
to equilibrium, and are known as relaxation time constants.
2.1.3 Relaxation
The excited spins return to thermal equilibrium by spin-lattice (T1), and spin-
spin (T2) relaxation processes, shown in Figure 5. Longitudinal relaxation, or T1
relaxation, corresponds to spins moving between energy levels to restore thermal
equilibrium. Moving from high to low energy states results in a release of energy
from the spins to the surrounding environment, the lattice. The T1 time constant is
defined as the time it takes for the signal to recover back to 63% of its original value
and is described by equation (2.9) [59]
Mz = M0(1− e−
t
T1 ) (2.9)
where t is the time delay allowed for longitudinal relaxation. The T2 relaxation, or
transverse relaxation, corresponds to the loss of phase coherence in the xy plane. After
an RF pulse, spins have a phase coherence by aligning in the transverse plane. Inter-
and intra-molecular interactions disrupt this phase coherence, which is eventually
lost. The T2 time constant is described by equation (2.10) [59].
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Fig. 5. Relaxation of an excited spin back to thermal equilibrium. Recovery of Mz
with longitudinal recovery and decay of Mxy with transverse relaxation over
time. The T1 relaxation time is defined as 63% of M0. The T2 relaxation time




The T2 time constant is highly susceptible to inhomogeneities in the applied
magnetic field, and the true decay recorded by the receiver coils is significantly faster
than natural T2. This faster rate is denoted as T2∗, and can be considered the observed
or effective T2
The three orthogonal components of the magnetization, Mx, My, and Mz can be

















= γMyB0 − MxT2
dMy
dt






The signal recorded during MR imaging is the transverse complex magnetization,











To solve this set of equations, we assume that at t = 0, the magnetization is
only present in the z-direction. Thus, the initial conditions for the magnetization are











The previous equations described methods which apply in both MRI and NMR.
This section introduces spatial encoding gradients, the main difference between MRI
and NMR that allows for image acquisition. The spatial encoding gradients include
the frequency, phase encoding, and slice selection gradients. These gradients apply
a spatially linear variation to the static magnetic field, adding or subtracting to B0
along their respective directions, as shown in Figure 6. Along the gradient, spins
precess at a decreased or increased rate dependent on their position. By applying an
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Fig. 6. An illustration of the magnetic field gradient and its impact on the B field and
spin precession frequency.(a) represents the magnetic field without a gradient
applied, resulting in a consistent precessional frequency over space. (b) rep-
resents the magnetic field with a gradient applied, resulting in an increase in
frequency as the B field strength increases.
RF pulse associated with a frequency along this gradient a slice of thickness T can





where BW is the RF pulse bandwidth, and GSlice is the slice selection gradient.
After the slice selective excitation pulse, a gradient is applied along one of the
remaining two directions. Again, spins experience different magnetic field strengths
depending on their position in space, and a phase shift is introduced between t = 0
and the recording of the signal. The phase accumulated during a pulse sequence for





′) · ~xdt′ = 2π~k · ~x (2.16)
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where ~k is the encoding vector, containing the information given by the gradients.
Finally, by adding a frequency encoding gradient in the third direction, the Larmor
frequency of spins are separated into a spectrum, resulting in a voxel location defined
by the slice, frequency, and phase information.
With the addition of complex transverse magnetization, and the presence of
imaging gradients, the change in Mxy over time in the presence of gradient fields is







The Larmor frequency is modified by gradients as follows.
ω = γB0 + γ ~Gim(t) · ~x (2.18)
Where ~Gim is the imaging gradient vector and ~x is the position vector of the






− iγ ~GIm(t) · ~xMxy (2.19)
And when solved for Mxy:
Mxy(t) = M0 exp (
−t
T2




′) · ~xdt′) (2.20)
To simplify the equation, relaxation effects are neglected and a rotating reference
frame, the solution for the Bloch equation in (2.20) becomes:




′) · ~xdt′) (2.21)
Using (2.16) and (2.21), a spatial frequency domain, or k-space, can be defined
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that contains the location information of encoding vector ~k. The total magnetization







The k-space described by equation (2.22) is of equivalent size to the final image;
however, a single pixel in k-space does not contain the information for a single voxel
in image space. The k-space holds an array of intensities along the axes of phase and
frequency. Image reconstruction using only part of k-space results in a blurred image
if only central k-space is used (low spatial frequencies) and an edge defining image if
the periphery of k-space is used (high spatial frequencies). An example of this can
be seen in Figure 7. From equation (2.22) the magnitude of magnetization, |Mxy(~x)|,
can be obtained by applying an inverse Fourier transformation.




Application of the Fourier transform results in an x-space MR image, which may
be used for image analysis.
2.1.5 Basic MR pulse sequences
To generate useful image contrast, the excitation and gradient selection pulses
must be applied at precise times and durations. These are described as MR pulse
sequences, a subset of which will be described below.
2.1.5.1 Gradient Echo Sequence
An illustration of the gradient echo pulse (GE) pulse sequence is shown in Figure
8. This pulse sequence utilizes 90 degree selective excitation pulse. A negative slice
25
Fig. 7. K-space spectra and their reconstructed images showing: (a) reconstruction
of all spatial frequencies, (b) low spatial frequencies (central 2.5% of k-space),
and (c) high spatial frequencies (peripheral 97.5% of k-space)
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Fig. 8. Sequence diagram for GE pulse sequence.
gradient is applied, causing rapid dephasing of the transverse magnetization for a
short time after the excitation pulse. After the negative lobe, a positive gradient is
applied which reverses the magnetic field gradient, causing spins to rephase. This
positive gradient only compensates for the negative gradient dephasing, and does not
refocus dephasing due to main magnetic field inhomogeneities or spin-spin relaxation.
The signal of the produced echo is determined by the FID decay curve and T2∗.




2.1.5.2 Spin Echo sequence
An illustration of the spin echo (SE) pulse sequence is shown in Figure 9. This
pulse sequence utilizes a 90 degree selective excitation pulse, tipping the spins into
the transverse plane. After a time delay τ during which the spins are dephasing, a 180
degree refocusing pulse is applied. Spins which were previously dephasing begin to
rephase, leading to the term refocusing pulse. This process is similar to the rephasing
of spins in GE pulse sequences, however it utilizes an inversion RF pulse, instead of
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Fig. 9. Sequence diagram for SE pulse sequence.
an equal and opposite magnetic field gradient. At t = 2τ , an echo forms, and this
time is defined as the echo time (TE). Static spins experience the same magnetic field
inhomogeneities during the time τ prior to the 180 degree pulse, and between the 180
degree pulse and the readout pulse. Due to the 180 degree pulse, T2 can be used,
instead of T2∗, to describe the signal intensity. The addition of the 180 degree RF
pulse increases acquisition time compared to GE acquisitions. This pulse sequence is
commonly used to produce T2w images with a signal described by equation (2.25)









where ∆B describes the magnetic field inhomogeneities, and D is the apparent
diffusion coefficient (ADC) of the tissue. Because D is typically around 10−3mm2/s
and TE is generally short compared with T2, equation (2.25) can be simplified to:





2.2 Diffusion MR imaging
Diffusion weighted imaging (DWI) is an important noninvasive tool for assessing
functional status of tissue in the body. This technique exploits the sensitivity of
MRI to diffusion of water in tissue while in the presence of diffusion gradient pulses.
The following sections will describe the origin of diffusion in the body, and how it is
measured with MRI.
2.2.1 Physical and biological origins
Robert Brown studied the motion of small particles inside a fluid and found a
type of motion common to all particles in this state, termed the random-walk, or
Brownian motion [60]. Brownian motion is the description of microscopic diffusion
phenomenon. It is caused by the thermal energy possessed by molecules, and results in
molecular mixing. This diffusion is intrinsic to a medium and is dependent on the size
of the molecules, temperature, and micro-structure. Albert Einstein later formulated












is the mean squared displacement of a particle diffusing during a
time T and in the dimension of displacement n. The Einstein equation describes
diffusion as a Gaussian function, where the width of the distribution is determined
by D. However, diffusion in biological tissue is not free, resulting in deviation from
the Gaussian behavior and the molecular displacement distribution becoming sharper
[62].
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Fig. 10. Sequence diagram for a PGSE sequence.
2.2.2 Measurement with MR
The measurement of diffusion with MRI is dependent on the concept of phase.
If we consider three sine waves oscillating at the same rate and at the same position
along the axis, the waves have the same phase. However, if two waves are shifted in
space relative to the other, the waves now have different phases, but retain the same
frequency. This instantaneous position of a wave can be equated to an angle describing
the position of protons relative to one another. Hahn was the first to recognize the
potential of the SE sequence to measure the diffusion coefficient [63]. In 1965 Stejskal
and Tanner proposed what would become the most commonly applied method for
producing diffusion-weighted contrast, the Pulsed gradient spin echo (PGSE) method
seen in Figure 10 [64].
The PGSE sequence adds two diffusion gradients, one before and one after the
180 degree pulse. The diffusion gradients allow differentiation between static and
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Fig. 11. A diagram of spin change during DWI when diffusion gradients are applied.
(A) indicates when the diffusion gradient is powered on and in what direction.
The first gradient pulse is applied, causing dephasing of spins depending on
location within the slice. In the case of no diffusive motion (B) the dephased
spins remain in position. When the rephrasing gradient is applied, the return
to their original orientation, maintaining signal intensity. When diffusive mo-
tion is present (C) the dephased spins do not remain at a constant location
between application of diffusion gradients. The change in location leads to
a different magnetic field being applied during each diffusion gradient. The
incomplete rephasing caused by different gradient strengths leads to reduced
signal intensity.
moving spins in the voxel. The stationary spins will be completely rephased by the
second gradient, while moving spins will not be. An illustration of this can be seen
in Figure 11. Two other parameters are defined by the PGSE sequence: the pulse
diffusion gradient duration, δ, and the time delay between the two diffusion encoding







where G is the diffusion encoding gradient strength. Le Bihan proposed simplifi-
cation of the exponential term by gathering parameters linked to the sequence or the
type of nucleus into one parameter, b [65].
SPGSE = S0e
−bD (2.29)
where b is defined in equation (2.30) and is called the b-value.
b = (γδG)2(∆− δ
3
(2.30)
The time that spins are allowed to diffuse is represented by the diffusion time







The descriptor ”apparent” was added due to the presence of pure diffusion within
tissue.
2.3 Perfusion MR imaging
Due to resolution limitations of MRI, direct imaging of microscopic phenomena
is not possible. However, macroscopic manifestations of these phenomena can be
imaged. The concept of diffusion imaging can be extended to the study of blood flow
within the capillary network.
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2.3.1 Biological origins
Incoherent motion is believed to arise from the micro-circulation of blood in the
capillary network. A model describing this, called intravoxel incoherent motion was
introduced in 1986 by Le Bihan et al. to explain the multi-exponential diffusion
signal decay observed with acquisition of multiple b-values [66]. The IVIM model
describes three parameters: the diffusion coefficient D, pseudo-diffusion or perfusion
coefficient, D*, and the perfusion fraction (PF) Its magnitude is described by the
volume fraction or PF. D, or Dslow describes the tissue water diffusion. D*, or Dfast
describes perfusion in the tissue and is only visible at low b-values. Imaging of Dfast
is limited to low b-values because blood flow is at least an order of magnitude greater
than the water diffusion coefficient, and signal is very short lived [67]. The IVIM
model considers perfusion as a form of incoherent motion, contributing towards the
observed diffusion signal attenuation.
2.3.2 Measurement with MR
Measurement of IVIM parameters utilizes multi b-value DW-MRI and the fitting
of the diffusion signal with IVIM models. Figure 12 shows that fitting with ADC is
unable to account for the multi-exponential diffusion signal decay. This discrepancy
between the mono-exponential decay model from equation (2.29) and what is seen
in multi b-value imaging is due to the significant contribution of perfusion to the
diffusion measurement because of the incoherent motion of blood in the pseudo-
random capillary network at the macroscopic level [66, 68, 69, 70, 71].
Multiple studies have shown that the choice of IVIM model, fitting algorithms,
and acquired b-values can have a strong impact on the post-processing calculation of
IVIM parameters [72, 73, 74, 75, 76, 77].
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Fig. 12. Multi b-value diffusion-weighted MR imaging. (a) Shows multiple DW-MR
images showing a decreased signal as b-value increases. (b) Shows a plot




The first IVIM calculation model was proposed by Le Bihan et al in 1986, utilized
only three b-values, and did not compute a value for D*. The model requires b-values
of 0, 100-300, and greater than 800 s/mm2 to be acquired [66, 69]. First, ADC is
calculated using equation (2.31). The ADC equation is used a second time with the b
= 0 image replaced by the b = 100-300 image; this removes the perfusion effects from
calculation of the diffusion coefficient. Finally, the perfusion fraction is calculated
using equation (2.32).
PF = 1− e−b1·(ADC−Dslow) (2.32)
The conventional model was also produced by Le Bihan et al. and allows for
calculation of all IVIM parameters using equation (2.33).
S(b) = S(0)[(1− PF )e−b·Dslow + PFe−b·Dfast ] (2.33)
Recently, a simplified IVIM model has been studied which requires as few as two
nonzero b-values in the regime where pseudodiffusion effects are negligible [78]. This
method also only returns D and PF values, and is described by equation (2.34).
S(b) = S(0)e(−bDslow+ln(1−PF )) (2.34)
All of these models allow for calculation on a voxel-by-voxel basis, and creation




Texture is an important property of objects, most commonly linked to the tactile
response when touching a surface, but this feature is also present in two-dimensional
pictures. Humans perceive objects as being coarse, fine, irregular, or smooth, but
struggle in identifying and discriminating between complex textures [79, 80]. Quanti-
tatively, texture can be defined and analyzed using many different methods of calcu-
lation [81]. The technique quantifies heterogeneity of a region of interest by analyzing
the distribution of pixel gray levels, and their relationship between one another, in
the image [82]. Texture analysis (TA) has been used as a means for qualitative and
quantitative classification of images at least since the mid-1950’s when Kaizer used
auto-correlation for the inspection of aerial photographs [83]. Now, TA is used for
machine vision in self driving cars, automated inspection for quality control, and in
medicine for identification of anatomical and pathological structures.
3.1 First-order textures
First-order texture features are statistics calculated from the original image val-
ues, and do not consider pixel neighborhood relationships [84]. The simplest of these
is the histogram of intensity levels in all or part of an image. These textures include:
mean, standard deviation, entropy, and range. First-order texture analysis is limited
in its utility because it provides no information about relative position of pixels to
one another.
The mean of the histogram is the mean of the gray-levels in an image
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Fig. 13. The utility of first-order texture features is limited because it does not in-
clude information about pixel intensity relative to other pixels. These three








where x is the pixel gray level, and n is the number of gray levels. Standard







(xi − x̄)2 (3.2)
Entropy is the statistical measure of randomness, achieving its largest value when





where I is the image. Range is the minimum and maximum value in a neighbor-
hood of specified height and width around a pixel. This method generates an image
where brightness represents texture or boundaries.
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Fig. 14. An example (a) template, (b) original image, and (c) co-occurrence matrix.
The 2 in the co-occurrence matrix indicates that there are two instances of a
pixel with gray level 3 immediately to the right of a pixel with gray level 1.
3.2 Second-order textures
Second-order texture features utilize a spatial gray level co-occurrence matrix to
consider the relationship among pixels and groups of pixels. Haralick suggested the
use of gray level co-occurrence matrices (GLCM), which have become one of the most
well known texture features [85]. GLCM illustrate how often each gray level occurs at
a pixel located at a fixed geometric position relative to each other pixel, as a function
of gray level, shown in Figure 14.
The GLCM can be used to directly measure the texture of an image or region,
but may also be converted into simpler scalar measures of texture. In an image
where intensity varies gradually, most of the non-zero entries in the GLCM for right
neighbors will be near the main diagonal because neighboring pixels will have nearly
equal gray levels.
The following equations describe the GLCM-based second order texture features
that are used in this dissertation. Homogeneity measures the distribution of elements
in the GLCM and their closeness to the GLCM diagonal. A diagonal GLCM will






1 + |i− j|
G(i, j) (3.4)
where G(i,j) is the probability of co-occurrence of the pixel gray-levels. Correla-
tion measures the correlation between a reference pixel to its neighbor over the whole
image, describing the joint probability occurrence of the specified pixel pairs. Corre-




(i− µ)(j − µ)G(i, j)
σ2
(3.5)
where µ and σ are the mean and standard deviation respectively. Energy de-
scribes the uniformity of the image, measuring the sum of squared elements of the






Contrast is a measure of the intensity difference between a pixel and its neighbor





|i− j|2G(i, j) (3.7)
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CHAPTER 4
DEVELOPMENT OF RESPIRATORY MOTION MANAGEMENT
DEVICE
4.1 Current respiratory motion management devices
As previously mentioned, respiratory motion in the thoracoabdominal cavity is a
major cause of organ motion and positional uncertainty in radiation therapy, imaging,
treatment planning, and treatment delivery. Various methods have been proposed to
reduce the positional uncertainty and motion, including: free breathing respiratory
gating, breath-hold techniques, abdominal compression, surface monitoring, and real-
time target tracking [56, 86, 87, 88, 89, 90]. The addition of the MR environment
makes many techniques impractical or impossible, due to the presence of the strong,
always on, magnetic field, and sensitivity of image acquisition to outside RF signals.
The commonly used active breathing coordinator (ABC) device cannot be used in
the MR suite due to the moving metallic parts and commercially available computer
system. MR imaging also requires the presence of an RF coil as close to the body
surface as possible for good image quality, and the enclosed space of the bore of the
magnet to produce a uniform magnetic field. These qualities make other popular
respiratory motion monitoring systems impractical. Optical surface tracking using
cameras cannot be performed because the patients skin is not visible. Compression
using the commercially available plates is not possible due to the confined spaces
and no attachment points available on the table. Compression belts are the final
form of respiratory motion management (RMM) systems available for use in the MR
environment; however, these are simply elastic belts strapped around the patient
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and require self-enforced breath holds without guidance. Gating methods using 1D
trackers are also available in MR systems, but these are not available on the standard
therapy linear accelerator, only specialized models equipped with integrated MRIs.
4.2 RMM device design
The design requirements for the RMM device designed for this dissertation in-
cluded:
1. A device compatible with all environments in the radiotherapy treatment pro-
cess, including MRI, CT, and the RT delivery system.
2. Biofeedback to the subject to guide their respiratory pattern.
3. Easy and reproducible setup with an absolute readout value.
4. Usable with limited coaching from treatment team to the patient, and patient
comfort during use.
The motion management system consisted of a belt with an interior pocket sewn
in to hold an air bladder (Vernier, Beaverton, OR, USA). The air bladder was con-
nected using a Luer Lock set, sealed with glue, to a 25 ft section of PVC tubing.
The tubing was connected to a gas pressure sensor (Vernier, Beaverton, OR, USA)
placed at the MR room wall next to the RF wave guide pass-through and connected
to a power data interface (PDI). The PDI then connected to a computer running the
LoggerPro software V3.14 (Vernier Software and Technology, Beaverton, OR, USA).
The LoggerPro screen was displayed to the subject using an in-room MR safe Sen-
saVue Display System (Invivo, Gainesville, FL, USA), and the subject wore mirrored
glasses so they could see the screen at the foot of the MR bore. A diagram of the
device and component locations can be seen in Figure 15, an image of the device can
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Fig. 15. A diagram of the device setup and placement of components within the MR
suite.
be seen in Figure 16, and the device setup on a patient in the MR suite can be seen
in Figure 17.
Figure 17 also displays a 110 second respiratory trace that would be visible to
the imaging subject while in the MR bore. The red line indicates their real time
respiratory trace, and the green and blue lines indicate a pre-positioned bounding
box to guide breath holds or respiratory amplitude.
4.3 Image Acquisition
All images were acquired on a 3-T Philips Ingenia MRI (Ingenia; Philips Health-
case, Best, Netherlands). A 30 or 60 second balanced turbo field echo (BTFE) CINE
acquisition was performed acquiring 250 frames of a single slice (TR: 2.12 ms; TE:
0.93 ms; Gradient echo train length: 47; Voxel size: 1.87 x 1.87 x 5 mm3, image ma-
trix: 160 x 160 pixels2). Initial tests were completed with a set of two investigators.
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Fig. 16. A photograph of the final respiratory motion management device, including
the belt, pressure sensor, and power-data interface.
Fig. 17. A photograph of the device setup on a patient without and with the RF coil
placed on the patient for imaging. Image C is an example respiratory trace
displayed to the patient and operators in real time.
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These tests were followed by a cohort of four healthy volunteers, and a second cohort
of two liver cancer patients.
4.3.1 Investigator imaging
The two investigators underwent two imaging sessions each, with sessions sepa-
rated by one week. During each imaging session, the investigators were first positioned
on the MRI with the motion management belt around their abdomen, without visual
guidance. A CINE MR acquisition was performed acquiring a single sagittal slice
through the liver every 120ms for 250 frames, while the investigator was under free-
breathing. Visual guidance was then set up for the investigators, allowing them to see
their respiratory trace in real time, as well as two horizontal lines indicating a guid-
ance window. Investigators were instructed to keep their respiratory trace between
those lines during imaging. CINE MR acquisitions were again performed as described
above while the investigator maintained their respiratory trace within a 1.0 kPa large
window or a 0.5 kPa small window. The respiratory traces were recorded throughout
imaging. Motion was defined as the peak liver dome position at exhale and inhale
over the entire CINE acquisition, which has been shown to be a good surrogate for
liver tumor motion [44]. Liver dome motion was measured using in-house software
developed using MATLAB (MATLAB 2018a, Mathworks, Natick, MA, USA).
4.3.2 Volunteer and patient imaging
Four healthy volunteers with no prior knowledge of the system underwent mul-
tiple anatomical and functional image acquisitions while utilizing respiratory motion
management including breath hold. Total imaging time was between 30 and 60 min-
utes, requiring 25 to 30 breath holds. CINE image sets were acquired for volunteers
maintaining their respiratory trace as consistently as possible while viewing the trace,
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but without a guiding window.
Two liver cancer patients were imaged pre-radiotherapy treatment and post-
treatment, also undergoing multiple anatomical and multi-parametric image acquisi-
tions while managing breath motion including breath hold. CINE image sets were
acquired for patients under free breathing while being able to view their respiratory
traces.
4.4 Trace Comparison
After image acquisition, the CINE images were analyzed to extract the liver
dome position using a 10-pixel average of diaphragm position in each frame. Figure
18 shows a montage of ROIs used to extract the liver dome.
Belt traces were converted from pressure to distance using equation (4.1).
scaled belt signal [mm] = (
xCINE,max − xCINE,min
Pbelt,max − Pbelt,min
) · (Pbelt − Pbelt,min) (4.1)
Where xCINE is the diaphragm position from CINE images, and Pbelt is the
pressure reading from the belt system. Normalized error between the scaled belt








Where xCINE,i is the position from CINE acquisition at time point i in mm, xbelt,i is
the position from the belt respiratory trace at time i in mm, n is the total number
of points collected, and A is the amplitude of the respiratory traces from the CINE
respiratory trace.
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Fig. 18. A set of ROIs from a 250 frame CINE acquisition showing the dome of the
liver and lung boundary. An average over ten pixels was used to calculate the




Investigators were able to successfully alter their respiratory traces to the con-
fined windows during image acquisition, reducing the free breathing amplitude, mea-
sured using the belt signal, from 1.8kPa to 0.7 kPa, within the window boundary
displayed to investigator 1, during the first imaging session. This reduction in am-
plitude corresponded to a peak to peak change in liver dome motion from 21.6 mm
without a guiding box, to 4.3 mm with a guiding box. Table 4 shows the aver-
age peak-to-peak motion and standard deviations for CINE images acquired under
free-breathing, with a large window guiding box, and a small window guiding box.
The respiratory traces for one investigator in free breathing, large window, and small
window guidance are shown in Figure 19.
4.5.2 Volunteer and patient study
Volunteers were able to follow the MR technologists instructions for breath hold
and guided breathing throughout the imaging session. Figure 20 shows the respira-
tory traces from the belt signal and CINE acquisitions extracted and overlaid, each
respiratory trace also includes five CINE frames from the indicated position in the
trace. Table 5 shows the difference between CINE respiratory trace and scaled belt
signal for volunteers and patients.
Liver cancer patients were also able to successfully follow the MR technologists
instructions for breath hold and guided breathing. Figure 21 shows the respiratory
traces from the belt signal and CINE acquisitions extracted and overlaid, with five
CINE frames from the indicated position in the trace. In Figure 21G, the patient
was instructed to breathe deeply twice before keeping their respiratory signal within
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Fig. 19. A-C represent respiratory traces acquired for an investigator with unguided
breathing, large window guidance, and small window guidance, respectively.
The grey box indicates the respiratory trace corresponding to the CINE im-
ages, Roman numerals I-V indicate the image position in the trace, the red
and yellow lines indicate minimum and maximum diaphragm position in the
boxed trace. The blue and green lines indicate the displayed or desired respi-
ratory boundary for each situation.
49
50
Fig. 20. Respiratory traces from four volunteers (A-D). The solid lines indicate the
CINE respiratory trace, the dashed line indicates the belt signal scaled to
distance, the dotted line is the difference between the two traces at each time
point, and the dot-dash line is the average difference between traces. Roman
numerals I-V in each graph are the matched positions to five frames taken
from the CINE acquisitions. In CINE image sets, the red and yellow lines

























None 30.6 7.8 21.6 40 47.00
Guided Large
Window
11.5 3.7 7.2 15.6 97.67
Guided Small
Window
5.6 0.9 4.3 6.1 85.33
Table 4. Peak-to-peak motion from CINE images for investigator respiratory traces
using three different motion management boundaries displayed by the mo-
tion management system with visual biofeedback. The duty cycle represents
the percent time the belt signal remained within the boundary window; the
window was set to the same scale for large window and without guidance.
a guiding window for the remainder of the image acquisition, which they did suc-
cessfully. A positional drift can be observed in the respiratory trace for patient 1
pre-RT.
Table 5 shows the motion amplitude, average difference between belt and CINE
signal, and the percent normalized error over the CINE acquisition.
4.6 Summary
This study found that SI motion of the liver could be greatly reduced using
the proposed respiratory motion management system with visual biofeedback in MR
simulation, reducing motion from 30.6mm to 5.6mm on average, over a 30s imaging
time period with the investigator group. This 30s time period is longer than the single
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Fig. 21. Respiratory traces from two patients pre- and post- radiotherapy (RT). In
image set B-Post-RT, the patient was instructed to breath deeply twice before
maintaining their guidance signal within the displayed lines. The solid red and
yellow lines indicate the minimum and maximum diaphragm positions. The











Volunteer 1 19.22 2.31 ± 1.51 12.09
Volunteer 2 40.13 3.49 ± 1.93 8.70
Volunteer 3 30.64 1.82 ± 1.58 5.94
Volunteer 4 22.17 2.30 ± 1.69 10.37
Patient 1 Pre-RT 17.15 1.28 ± 1.07 7.49
Patient 1 Post-RT 16.26 2.18 ± 2.64 13.41
Patient 2 Pre-RT 12.69 2.06 ± 1.32 16.26
Patient 2 Post-RT 32.18 3.21 ± 2.17 9.98
Mean 23.81 2.33 ± 2.33 10.53
Table 5. Comparison of respiratory traces from motion management system and CINE
acquisitions for investigators, volunteers, and patients pre- and post-treat-
ment. Motion amplitude is the peak-to-peak motion of the diaphragm from
CINE acquisitions. Average difference is the average difference between CINE
motion and belt signal. Normalized error is average difference divided by mo-
tion amplitude.
breath hold delivery time for most arcs of an SBRT treatment in our clinic, and is
more achievable than deep inspiration breath hold for the same amount of time based
on volunteer and patient feedback. The volunteers, with no prior knowledge of the
device, did not have difficulty maintaining their respiratory traces within the guiding
windows and were able to continuously do so for 60s. Patients were also able to
maintain consistent breath holds across acquisition time points. In some cases, where
windowed guidance was not present, but the subjects could still see their respiratory
trace, a drift in position was observed, such as with patient A pre-RT. This may be
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because of the patient relaxing or changing their respiratory method over time. Use
of a guiding window is able to prevent these changes. The belt was able to track liver
dome motion with a simple linear conversion from pressure to distance when compared
to CINE images with an average error of 2.3mm. This motion estimation could be
improved by using a non-linear pressure conversion, but that was not investigated in
this work. Unfortunately, tumor motion was not compared to the pressure data in
this study due to poor tumor volume visibility in the CINE acquisitions; this would
have allowed a full comparison of the system's ability to use respiratory amplitude as
a surrogate for tumor motion.
Implementation of this device within the clinic would require more careful cal-
ibration of the device to each patient. This could be achieved by acquiring CINE
images under FB to compare motion and pressure amplitudes, and a second acquisi-
tion under the desired respiratory motion management technique to assess the amount
of motion over BH at different volumes, or during windowed breathing. A demar-
cation for indexing each patient's belt tightness would be required, but that may
change over time due to patient weight loss or other physiological changes and would
need to be accounted for. Use of the belt would also require some patient coaching;
however, this required limited time during this study. Further, if windowed guidance
was the desired method, multiple window sizes could be used depending on the pa-
tient's lung function and ability to perform the windowed breathing for the length
of treatment delivery. During treatment, this device would provide better duty cycle
than breath hold if windowed guidance is used because it removes the recovery and
gantry re-positioning time required between BH.
Interfraction respiratory motion variability could be reduced by using a consistent
pressure reading at set up and maintaining the same guiding window. In this study
the pressure readings were converted to liver motion in mm; however, the device
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is not intended for measuring the absolute displacement of objects in the body, or
as a tumor position surrogate for target tracking or beam control with real time
MR-guided RT. The proposed motion management system can provide continuity of
device across pre-treatment imaging platforms including MRI and CT, and treatment
delivery due to its lack of high Z material, or ferromagnetic parts. Utilizing the same
device throughout the entire treatment process allows for more consistent setup of
the patient and respiratory motion. The developed motion management belt is also a
candidate for respiratory motion management during MR-LINAC treatments because
of its transparency to the treatment beam.
57
CHAPTER 5
DEVELOPMENT OF IMAGING PROTOCOL
The second aim of this work is to develop a set of MR imaging sequences that pro-
vide anatomical and functional information for the liver. The framework of this
imaging protocol is built around anatomical imaging, including T1 and T2 weighted
images, and DWI, utilizing sufficient b-values for IVIM analysis. This imaging pro-
tocol must be acquired in under one hour due to limited MRI availability, with an
ideal completion time of 30 minutes. Anatomical images will be used for comparison
of conventional and quantitative data. The anatomical images may also be compared
to the CTsim and CBCT data sets produced during the current protocol in place for
treatment of liver lesions with SBRT at VCU Health. Due to the significant respira-
tory motion that occurs, these images must be acquired during breath hold. The MR
safe visual feedback system developed for aim 1 will be used to provide guidance to
the patient for breath holds.
All cohorts were imaged with anatomical images, including T1w turbo field echo
(TFE) sequence (Repetition time = 10.0 ms, echo time = 2.3 ms, pixel size = 1 x 1
mm2, slice thickness = 5 mm; matrix = 268 x 200) and T2w turbo spin echo (TSE)
sequence (Repetition time = 1338.8 ms, echo time = 80.0 ms, pixel size = 0.9375 x
0.9375 mm2, slice thickness = 3 mm; matrix = 376 x 319) image sets (Table 6), a
CINE acquisition described in Chapter 4, and a quantitative susceptibility mapping













T1w TFE 10.0 2.3 1 268x200 1.00x1.00 5 FB
T2w TSE 1338.8 80.0 1 376x319 0.94x0.94 3 4
Table 6. Sequence parameters for anatomical images acquired for all imaging cohorts.
TR - repetition time, TE - echo time, NSA - number of signal averages, T -
slice thickness, No. of BH - number of breath holds to acquire image.
5.1 Design of IVIM protocols
The IVIM imaging protocols were developed using the investigator and volunteer
cohorts. Total acquisition time and the number of breath holds required for comple-
tion of the scans were the main concern due to the physical and mental stress which
may be caused by the MRI and breath hold conditions, as well as the limited avail-
ability of MRI scan time. The next concern for imaging was the number of b-values
acquired and the quality of the images. IVIM analysis requires a range of b-values to
be acquired, typically from 0-1000 s/mm2; however, due to the liver having relatively
higher perfusion fraction and pseudodiffusion values than other popular IVIM targets
such as the brain, the low b-value region becomes more important for generating re-
producible values [91, 92, 93, 94, 95, 96]. Multiple IVIM studies in normal liver have
used different b-value distributions, resulting in varying IVIM parameter values [91,
92, 94, 97, 98]. For example, Patel et al. used b-values b = (0, 50, 100, 150, 200,
300, 500, 700, and 1000) s/mm2 and found normal liver values of 32%, 1.2x10−3, and
40x10−3 mm2/s for PF, D, and D* respectively [91]. Luciani et al. used b-values b
= (0, 10, 20, 30, 50, 80, 100, 200, 400, and 800) s/mm2 and obtained values of 26%,
1.2x10−3, and 85x10−3 mm2/s for PF, D, and D* respectively, a D* value twice as
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Fig. 22. Images acquired using the designed protocol for T1w (top row) and T2w (bot-
tom row) acquisitions. The left column images are from a healthy volunteer,
center column from a pre-treatment cancer patient, and right column from
the same cancer patient post-treatment.
high as Patel et al. found [92]. Further, studies have shown that IVIM parameters
have poor repeatability for PF and D*, with coefficients of variation ranging from
7.7-25% for PF, and 14.6-59% for D* [91, 99]. b-value distributions are shown in
Table 7. Therefore, multiple b-value sets, acquisition types, and signal averages were
used to develop the final IVIM imaging set (Table 8).
5.1.1 Investigator cohort
The first cohort to be imaged consisted of two investigators. Two different DW
image sets were acquired. The first included 10 b-values b = (0, 10, 30, 60, 100, 150,
200, 400, 600, and 1000) s/mm2, and required an average of 25 breath holds of 18
seconds, over the course of 20 minutes (Table 8 # 1). The second included 8 b-values
b = (0, 20, 40, 80, 100, 300, 600, and 1000) s/mm2, and required an average of 20






















3.0 4 0, 10, 80, 800 1 FB
Taimouri et al.
2015 [102]
1.5 7 5, 50, 100, 200,
400, 600, 800
1 FB
Patel et al. 2010
[91]






1.5 10 0, 10, 20, 30,
50, 80, 100, 200,
400, 800
3 Gating
Table 7. b-value distributions, respiratory motion management method, and number
of signal averages for previous studies. NSA - number of signal averages,
RMM - respiratory motion management, FB - free breathing, BH - breath
hold.
10 b-value acquisition are shown in Figure 23.
Severe motion artifact can be seen on the anterior surface of the abdomen, as
well as the posterior of the liver and the stomach. These acquisitions were performed




















This work # 3 3.0 14 0, 10, 20, 30,




Table 8. b-value distributions, respiratory motion management method, and number
of signal averages for this study. NSA - number of signal averages, RMM -
respiratory motion management, BH - breath hold.
device, with the pressure reading displayed in Figure 24.
Due to the severe motion artifacts, it was decided that all acquisitions would be
performed using expiration breath hold. Expiration resulted in a much more steady
RMM device signal, shown in Figure 25
5.1.2 Volunteer cohort
The investigator cohort was imaged using multiple acquisition types. DW image
sets with 8 b-values b = (0, 20, 40, 80, 100, 300, 600, and 1000) s/mm2 utilizing the
native respiratory trigger, 1D navigator, and breath hold required 10, 5.5, and 15
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Fig. 23. Images acquired using the 10 b-value image set on a single investigator, show-
ing b-values 0, 10, and 150 s/mm2, from left to right, acquired during inhala-
tion breath hold. Severe motion artifacts are seen on all images, indicated by
blue arrows on the chest wall and red arrows on the posterior surface ghosting
artifacts.
Fig. 24. Respiratory trace and bounding window for an investigator holding deep in-
spiration breath hold. Even without exhalation, the abdomen falls over time,
reducing pressure on the belt and causing motion of the abdominal organs.
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Fig. 25. Respiratory trace and bounding window for an investigator holding full ex-
piration breath hold. Pressure on the abdomen remains considerably more
consistent over time.
minutes with 15-20 breath holds of 20 seconds, respectively, and included two signal
averages (NSA). Figure 26 shows three DW images from the breath hold acquisition.
This was followed by a 14 b-value image set b = (0, 10, 20, 30, 40, 80, 100, 150, 200,
250, 300, 600, 800, and 1000 acquired under free breathing with a navigator, and
NSA = 1, requiring 8 minutes to complete (Table 8 # 3). Figure 27 shows three DW
images from the free breathing acquisition.
Utilizing the free breathing protocol, images had low signal to noise (SNR) due
to NSA = 1, motion blurring near the periphery of the liver, and movement in and out
of the imaging plane, causing slices to be mismatched along the SI axis. The images
in Figure 28 show three consecutive slices, where the left kidney appears in the frame,
is absent, and then re-appears, indicating SI motion in between slice acquisition. The
8 b-value acquisition with NSA = 2 was chosen for imaging with the patient cohort
due to the limitations of the free breathing protocol.
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Fig. 26. Three DW images with b = 0 (A), 20 (B), and 300 (C) s/mm2 for the 8
b-value acquisition under breath hold with NSA = 2. The selected b-values
are different from previous figures because the same b-values were not acquired
in this image series.
Fig. 27. Three DW images with b = 0 (A), 20 (B), and 300 (C) s/mm2 for the 14
b-value acquisition under free breathing with NSA = 1.
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Fig. 28. Three DW images with b = 0 (A, D, G), 20 (B, E, H), and 300 (C, F, I)




The patient cohort was imaged with the 8 b-value DWI protocol, including b
= (0, 20, 40, 80, 100, 300, 600, and 1000) s/mm2, and NSA = 2. The acquisition
required 16-22 breath holds, lasting 19-22 seconds each, and totaling 15-18 minutes
of acquisition time (Repetition time = 806.1 ms, echo time = 59.3 ms, field of view
= 450 mm, slice thickness = 3 mm; matrix = 256 x 256).
5.2 Summary
The final imaging protocol provides high resolution T1w and T2w images with
limited motion artifacts and no artifact from the RMM device. The IVIM DWI
acquisition was completed within an acceptable amount of time with number and
length of breath holds achievable by all volunteers and the two patients in the initial
imaging cohort. The total number of breath holds required for full acquisition was
26-34, and required 30-60 minutes from patient laying down on the table to coming off
the table. This range in number of breath holds and imaging time was dependent on
the number of slices required to gain imaging coverage of the entire liver, and amount
of time for the subject to recover after each breath hold. Patients undergoing SBRT
of the liver are treated under breath hold and the cancer patients from this study
were able to perform the requested breathing pattern in two of three cases, with the
third case requiring a small guiding window instead. The current clinical protocol
requires approximately 45 minutes to complete, and the duration would be increased




IVIM AND TEXTURE ANALYSIS OF THE LIVER AND LIVER
LESIONS
6.1 Introduction
Accurate measurement of normative IVIM parameters for the liver is vital to
the translation of IVIM to the clinical environment. Variation occurs due to mag-
netic field strength, number of b-values, fitting algorithm, respiratory motion, and
fitting model [68]. Currently, only a single liver IVIM study other than this work
uses breath hold for DWI acquisition. Li et al. found that there was no significant
advantage to respiratory triggering versus free breathing for IVIM acquisition when
comparing coefficient of variations (CoV) for D, D*, and PF [68]. Multiple studies
have been performed to determine the optimal number of b-values to acquire for the
best parameter fitting, with the number of b-values acquired reaching as many as 25
[103, 104, 105, 106]. There is no consensus on the correct distribution, but a general
rule follows, that the most b-values should be in the range 0 to 100 s/mm2, fewer in
the range of 450 to 800 s/mm2, and a maximum value of 1,000 s/mm2 [103]. Table
9 presents a summary of results from published studies for normal liver parenchyma.
These studies used various fitting algorithms including asymptotic fitting [91, 92, 100,
101, 102, 105, 107, 108, 109, 110, 111, 112, 113], nonlinear least square fitting [114,
115, 116, 117, 118, 119], and Bayesian fitting [94, 114, 120, 121, 122]. This work
has selected least squares fitting with a Levenberg-Marquardt algorithm for fitting.
Multiple studies have also suggested that IVIM parameters may be improved using
denoising methods, including non-local means (NLM) filtering, local principal com-
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Median 1.09 70.6 22.40
Range 0.66-1.50 13.60-136.00 5.50-47.07
Mean 1.09 70.02 23.05
SD 0.17 31.01 8.48
CoV 0.16 0.44 0.37
Table 9. A summary of results reported in literature for PF, D, and D* using biexpo-
nential fitting.
6.2 Retrospective studies with clinical scans
This section describes a study based on retrospective analysis of consecutive
liver SBRT patients treated at our clinic who had pre-treatment and post-treatment
DW MRI scans available. Retrospective studies were investigated to determine if
the available data was sufficient to apply a simplified IVIM model and if ADC could
differentiate normal and diseased tissue, as well as pre- and post-treatment changes.
6.2.1 Images and data processing
The retrospective clinical data set included ten liver cancer patients who had
undergone SBRT and received DW MRI scans pre- and post-treatment. All patients
had b-values of 50, 400, and 800 s/mm2, T1w and T2w acquisitions, acquired during
respiratory triggering. The images were acquired on a 1.5T MRI (repetition time =
6347 ms, echo time = 79.0 ms, pixel size = 1.82x1.82 mm2, slice thickness = 6 mm,
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Fig. 29. Three DW images with b = 50, 400, and 800 s/mm2 acquired for a previously
treated patient. The top row shows pre-treatment and the bottom row shows
post-treatment images. The hyper-intense region near the posterior wall of
the liver shows the position of the tumor in these images.
number of sample averages = 4). An example of pre- and post-treatment DW images
can be seen in Figure 29.
Due to only three b-values being imaged in the clinical data, equations (2.32)
and (2.34) were used to calculate f and D. ADC values were calculated using b-value
images b = 50 and 800 s/mm2 and b = 50 and 400 s/mm2.
6.2.2 Results
The Wilcoxon Rank Sum Test was used to compare parameter values acquired
from ADC calculation and fitting of DW image values to the LeBihan model. There
was a statistically significant difference between healthy tissue pre- and post-treatment,
and between diseased tissue pre- and post-treatment for ADC (p = 0.0001, 0.003).
There was also a near significant difference between healthy and diseased tissue pre-
treatment for ADC (p = 0.081). This indicates that the parameters derived from
the LeBihan method were not sufficient to distinguish between healthy and diseased
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Tumor Pre. 0.62±0.32 0.31±0.30 3.12±5.10
Tumor Post. 0.65±0.60 0.34±0.41 4.10±7.16
Table 10. A summary of mean ± standard deviation for retrospectively sampled pa-
tients, with three b-value DWI images, and values calculated using LeBi-
han’s method.
6.2.3 Summary
The absence of statistically significant differences for IVIM parameters calculated
using LeBihan’s method for diseased and normal tissue in the liver suggests that this
method may not be sufficient for IVIM analysis. ADC was also not significantly
different between diseased and healthy tissue, indicating that ADC alone may not be
sufficient for distinguishing diseased tissue from healthy liver parenchyma. Further,
these images were acquired on a different imaging system, with a lower field strength,
and without breath hold, than the other images used for this work. The low field
strength could increase the amount of noise present in the image, degrading the
quality of the calculated IVIM parameters, and respiratory motion could cause further
reduction in quality. This section shows the utility of DWI for identifying treatment




This section describes the image acquisition, post-processing, analysis, and re-
sults for the volunteer cohort study performed in this work. The values obtained from
the volunteer cohort also provide a baseline value for healthy liver tissue to compare
with diseased livers from the patient cohort.
6.3.1 Images and data processing
The volunteer cohort data set included five volunteers imaged twice, with imaging
sessions separated by one week. Images were acquired under expiration breath hold,
with guidance from the RMM device developed in Chapter 4. Eight b-value images
were acquired, with b = (0, 20, 40, 80, 100, 300, 600, and 1000) s/mm2 (Repetition
time = 806.1 ms, echo time = 59.3 ms, field of view = 450 mm, slice thickness = 3
mm; matrix = 256 x 256).
Before IVIM analysis, images were processed using a custom MATLAB script.
DW images were registered for each slice, using a rigid 2D registration, based on
mutual information (MI). MI was chosen for the fitting metric because it is not
sensitive to extreme contrast changes between images, such as those seen in DW
images with low and high b-values. Second, a non-local means filter was applied for
denoising. Equation (2.33) was then used for the model, and PF, D, and D* values
were generated using a Levenberg-Marquardt algorithm. This generated quantitative
maps of all parameters, and ADC maps using b = 0 and 1000 s/mm2. ROIs were
drawn manually in a selection of slices throughout the liver. Poorly fitted data were
removed, using the 90th percentile normalized residual as the cutoff point. Texture
analysis was then performed for texture described in Chapter 3 using custom built
MATLAB code, in the same ROIs as those used for IVIM parameters.
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6.3.2 Results
The Wilcoxon Rank Sum Test was used to compare IVIM parameters acquired
during the initial and second imaging sessions. There was a statistically significant dif-
ference between ADC values for volunteers 1, 2, and 5 (p = 0.0007, 0.0009, <0.0001),
and between D values for volunteer 2 (p = 0.0447). No significant difference between
first and second imaging session values were found for D* or f in any of the five volun-
teers. The values for both scans of each volunteer are displayed in Table 11. Figure
30 shows box and whisker plots for IVIM parameters of one volunteer’s two imaging








V1A 0.95±0.72 0.85±0.30 53.41±31.41 28.24±12.43
V1B 1.06±0.59 0.89±0.26 60.57±34.76 31.28±11.41
V2A 0.76±0.62 0.76±0.19 61.91±31.05 23.67±12.08
V2B 0.90±0.41 0.88±0.22 63.51±30.76 27.11±12.49
V3A 1.33±0.68 0.96±0.29 53.42±33.42 32.06±13.22
V3B 1.17±0.59 0.96±0.29 52.65±32.46 33.75±11.74
V4A 1.18±0.77 0.94±0.29 46.15±33.71 25.91±11.43
V4B 1.39±0.63 1.01±0.30 48.53±30.98 23.24±12.77
V5A 1.17±0.66 0.90±0.18 61.89±21.64 19.27±8.84
V5B 1.39±0.56 0.94±0.31 70.08±38.26 23.28±11.48
Average 0.95±0.59 0.89±0.28 54.45±33.19 28.41±12.53
Table 11. A summary of mean ± standard deviation for all volunteer scans for PF,
D, and D* calculated in ROIs, with a total of 1200 voxels for each imaging
session.
73
Fig. 30. Box and whisker plot showing the median as the central lines, the 25th to 75th
percentiles within the box, and the whiskers extending to the most extreme
outlier, for one volunteer, with both first (A) and second (B) imaging sessions.
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The texture features for all volunteers in aggregate for b-value 0 images is shown
in Table 12. Texture features were extracted from the same ROIs used for IVIM
parameter assessment. These values provide a baseline of the statistical variations














Table 12. A summary of mean ± standard deviation for volunteer scans for first- and
second-order texture features calculated in ROIs of b0 images, with a total
of 1200 voxels for each imaging session.
6.3.3 Summary
The low reproducibility of IVIM parameters experienced in previous works is not
seen to a high degree in the volunteer study. It is encouraging that there was not a
statistically significant change in IVIM parameters between the first and second scan
for volunteers, especially in D* and f parameters, which are more susceptible to noise,
organ motion, and imaging parameters. However, relatively large standard deviations
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are apparent, and the variation in all parameters across all volunteers is large. This
variation may represent an impediment to comparing IVIM parameters across imaging
subjects. Separation of parameters by demographics may be necessary to generate
a better picture of healthy liver IVIM parameter values. These differences may also
be compounded by alcohol or tobacco use, diet, and iron content of the blood. This
section has shown the feasibility of IVIM in the liver, with breath hold guided by
visual biofeedback.
6.4 Patient cohort
6.4.1 Images and data processing
The patient cohort included two patients, out of five recruited for this study
between November 2017 and February 2019. Two patients were ineligible for imaging
on a 3T MRI due to the presence of metallic objects within their bodies, and the third
was unable to complete the imaging study due to a deterioration in health, leading
to in-patient status. Patients were imaged three times, once a week pre-treatment,
and twice post-treatment, within one week, and a month after the completion of
treatment delivery. Image acquisition parameters are described in Table 13. Each
imaging session required 30 to 60 minutes to complete, and 20 to 30 breath holds.
Scan length depended on the size of the liver, with larger livers requiring more slices
for complete coverage, the patient's ability to perform breath hold, and their recovery
time after breath hold.
Image post-processing was performed in the same way as described for the vol-
unteer cohort. Image registration and denoising were performed, prior to non-linear
least squares fitting of all b-values to the biexponential IVIM model. After fitting










TR (ms) 10 1338.8 806.1 806.1
TE (ms) 2.3 80.0 59.3 59.3
No. of b-values NA NA 5* 4+
NSA 1 1 2 2
Matrix 268x200 376x319 256x256 256x256
Pixel size
(mm2)
1x1 0.94x0.94 1.76x1.76 1.76x1.76
Slice thickness
(mm)
5 3 3 3
No. of BH FB 4 10 10
Table 13. A summary of MRI sequence parameters used for in vivo liver studies of
SBRT patients. NSA: Number of signal averages; *5 b-values: 0, 20, 40, 80,
100 s/mm2; +4 b-values: 0, 300, 600, 1000 s/mm2; BH: Breath holds; FB:
Free breathing.
accumulated dose from radiotherapy treatment.
6.4.2 Dose Information
Radiotherapy planning included simulation (MRI and 4DCT) to evaluate liver
motion and screen patients for eligibility for SBRT, with repeat inhalation breath
hold using an Active Breathing Coordinator (Elekta). All treatment planning was
performed using the Pinnacle Treatment Planning System on CT imaging with pa-
tients treated in inhalation breath hold with a uniform planning target volume (PTV)
margin of 5mm. The prescription dose (DRx), was 50 Gy, in 5 fractions, delivered
over two weeks. RT was delivered under daily image guidance on a Varian Truebeam.
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Planning CT and DW images were fused by a physician in Radiation Oncology, and
dose contours were transferred to the DW images. ROIs were generated for tumor,
normal tissue, and at isodose contours of 50 to 80% (I25−40) of DRx and greater than
95% (I47.5) of DRx
6.4.3 Results
IVIM parameters and texture features were calculated for three ROIs at each
imaging time point. IVIM values, as mean ± standard deviation are gathered in
Table 14 for each ROI and time point. Tables 15-17 show the IVIM parameter values
separated by patient. When tabulated by patient, it is apparent that the changes
differed between the two patients, with patient 1 having a decrease in ADC and D,
while patient 2 displayed an increase in ADC and D between pre-treatment and post-
treatment 1. The tumor volume of patient 2 also experienced a large increase in D*
and f between pre-treatment and post-treatment 1 imaging sessions. Color maps for
both patients are shown in Figures 31 and 32; the field of view is identical in these
image sets, the apparent size difference is due to the difference in tumor location. In
patient 1, the lesion is near the center of liver mass, while the tumor is located at the
inferior tail of the liver for patient 2.
Comparison of ROI values of the tumor volume showed a significant difference
in ADC, D, and f between pre- and post-1 (p = <0.0001, <0.0001, <0.0001), as well
as for ADC and D for pre- and post-2 (p = <0.0001, <0.0001), but not for D* and
f (p = 0.059, 0.102). Within the dose regions, significant changes were observed for
the I25−40 pre-treatment and post-1 for ADC (p <0.0001), and pre-treatment and
post-2 for ADC, D, and f (p = <0.0001, <0.0001, <0.0001). For the dose region I47.5,
pre-treatment and post-1 values were significantly different for ADC, D, D*, and f (p












Pre 1.35±0.49 1.04±0.54 61.37±59.50 34.73±16.31
Post-1 1.30±0.55 1.03±0.54 62.95±59.67 33.47±16.48
Post-2 0.79±0.55 0.66±0.42 62.79±60.92 23.40±18.36
I47.5
Pre 1.49±0.49 1.20±0.59 60.93±60.14 33.70±17.54
Post-1 1.49±0.57 1.20±0.60 67.95±59.66 36.1±15.82
Post-2 0.86±0.54 0.74±0.45 65.96±61.32 23.91±18.49
Tumor
Pre 1.57±0.50 1.34±0.54 52.47±58.17 27.70±18.41
Post-1 1.55±0.65 1.3±0.54 70.18±55.06 34.99±14.39
Post-2 0.98±0.56 0.83±0.49 63.73±60.31 24.69±19.41
Table 14. Mean ± standard deviation for patient scans for PF, D, and D* calculated
in ROIs, with a total of 1000 voxels for each ROI. Post-1 indicates the first
post-treatment scan, post-2 indicates the second post-treatment scan.
= <0.0001, 0.0002, 0.037, <0.0001).
Texture feature values for the previously described ROIs are shown in Table
18, for b0 DW images. At high b-values, the standard deviation of texture features
increased substantially due to the low SNR inherent of these DW images. Texture fea-
tures showed statistically significant differences between healthy liver and diseased tis-
sue, including standard deviation, correlation, energy, and homogeneity (p = 0.0001,
0.007, 0.0001, <0.0001). Correlation between texture features and IVIM parameters
was investigated using the Pearson Correlation Coefficient. However, there was no
consistently strong correlation between IVIM parameters and any of the measured
texture features across imaging sessions for diseased tissue, patient liver, or volunteer
liver.
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Fig. 31. The top row displays images from a liver cancer patient pre-treatment, the
center row from post-1 acquisition, and the bottom row from the post-2 ac-
quisition, with the slice selected from approximately the same location within
the liver. The red circle and arrow indicate the tumor position.
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Fig. 32. The top row displays images from a liver cancer patient pre-treatment, the
center row from post-1 acquisition, and the bottom row from the post-2 ac-
quisition, with the slice selected from approximately the same location within
the liver. The red circle and arrow indicate the tumor position.
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Fig. 33. Pre-treatment T1w (A) and T2w (B) images, and ADC (C), D (D), D* (E),
and f (F) parameter maps for patient 1, with registered isodose lines shown
for 47.5 Gy (red), 40 Gy (blue), and 25 Gy (purple).
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Fig. 34. Post-treatment 1 T1w (A) and T2w (B) images, and ADC (C), D (D), D* (E),
and f (F) parameter maps for patient 1, with registered isodose lines shown
for 47.5 Gy (red), 40 Gy (blue), and 25 Gy (purple).
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Fig. 35. Post-treatment 2 T1w (A) and T2w (B) images, and ADC (C), D (D), D* (E),
and f (F) parameter maps for patient 1, with registered isodose lines shown



























































Table 15. Mean ± standard deviation for pre-treatment patient scans for PF, D, and
D* calculated in ROIs, with a total of 1000 voxels for each ROI.
Texture features were significantly different between healthy tissue and diseased
tissue pre-treatment, for entropy, standard deviation, correlation, energy, and ho-
mogeneity (p = 0.0001, 0.0001, 0.007, 0.0001, and <0.0001). When comparing pre-
and post-treatment disease, contrast, correlation, energy, and homogeneity all showed
statistically significant differences (p = <0.0001, <0.0001, 0.0001, 0.0001).
6.5 Summary
These results indicate that IVIM is sensitive to diffusion and perfusion changes
in the liver, which occur due to dose deposition during SBRT. Further, this work
found significant changes in texture features in the liver and tumor pre- and post-
SBRT. This demonstrates the utility of IVIM and texture analysis for observing post-



























































Table 16. Mean ± standard deviation for the first post-treatment patient scans for
PF, D, and D* calculated in ROIs, with a total of 1000 voxels for each ROI.
dose due to imperfect dose conformity.
In this study, values of D* and f had standard deviations greater than half their
mean. This indicates that their values have large variations, especially within the
inhomogeneous tumor volumes. Further analysis showed that ADC had statistically
significant differences between more tissue types and treatment time points than
IVIM-derived parameters. Across all parameters, ADC had the greatest ability to
distinguish analysis groups, while D* had the worst performance. These findings are
contrary to what is expected from IVIM theory, which allows for molecular diffusion
and blood perfusion to be distinguished, compared to ADC measurement where these
two parameters are combined. Previous studies have attempted to use IVIM as a
diagnostic tool for liver lesion characterization. Yoon et al. and Penner et al. found



























































Table 17. Mean ± standard deviation for the second post-treatment patient scans for
PF, D, and D* calculated in ROIs, with a total of 1000 voxels for each ROI.
liver lesions[127, 128]. In contrast, Colagrande et al. and Zhu et al. found that ADC
and D values had the better chance of characterizing liver lesions [129, 115]. This work
found that ADC and D values had a greater probability for correctly characterizing
liver lesions, while f did not have a significant difference between tumor and healthy
tissue. These discrepancies highlight the difficulty of producing repeatable IVIM
parameter maps and validation of results across centers.
As mentioned previously, multiple factors can influence the calculated values, de-
pending on factors related to anatomy, imaging, and analysis methodology. A study
by Fan et al. showed that HCC tumor size had a major impact on tissue structure,
with tumors larger than 3cm in diameter being poorly differentiated, and having more
necrosis and liquefaction of tissue than those smaller than 3cm [130]. Fan et al. also
reported that highly differentiated tumors receive their blood supply from multiple
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Table 18. Mean ± standard deviation for texture features calculated for the specified
ROIs.
sources, while less differentiated tumors receive blood mainly from the hepatic artery.
In addition to this, Yin et al. presented that location has a significant effect on the
blood supply [131]. Classification by blood supply location may reduce the fluctuation
of D* and f values. The choice of b-values can significantly impact IVIM parame-
ters, with multiple studies performed attempting to determine the optimal b-value
distribution which would lead to reduced errors in IVIM parameter calculation [72,
73, 91, 103, 104, 105, 121, 132, 133, 134]. Optimization of acquisition protocol and
post-processing algorithms may also minimize errors in parameter estimation, and
are required for a robust clinical application [74, 99, 112, 135, 136].
88
CHAPTER 7
DEVELOPMENT OF AN IVIM AND TEXTURE ANALYSIS
TOOLBOX
This Chapter describes a GUI, controlling a set of scripts and functions, developed in
MATLAB for streamlining the calculation of IVIM parameters and texture features.
7.1 Toolbox program
The toolbox program developed for this work incorporates multiple modules, and
is compatible with input data of multiple types. A screen capture of the GUI used
for this program is shown in Figure 36. The first set of radial buttons allows the
user to select the number of folders that contain the DW image set that is set to be
analyzed, and will prompt the user to select the enclosing folder(s) when executed.
The single folder option will read in all images, and their associated b-values and
slice position. Slices are then sorted by b-value and slice position into a 4D matrix.
The two folder option reads image files in from two enclosing folders; this was added
because IVIM image sets were acquired in two separate protocols in this work. The
images are again sorted by b-value and slice location, and duplicate b-value images
for the same slice position are averaged. The resultant 4D matrix is then passed to
the next selected option. Users have the option to define their calculation volume,
using either ”No ROI”, ”Load ROI from .mat file” and ”Draw custom ROI.” The ”No
ROI” option will perform the selected calculations on the entire image volume, and
may require a significant amount of computation time. If ”Load ROI from .mat file”
is selected, the program prompts the user to select a binary .mat file of the same size
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as the image volume to constrain the calculation volume. The ”Draw custom ROI”
option will prompt the user to draw custom ROIs on each slice of the image volume
using an ROI tool in MATLAB. The third set of radial buttons allows for image
denoising to be selected. The program removes intensity outliers greater than 10
times the mean tissue value, and uses a non-local means filtering algorithm described
by Buades et al [137]. The ”Perform Texture Analysis” check box selects for texture
analysis values and maps to be calculated within the desired calculation volume, and
includes the texture features described in Chapter 3. The ”Perform ADC calculation”
check box selects for calculation of ADC in the designated calculation volume. ADC
calculation uses equation (2.31), and selects the minimum and maximum b-value
images. The fourth radial button selection, ”Perform image registration” designates
if registration should be performed. The program utilizes a mutual information based
rigid registration algorithm. Mutual information was chosen for its performance with
DW images, where contrast varies significantly between moving and fixed images,
but the structure remains constant. The images associated with the lowest b-value
are used as the fixed images, and the remaining b-value images at each slice location
are designated as the moving images. The final radial button box allows the user to
select what model to use for calculation of IVIM parameters. The mono-exponential
method uses Equation (2.34), requires at least two b-values, and does not provide D*
maps. The LeBihan method uses Equation (2.32), requires at least three b-values,
and does not provide D* maps. The bi-exponential method uses Equation (2.33),
requires at least three b-values, and provides D, D*, and f values. However, the bi-
exponential method is significantly more computationally expensive than the other
options. Once the operator has selected their desired options, they click ”Done” and
will be prompted to select their desired input folders and files before the program
will continue. The toolbox was tested with three different data sets, of different
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Fig. 36. A screen shot of the GUI developed for this work. Radial buttons and check
boxes can be selected in each category to select data input type and desired
output.
image sizes, number of b-values, and anatomical sites, which will be discussed in the
following sections.
7.2 Testing with brain data
The first data set used for testing with the toolbox was a 21 b-value brain data
set from the diffusion imaging in Python (DIPY) project by Garyfallidis et al [138].
An example slice with all b-values is shown in Figure 37, with b-values of: 0, 10, 20,
30, 40, 60, 80, 100, 120, 140, 160, 180, 200, 300, 400, 500, 600, 700, 800, 900, and
1000 s/mm2. Data was initially in DICOM format.
To test the b-value and slice location sorting ability of the program, DICOM files
were opened at random from the folder by selecting a random number between 1 and
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Fig. 37. A montage of all b-value images from a single slice in brain. The data set is
from the DIPY project by Garyfallidis et al [138].
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the total number of image files. Images were properly sorted into the final 4D image
volume.
The image denoising ability was then tested by adding noise at six different levels,
corresponding to SNRdB of 30, 25, 20, 15, 10, and 5, where an SNRdB of 30 would
correspond to excellent image quality and 20 corresponds to acceptable image quality.
The original SNRdB of the images ranged from 34.17 to 31.14 dB in the b-value =





An example slice with added noise at each level is shown in Figure 38. These
noisier images resulted in a poor fitting of data compared to the original image. The
IVIM biexponential fit for original and added noise images is shown in Figure 39
After the addition of noise, IVIM parameters were calculated at hand drawn
ROIs in the white matter of the brain. Increased noise resulted in a larger standard
deviation value, and a change in the mean parameter values. When denoising was
applied before IVIM analysis, the standard deviations decreased across all added
noise levels, and for the values calculated for the original image. The values for IVIM
parameters and their standard deviations with and without denoising are shown in
Table 19.
This demonstrates that the denoising used in this project is able to remove noise
from images without altering the resulting parameter values from their original val-
ues. The preservation of original, or true, parameter value with denoising is highly
important due to the sensitivity of IVIM values to noise and voxel intensity fluctua-
tions.
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Fig. 38. A slice of the brain from the DIPY image set with added noise at 30, 25, 20
dB in the first row, and 15, 10, and 5dB in the second row. The original image
had a noise level of 32dB
7.3 Testing with liver data
The toolbox was then tested with volunteer and patient data collected by this
study. LeBihan’s method and the biexponential model were applied to the volunteer
liver, and to patient liver outside of the treatment area, and within the tumor volume.
Parameter values are displayed in Table 20, and were calculated for 1200 voxels from
ROIs placed on multiple slices.
The parameter calculation modules performed the correct calculations on the
desired ROIs, which were placed in the same location across multiple slices for each
of the 3 ROIs used, with 400 voxels within each ROI, for each volume investigated. It
is noted that the biexponential model and LeBihan’s method produce similar values
for D, but have significantly different values for perfusion fraction. This is due to the
direct fitting of the perfusion fraction with the biexponential model, while LeBihan’s
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Fig. 39. A plot of relative signal intensity versus b-value, with a biexponential fit line
of IVIM parameters for an ROI of the original image, and of an ROI with































































Table 19. Mean ± standard deviation of IVIM parameters for the DIPY brain data set,
calculated after noise was added, and after denoising to compare the results
of denoising on the parameter values. The original noise values ranged from
34.17 dB to 31.14 dB in the 0 s/mm2 and 1000 s/mm2 images.
method attempts to do this calculation without input data which gives information
on the perfusion region of the signal decay curve.
7.4 Summary
For application of IVIM analysis in the clinical setting, the ability to perform
parameter calculation must be made accessible, reliable, and be presented in a straight
forward manner. The developed toolbox generates a simple interface for selecting
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1.04 ± 0.30 1.09 ± 0.39 1.77 ± 1.92 1.28 ± 0.47
D Biexp.
(x10−3mm2/s)
0.71 ± 0.14 0.75 ± 0.27 0.66 ± 0.08 0.92 ± 0.37
D LeBihan
(x10−3mm2/s)






























20.02 ± 3.96 18.49 ±
12.91
Table 20. Mean ± standard deviation for IVIM parameters, calculated using the bi-
exponential and LeBihan methods, for healthy volunteer liver, patient liver
outside of the treatment field, and liver tumor pre- and post-treatment.
image sets, drawing ROIs, and selecting what calculations to perform. The toolbox
provides output data including the post-processed image volume with the selected
post-processing methods applied, ADC and IVIM parameter maps for the method
requested by the user, and texture feature maps and values for some of the most
popular texture features in MRTA. This toolbox may also be used as a research tool
for collection and analysis of data acquired in a larger study. The inclusion of less
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accurate but also less computationally expensive models, could allow for an initial




The final Chapter of this dissertation gives a summary, discussion of some of the
limitations of this work, possible improvements leading to future work, and a general
conclusion to this body of work.
8.1 Summary
The work presented in this dissertation has demonstrated the feasibility of im-
plementing an IVIM imaging protocol for use with SBRT of the liver. This research
sought to accomplish three specific aims: The development, production, and evalua-
tion of an MR safe respiratory motion management device with patient biofeedback,
the development and implementation of an anatomical and functional imaging pro-
tocol, focusing on DWI and IVIM, for use with patients undergoing SBRT of the
liver, and finally, the use of the developed motion management device and imaging
protocol to develop a workflow for IVIM analysis and investigation of liver tumors
treated with SBRT.
Fulfillment of the first specific aim was completed by design and production of
the motion management device described in Chapter 4. Using CINE acquisition, belt
signal was correlated with internal motion and shown to have small deviations from
true internal motion. The belt was specifically designed to be usable across the entire
radiotherapy workflow and is highly radiotransparent to kV and MV photons. Once
testing was completed, and the motion management device was deemed to be fully-
functioning, the second specific aim was undertaken. This aim was completed utilizing
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imaging resources available at the CARI institute, and the device developed in aim
1. With the establishment of an imaging protocol with healthy volunteers, patients
were recruited and imaged under the protocol. With patient data, this work moved to
aim 3, and developing a workflow for IVIM analysis. The developed workflow allowed
for image post-processing and analysis with minimal input from the operator using
the custom designed GUI. With IVIM and texture analysis parameters acquired from
the workflow, statistically significant differences in tissue were observed both between
healthy and diseased tissue, and between pre-treatment and post-treatment volumes
at various dose levels. This work shows the ability for IVIM to be used in the liver,
and as an indicator of anatomical change due to radiotherapy, without the need to
significantly impact the clinical workflow.
8.2 Limitations
This work is subject to several limitations. Some of these limitations are detailed
in this section.
8.2.1 Limited patient number
The major limitation to this study is the limited patient cohort size. A total of
five patients were recruited to the study, however only two completed the imaging
protocol due to various reasons described in Chapter 6. Further validation with a
larger data set in a clinical setting must be performed to verify statistical significance
and investigate changes with different histopathologies, liver locations, and demo-
graphics. However, initial results from this cohort were promising and suggest that
discrimination between tissue types and dose deposited is possible.
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8.2.2 Volunteers and patients
A second limitation to this study is the demographic difference between the
volunteer cohort, and the difference between the two patients. Diseases and charac-
teristics of the liver are highly dependent on race, age, country, lifestyle, and liver
function. The volunteer cohort in this study was much younger on average than the
patients recruited from the radiation oncology clinic. This may skew data based on
age, rather than true differences between liver IVIM parameters and texture features.
Further, the two patients were different in many ways, including gender, race, age,
and presence of liver cirrhosis. Liver cirrhosis may have a serious impact on values,
especially those in the low dose region of the liver. The two patients also had pri-
mary versus metastatic lesions, and different responses to treatment. Patient 1 had a
primary liver cancer and responded well to treatment, while patient 2 had metastatic
HCC, and was showing limited response to treatment at the latest follow-up imaging
session.
8.3 Future work
With the development of a robust toolbox for image evaluation, future efforts
will be focused on expanding the patient cohort size and investigating parameter
dependence on a variety of variables.
A vital component for continuation of work in this field is to accrue a larger
patient data set. Currently, with only two clinical patient data sets the applicability
of findings in this work to the clinical setting is limited. While a larger clinical study
is needed, it represents another area of future work, for the study of IVIM parameter
consistency between magnetic field strength, respiratory motion management styles,
b-value selection, and even individual MRI machines. Due to the reliance of IVIM
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parameters on signal decay, magnetic field inhomogeneities and strength will impact
the computed values, and this change must be quantified or a method of correction
needs to be produced for multi-center trials. In addition to parameter reproducibility,
calculation time and operator input time can be significant factors in the application of
IVIM to the clinical environment. Currently, liver segmentation must be performed by
hand to create calculation ROIs. This is a time consuming task, even when contours
do not need to be highly detailed. The development of a liver auto-segmentation tool
would be valuable to the deployment of the protocol and workflow developed in this
work to the clinic.
8.4 General conclusions
This dissertation investigated the development of an MR safe respiratory motion
management device and explored IVIM and texture analysis parameters in the liver,
including for patients receiving SBRT for liver cancer. This research was driven by
three specific aims.
The first, to develop an MR safe respiratory motion management device, was
necessary due to the lack of a device which is both MR compatible and can be used
in the radiotherapy environment. A device was developed, constructed, and tested
during MR acquisition to evaluate its impact on image quality, ease of use, and re-
duction of respiratory motion of the liver. The evaluation with an investigator cohort
showed significantly reduced motion with CINE imaging, and both volunteer and pa-
tient cohorts were able to successfully learn proper use of the device and use it during
image acquisition without significant time required for training. This novel approach
to respiratory motion management with biofeedback allowed for implementing guided
breath holds during image acquisition required for the next aim.
The second aim required the development of an MRI protocol, combining anatom-
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ical and DWI sequences for IVIM analysis. Multiple DWI acquisitions were evaluated
using different sets of b-values, motion management techniques, and signal averages.
It was determined that exhalation breath hold was required during image acquisi-
tion to reduce motion, and eight b-values provided sufficient data sampling while not
requiring an excessive number of breath holds or scan time. Consistent imaging pa-
rameters for DWI acquisition to be used with IVIM analysis were used for cohorts
of volunteers and liver cancer patients, providing the required raw data for the third
aim.
The third aim included the development of an IVIM analysis workflow, incor-
porating image post-processing methods to improve IVIM parameter quality, and
applying the workflow to healthy volunteers and liver cancer patients pre- and post-
treatment with SBRT. This was extended to include texture analysis and a compari-
son of values based on isodose lines. Significant differences were found between pre-
and post-treatment tumors for IVIM parameters and texture features. It was also
found that significant changes in IVIM parameters may occur outside of the treatment
volume in the lower dose region over time. The data collected in this study repre-
sents the first attempt to quantify IVIM and texture analysis parameter changes due
to radiotherapy for liver cancer. The results, while representing a small cohort, are
promising for the use of IVIM and texture analysis in assessing treatment response
to SBRT, and possibly as a pre-treatment indicator for efficacy of radiotherapy for
individuals. As stated above, further investigation is required utilizing a larger cohort
before the implementation of IVIM as an imaging biomarker, and the workflow and
toolbox developed in this dissertation provide a means for expansion of this study.
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1 BACKGROUND 
1.1 Overview  
Approximately 40,000 liver tumors are diagnosed each year in the United States (1) with 
only a small fraction of those eligible for curative resection or transplant. Alternative local 
therapies, such as stereotactic body radiotherapy (SBRT), are therefore a huge potential 
benefit due to excellent rates of local control and tolerability. SBRT delivers a large 
radiation dose to a highly localized target in a relatively small number of treatments, 
however, risk to normal tissue is increased. This is compounded by the current image  
co-registration performed with magnetic resonance imaging (MRI) and respiratory motion-
managed computer-aided tomography (CT), which introduces large errors in the images. 
Although registration software has made great advances, the CT and MRI images are 
acquired using different methods of respiratory motion management. Currently, there is no  
MRI-compatible patient interactive breathing motion management system available, unlike 
for CT. Without this hardware, MRI images are time averaged over the course of imaging, 
while the CT images are gated to a specific phase of the respiratory cycle. Increased error 
leads to expanded margins around the target volume, which includes a greater volume of 
normal tissue. If the margins could be reduced by using only 4D MRI, then normal tissue 
sparing could be increased and dose escalation could be implemented to improve the 
probability of local tumor control.  
1.2 Respiratory Motion Management 
Patients with primary or metastatic cancer in the liver who are referred for SBRT, where 
focused high radiation dose delivery is made over a course of few treatments, typically 
have a diagnostic MR imaging scan. In the treatment planning stage, a four-dimensional 
(4D) CT scan is performed (2) or a breath-hold CT scan is conducted, if applicable (3-5), 
because tumors in the thorax can move significantly, up to a 5 cm range, during respiration 
(2, 6). Image co-registration is then performed between the MRI and respiratory motion-
managed CT in the treatment position. This image fusion is often subject to significant 
uncertainties caused mainly by both inadequate breathing motion management during MR 
imaging procedures and inconsistent motion management between different imaging 
procedures (ie, MR scan and CT scan). Because of such uncertainties, it is common 
practice to generously encompass surrounding normal liver tissue in the radiation target 
volume to ensure adequate dose delivery to tumor cells. This practice can sometimes 
become a cause of surrounding normal tissue toxicity (2). 
In current radiation oncology clinical practice, motion related to normal breathing is 
typically assessed with a single 4D CT imaging set for treatment planning. 4D CT scans 
use a reference respiratory cycle to sort images in each phase of the breathing motion. In 
reality, however, tumor motion is not the same from one cycle to another. Therefore, tumor 
trajectory should be taken into account as a probability density function rather than a 
simple deterministic function in sorting images for 4D motion. In order to accurately target 
the tumor at all times, the entire range of tumor motion must be captured and such  
cycle-to-cycle variation must be included in tumor motion management. 
Accomplishing such a task requires multiple acquisitions of high quality images, which is 
not applicable to conventional 4D CT simulation due to excessive imaging radiation doses 
and inferior soft tissue contrast. Contrary to CT, MRI is free from ionizing radiation risk and 
provides superior soft tissue characteristics. MRI is generally believed to be a de facto 
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standard in soft tissue imaging. Unfortunately, however, 4D MR imaging has not been 
implemented in current clinical practice because existing non-optimized procedures 
degrade image quality and lengthen scan time by approximately 30 minutes/4D MR scan 
compared to approximately 5 minutes/4D CT scan. In addition, there has been no clear 
and concerted effort made in establishing an optimal and practical procedure for MR 
imaging without degrading image quality. 
We have recently demonstrated that patient interactive respiratory motion management 
can be utilized in medical imaging techniques including MRI and CT (7-11). The feasibility 
of infrared camera-based respiratory motion management using the AV-aided patient 
interactive system was performed with healthy participants by our team using multiple 3T 
MRI systems (Siemens and GE MRI) and a CT system (GE CT) as shown in Figure 1. Our 
studies demonstrated a reduction of motion artifacts, improvement of organ motion 
reproducibility in MRI, a reduction of residual motion within the gating window, and an 
improvement of scan efficiency in CT using the AV-aided patient interactive system in 
conjunction with the infrared camera-external position management system. 
 
 
Figure 1. Infrared Camera-Based Respiratory Motion Management 
Infrared camera-based respiratory motion management for healthy human participants using the AV-aided 
patient interactive system with (a) 3T GE MRI (b) 3T Siemens MRI and (c) GE CT systems. The system 
utilized an external marker position detected by an infrared camera temporarily installed at the MRI/CT room 
to monitor external respiratory motion and an in-house made AV-aided interactive system to guide the 
human participants for regular respiratory motion. 
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In summary, respiratory motion management provides superior image quality and accurate 
characterization compared to conventional free-breathing imaging techniques. Therefore, 
an MR-compatible patient interactive breathing motion management system will be 
developed in this pilot study (5, 12). Upon successful completion of this study, current 
practice will be improved with adequate and consistent respiratory motion management. 
This will facilitate accurate co-registration of MRI with CT images and improved 
target/organs delineation. Improved delineation will not only allow for improved targeting 
and increased subsequent local tumor control, but also decrease the dose to the normal 
surrounding tissues and risk of complications such as radiation-induced liver disease. 
1.3 Optimal 4D Magnetic Resonance Imaging Acquisition Procedures 
It is well known that soft tissue images of MRI are in higher quality than those of CT. 
Several studies, in fact, have demonstrated that MRI-based treatment planning is superior 
to CT-based treatment planning for liver metastases as the target is often inadequately 
covered with CT imaging alone, which can lead to decreased local control (13, 14). 
The feasibility of real-time position management (RPM)-based retrospective 4D MR 
measurements with healthy human participants was tested on a 3T GE MRI with/without 
AV-aided patient interactive guidance by our team (Figure 2). Multiple coronal-plane 2D 
MR images were measured for a designated time (< 10 minutes) and 4D MR images were 
reconstructed using a conventional phase-based reconstruction method. Sagittal and axial-
plane images were reformed from the coronal-plane images to evaluate image quality and 
process compliance. As shown in (b) and (c), irregular respiratory motion affected image 
quality on sagittal and axial-plane images (dark stripes on the images) with free breathing. 
In contrast, the RPM-based 4D MR measurement with AV-aided patient interactive 
guidance regulated respiratory motion, increasing image quality and process compliance in 





Figure 2. RPM-based 4D MRI of a Healthy Volunteer 
RPM-based 4D MRI of a healthy volunteer with free breathing as presented in (a), (b), and (c) and 
with AV-aided interactive motion management system as shown in (d), (e), and (f): Multiple coronal-
plane 2D MR images were measured for a designated time and 4D MR images were reconstructed 
using the conventional phase-based reconstruction method. Sagittal and axial-plane images were 
reformed from the coronal-plane images. The blue cross lines in (a) and (d) indicate the reformed 
image planes. The red arrows in (b) and (c) indicate the missing data from the coronal plane.  
 
However, the preliminary results have not been optimized, so image quality and acquisition 
time can be further improved through procedure optimization including pulse sequence 
selection, repetition time (TR), echo time (TE), acquisition mode, and reconstruction 
technique. Studies will be performed to achieve optimal 4D MR configurations with the  
AV-aided patient interactive motion management system described in Section 6.1. Upon 
successful completion of this pilot study, the current practice with 4D CT scan for tumor 
motion evaluation can be changed to 4D MRI scan-based enabling more precise tumor 
identification. This will facilitate more accurate and consistent target delineation, which 
would ultimately translate into better local control and less treatment toxicity. 
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1.4 Purpose-Oriented Sampling Approach for 4D Magnetic Resonance Imaging 
Tumor motion is not the same from one breathing cycle to another (2, 6). In order to 
irradiate the tumor at all times, the entire range of tumor motion including cycle-to-cycle 
variation must be included in radiotherapy, which requires a large number of 4D imaging 
scans to extract reliable statistical behavior of tumor motion. However, conventional 4D CT 
simulation is not applicable for this purpose due to excessive imaging radiation doses and 
inferior imaging quality. Obviously, MRI, having no associated radiation dose, has great 
potential for this purpose. However, even though there is a huge benefit in using MRI, a 
conventional single 4D MRI acquisition would take about 30 minutes, so it is not 
appropriate for multiple acquisitions of images under current practice. 
An illustration of 2D tumor motion studied by our team is shown in Figure 3. In order to 
irradiate the tumor at all times, the entire range of tumor motion must be utilized and such 
cycle-to-cycle variation must be included in tumor motion management. 
 
Figure 3. Distribution of Tumor Motion and Outlier Motion for Patients with Lung Cancer 
The color bar scale indicates the ratio of the distribution of tumor motion. 
Upon completion of the breathing motion management system, we will further develop 4D 
MR imaging strategies to take cycle-to-cycle variation into account for target definition. To 
achieve this goal, we will use a purpose-oriented sampling approach (PoSA) which 
provides statistical information of tumor motion over each breathing cycle. The developed 
4D MRI simulation should be fast enough to acquire multi-respiratory cycles of the tumor 
motion (< 5 minutes), enabling the use of 4D MRI for the establishment of a statistical 
model of tumor motion under a reasonably acceptable time frame in the clinic. Specifically, 
we will develop a PoSA for confidence-weighted target definition based on a sectional-
view-aided pseudo-4D MRI (SAP-4D MRI).  
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1.5 Diffusion Tensor Imaging and Magnetic Resonance Elastography 
An optimized set of diffusion tensor imaging (DTI) and magnetic resonance elastography 
(MRE) acquisition parameters for application to liver SBRT is not currently available, but is 
proposed in this study. Once these parameters have been determined they may be 
evaluated against the conventional MR-based assessment tools for tissue characterization. 
1.5.1 Diffusion Tensor Imaging 
Diffusion-weighted imaging (DWI) MRI of diseased livers has been extensively used 
in clinical practice because it offers noninvasive indirect assessment of 
microstructure and microcirculation using microscopic diffusion of water molecules. 
For example, ADC has been used as a practical MR parameter to identify liver 
tumors , fibrosis, and inflammation (15). Furthermore, DWI has been included in a 
radiotherapy assessment MRI protocol in addition to conventional MRI techniques 
(16). ADC from DWI, however, is insensitive to the characteristics of diffusion in 
anisotropic environments, and diffusion in heterogeneous tumors is not well 
identified. Therefore, DTI with additional diffusion gradients (DWI: 3 directions and 
DTI: 6 or more directions) has been introduced to obtain more precise ADC 
calculation and information on anisotropic diffusions and orientations. DTI requires 
long scan time and can be adversely affected by motion which is why the utilization 
of DTI has been limited mainly to brain imaging where patient motion is minimal. 
Once the motion management technique is established, we believe DTI can be 
applied to liver regions. Before practical utilization of DTI on liver regions, however, 
DTI acquisition procedures must be optimized with scan parameters, scan time, the 
number of diffusion gradient directions, and image quality. 
1.5.2 Magnetic Resonance Elastography 
Another useful MR technique for liver disease is MRE. MRE is an emerging clinical 
technique to assess chronic liver diseases because it offers noninvasive 
assessment of mechanical properties of tissue such as tissue stiffness 
(elastograms) (17, 18). Because stiffness of a diseased liver increases with the 
development of fibrosis, MRE can be used in clinical practice to assess liver fibrosis 
and cirrhosis instead of using a needle biopsy. It can be a reliable and noninvasive 
tool for assessing hepatic fibrosis. In addition, several studies found that MRE can 
be used to characterize hepatic tumors because the stiffness of malignant liver 
tumors is considerably different than that of benign tumors. MRE, a highly advanced 
technology, is available at VCU to support the MRE protocol in clinical research. 
MRE is obtained in multiple sessions, thus, parameter optimization of MRE with 
consistent motion management is also needed before its practical utilization for liver 
regions. 
In this pilot study, the optimal DTI and MRE acquisition procedures will be first provided for 
liver SBRT in terms of MR pulse sequence parameters, image analysis, and assessment 
tools such as diffusivity maps and elastograms. In the evaluation, the proposed 
assessment tools from DTI and MRE will be compared with conventional MR-based 
assessment tools on tissue characterization. Upon successful completion of this pilot 
study, we will have novel tools to quantitatively assess liver tumors, thus providing 
clinicians with the ability to functionally distinguish between healthy and tumor tissues. 
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1.6 Proposed MR Procedures 
The proposed MR imaging procedures combined with the AV-aided patient interactive 
system is illustrated schematically in Figure 4. 
 
Figure 4. Schematic of Respiratory Motion Management System-based MRI Procedures 
(a) Current 3D MRI procedures; (b) Proposed MRI procedures combined with AV-aided 
patient interactive guidance with MR compatibility 
1.7 Known and Potential Risks and Benefits 
1.7.1 Risks 
It is possible that participants in the MRI phases of the study may experience 
claustrophobia-related anxiety. There are no other anticipated risks associated with 
the strategies planned in this feasibility study.  
1.7.2 Benefits 
Upon successful completion of this pilot study, the following will be established: 
1) an audiovisual-aided patient interactive respiratory motion management system 
for imaging and radiation treatment; 2) optimized 4D MRI procedures under 
consistent breathing; and 3) optimized DTI and MRE procedures under consistent 
breath-hold for radiotherapy planning. The potential benefits include:   
• Reduction in tumor motion variation among the various medical procedures 
using the proposed patient interactive respiratory motion management system 
• Image artifact reduction 
• More accurate and consistent tumor localization with consistent breathing 
control  
• Precise delineation of tumors and normal tissues in radiotherapy 
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2 OBJECTIVES 
2.1 Primary Objectives 
2.1.1 To develop an MR-compatible audiovisual (AV)-aided patient interactive breathing 
motion management system 
2.1.2 To develop optimized MRI procedures for 4D and multiparametric MRIs with the 
assistance of an MR-compatible audiovisual (AV)-aided patient interactive breathing 
motion management system 
2.2 Secondary Objectives 
2.2.1 To establish optimal DTI and MRE acquisition procedures with the AV-aided patient 
interactive motion management system and 4D motion phantom 
2.2.2 To compare DTI and MRE acquisition from participants with primary or metastatic 
cancer in the liver to conventional MRI acquisition metrics 
2.2.3 To compare DTI and MRE acquisition from participants with primary or metastatic 
cancer in the liver to the DTI and MRE results of the healthy participants 
2.2.4 To develop a SAP-4D MRI acquisition to obtain multi-dimensional statistical tumor 
motion information for confidence-weighted target definition 
3 STUDY DESIGN 
3.1 General Description 
The purpose of this pilot study is to develop MRI-compatible systems and procedures to 
optimize SBRT treatment planning. During the first phase of the study, an in-room patient 
interactive motion management system will be developed and its feasibility will be 
evaluated.  
In the second phase, MR imaging on a 4D motion phantom will be performed. Using a 4D 
motion phantom provides a standard to generate optimal imaging and image analysis 
parameters before evaluating the procedures with healthy participants who have an 
unknown set of contrast and motion values. Following completion of MR imaging with the 
MRI-compatible patient interactive breathing motion management system in healthy 
participants, MR imaging will be conducted with participants who have primary or 
metastatic cancer in the liver. The results from healthy participants will be used for 
comparison with the results from the participants with cancer in the liver to evaluate how 
healthy and unhealthy liver structure varies. All of the human scans will be conducted 
using the AV-aided patient interactive motion management system to reduce variation in 
breathing motion. 
3.2 Investigational Device 
This feasibility study includes the development of a breathing motion management system. 
A component of this system is a non-significant risk (NSR) investigational device which is 
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illustrated in Part B of Figure 5.  
MCC-16-13073 study will be conducted according to the abbreviated investigational device 
exemption (IDE) requirements of the Food and Drug Administration [21 CFR 812.2(b)]. 
3.3 Cohort Definitions 
The study plan will be carried out with 4 participant cohorts. 
• Cohort A: Healthy participants who will have photographs and/or videos taken of their 
dental structure and oral cavity (Section 6.1.3) 
• Cohort B: Healthy participants who will test the effectiveness of the respiratory motion 
management system (Section 6.1.4) 
• Cohort C: Healthy participants who will have MRI scans of the torso while using the  
MRI-compatible in-room patient interactive respiratory motion management system 
mouthpiece and breathing device (Sections 6.2.2 and 6.3) 
• Cohort D: Patients with primary or metastatic cancer in the liver who require SBRT will 
have MRI scans of the torso using the MRI-Compatible In-Room Patient Interactive 
Respiratory Motion Management System (Sections 6.4.2 and 6.5) 
3.4 Study Accrual 
A maximum total of 33-47 participants will be enrolled in the study. Because healthy 
participants may be enrolled in more than one of the 3 healthy participant cohorts, the total 
number of participants may be fewer than 33. 
Accrual in the 4 cohorts will be: 
• Cohort A: 15-20 healthy participants 
• Cohort B: 10-15 healthy participants 
• Cohort C: 4-6 healthy participants 
• Cohort D: 4-6 participants with primary or metastatic cancer in the liver who are 
candidates for SBRT 
3.5 Primary Endpoints 
3.5.1 Variation in breathing motion of the MR-compatible AV-aided patient interactive 
motion management system when compared to free breathing and the Elekta ABC 
system currently used in clinical practice during CT scans 
3.5.2 The acquisition speed and image accuracy provided by the optimized 4D MRI, DTI, 
and MRE image parameters developed in this pilot study compared to current 
clinical MR-based assessment tools for tissue characterization and motion 
monitoring 
3.6 Secondary Endpoints 
3.6.1 Optimal DTI and MRE acquisition procedures with the AV-aided patient interactive 
motion management system with a 4D motion phantom 
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3.6.2 DTI and MRE acquisition from participants with primary or metastatic cancer in the 
liver compared to conventional MRI acquisition metrics 
3.6.3 DTI and MRE acquisition from participants with primary or metastatic cancer in the 
liver compared to the DTI and MRE results of the healthy participants 
3.6.4 SAP-4D MRI acquisition to generate multi-dimensional statistical tumor motion 
information based on 2 orthogonal 2D-cine MRIs for confidence-weighted target 
definition 
4 PARTICIPANT SELECTION 
The inclusion and exclusion criteria are specific for each of the 4 participant cohorts. 
Descriptions of the 4 cohorts are provided in Section 3.3 and the cohort-specific research 
activities are described in Section 6. 
Refer to Sections 4.1 and 4.2 for Cohort A; Sections 4.3 and 4.4 for Cohort B; Sections 4.5 
and 4.6 for Cohort C; and Sections 4.7 and 4.8 for Cohort D. 
Note: Healthy participants may be enrolled in more than one of the 3 cohorts for healthy 
participants (ie, Cohorts A, B, and C) assuming that the participant is eligible and has signed 
the cohort-specific consent form. 
4.1 Inclusion Criteria for Healthy Participants – Cohort A 
Healthy individuals being considered for participation in Cohort A must meet all of the 
following inclusion criteria to be eligible to participate in this pilot study. 
4.1.1 Age ≥ 18 years 
4.1.2 Karnofsky Performance Status score of ≥ 70 % (see Appendix 2 for KPS criteria) 
4.1.3 Ability to understand and the willingness to sign a written informed consent 
document 
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4.2 Exclusion Criteria for Healthy Participants – Cohort A 
Individuals who meet any of the following Cohort A exclusion criteria are ineligible to 
participate in this pilot study. 
4.2.1 Dentures 
Note: Individuals with dental bridges, implants, and crowns should not be excluded. 
4.2.2 Medical, psychological, or social condition that, in the opinion of the investigator, 
may increase the participant’s risk or limit the participant’s adherence with study 
requirements 
4.3 Inclusion Criteria for Healthy Participants – Cohort B 
Healthy individuals being considered for participation in Cohort B must meet all of the 
following inclusion criteria to be eligible to participate in this pilot study. 
4.3.1 Age ≥ 18 years 
4.3.2 Karnofsky Performance Status score of ≥ 70 % (see Appendix 2 for KPS criteria) 
4.3.3 Ability to maintain breath hold for at least 20 seconds repeatedly (ie, approximately 
10 repetitions with breaks of about a minute between each) 
Note: The patient’s ability to maintain breath hold for 20 seconds should be 
demonstrated to determine eligibility. Repeating the breath hold for 10 repetitions is 
not required for eligibility screening. 
4.3.4 Ability to understand and the willingness to sign a written informed consent 
document 
4.4 Exclusion Criteria for Healthy Participants – Cohort B 
Individuals who meet any of the following Cohort B exclusion criteria are ineligible to 
participate in this pilot study. 
4.4.1 Respiratory conditions (eg, asthma) or illnesses that are symptomatic (eg, upper 
respiratory infection) that will affect participation in Cohort B study requirements 
4.4.2 Medical, psychological, or social condition that, in the opinion of the investigator, 
may increase the patient’s risk or limit the patient’s adherence with study 
requirements 
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4.5 Inclusion Criteria for Healthy Participants – Cohort C 
Healthy individuals being considered for participation in Cohort C must meet all of the 
following inclusion criteria to be eligible to participate in this pilot study. 
4.5.1 Age ≥ 18 years 
4.5.2 Karnofsky Performance Status score of ≥ 70 % (see Appendix 2 for criteria) 
4.5.3 Determination that the patient is an acceptable candidate for an MRI at the CARI 
facility (see Section 6.6.2) 
4.5.4 Ability to lie flat for about 2 hours 
4.5.5 Ability to maintain breath hold for at least 20 seconds repeatedly (ie, approximately 
10 repetitions with breaks of about a minute between each breath hold) 
Note: The patient’s ability to maintain breath hold for 20 seconds should be 
demonstrated to determine eligibility. However, repeating the breath hold for 10 
repetitions is not required to determine eligibility. 
4.5.6 A woman of childbearing potential, defined as a woman who is < 60 years of age 
and has not had a hysterectomy, must have a documented negative pregnancy test 
within 14 days prior to the pilot study MRI 
4.5.7 Ability to understand and the willingness to sign a written informed consent 
document 
4.6 Exclusion Criteria for Healthy Participants – Cohort C 
Individuals who meet any of the following Cohort C exclusion criteria are ineligible to 
participate in this pilot study. 
4.6.1 Respiratory conditions (eg, asthma) or illnesses that are symptomatic (eg, upper 
respiratory infection) that will affect participation in Cohort C study requirements 
4.6.2 Requirement for sedation or anti-anxiety medications to manage MRI-related 
claustrophobia 
4.6.3 Pregnancy 
4.6.4 Medical, psychological, or social condition that, in the opinion of the investigator, 
may increase the patient’s risk or limit the patient’s adherence with study 
requirements 
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4.7 Inclusion Criteria for Patients with Cancer in the Liver – Cohort D 
Patients being considered for participation in Cohort D must meet all of the following 
inclusion criteria to be eligible to participate in this pilot study. 
4.7.1 Age ≥ 18 years 
4.7.2 Karnofsky Performance Status score of ≥ 70 % (see Appendix 2 for criteria) 
4.7.3 Documented primary cancer in the liver or liver metastases from any solid tumor 
4.7.4 Determination by the treating radiation oncologist that the patient is a candidate for 
SBRT to tumor(s) in the liver 
4.7.5 Determination that the patient is an acceptable candidate for an MRI at the CARI 
facility (see Section 6.6) 
4.7.6 Ability to lie flat for about 2 hours 
4.7.7 Ability to maintain breath hold for at least 20 seconds repeatedly (ie, approximately 
10 repetitions with breaks of about a minute between each breath hold) 
Note: The patient’s ability to maintain breath hold for 20 seconds should be 
demonstrated to determine eligibility. However, repeating the breath hold for 10 
repetitions is not required to determine eligibility. 
4.7.8 A woman of childbearing potential, defined as a woman who is < 60 years of age 
and has not had a hysterectomy, must have a documented negative pregnancy test 
within 14 days prior to the pilot study MRI 
4.7.9 Ability to understand and the willingness to sign a written informed consent 
document 
4.8 Exclusion Criteria for Participants with Cancer in the Liver – Cohort D 
Patients who meet any of the following Cohort D exclusion criteria are ineligible to 
participate in this pilot study. 
4.8.1 Respiratory conditions (eg, asthma) or illnesses that are symptomatic (eg, upper 
respiratory infection) that will affect participation in Cohort D study requirements 
4.8.2 Requirement for sedation or anti-anxiety medications to manage MRI-related 
claustrophobia 
4.8.3 Pregnancy 
4.8.4 Medical, psychological, or social condition that, in the opinion of the investigator, 
may increase the patient’s risk or limit the patient’s adherence with study 
requirements 
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5 STUDY ENTRY AND WITHDRAWAL PROCEDURES 
5.1 Study Entry Procedures 
5.1.1 Required Pre-Registration Screening Tests and Procedures 
Refer to the appropriate cohort-specific study calendar in Section 8 for the screening 
tests and procedures that are required prior to registration and for the timing of 
these events relative to the start of the study intervention. 
5.1.2 Registration Process 
Study registration will be performed by the study team (email: 
masseyradonc@vcu.edu). The following documents are required for study 
registration: 
• Completed registration cover sheet 
• Completed, signed, and dated eligibility checklist 
• Signed and dated consent form 
The registrar will complete the registration process by assigning a study ID number 
and forwarding the “Confirmation of Registration” form to the registering study team. 
The study intervention may not begin until the Confirmation of Registration has been 
received and a study ID number has been assigned. 
The study team will enter the patient’s initial enrollment data (eg, demographics, 
consent, eligibility) into the OnCore database following study registration (before 
study procedures are initiated). 
5.2 Study Withdrawal Procedures 
A participant, either a healthy participant or a patient with primary or metastatic cancer in 
the liver, may decide to withdraw from study participation at any time. Participants must be 
removed from the study when any of the following occurs: 
• The participant has withdrawn consent for the cohort-specific study procedures 
• If, in the investigator's opinion, continuation of the cohort-specific study requirements 
would be harmful to the participant’s well-being 
• The participant cannot be contacted prior to completing study requirements 
• The sponsor has terminated the study 
The reason for and date associated with study withdrawal or removal from the study must 
be documented in source documents and in the OnCore database. 
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6 STUDY PROCEDURES/EVALUATIONS 
6.1 Development of MRI-Compatible In-Room Patient Interactive Respiratory Motion 
Management System 
6.1.1 Overview  
We will utilize our previous motion management experience to develop an MRI-
compatible in-room patient interactive respiratory motion-management system with 
the Philips 3 Tesla (3T) MRI located at and in cooperation with the Collaborative 
Advanced Research Imaging (CARI) facility. The participant’s abdominal position 
from an infrared camera will be fed into the breathing management system to 
control the participant’s breathing motion. Under this control, participants will be 
guided for regular breathing or breath-holding at designated levels and times during 
MR imaging. 
In Figure 5 (a) and (b), a mouthpiece of the Active Breathing Coordinator (ABC) 
System from Elekta, which is currently used in radiotherapy, is presented. Due to its 
unsatisfactory connectivity and patient discomfort, significant modification of the 
mouthpiece is required. Our dentistry team will develop an improved connection 
mechanism for the breathing control system that will offer improved patient comfort 
as well as more secure airflow control as illustrated in (b), (c), and (d). The 
mouthpiece in (b) will be replaced with the novel thru-mouth-breathing airflow 
control mouthpiece developed by our dentistry team. The same guidance for 
breathing control will be tested in the planning CT scan procedure and radiotherapy 




Figure 5. Proposed Respiratory Tubing System 
The system utilizes pneumatic power and MR-compatible materials in a piston form to control 
respiratory motion. An in-house AV-aided interactive system will be used to guide participants in 
achieving regular respiratory motion. (a) Commercial mouthpiece (arrow) connected to a 
respiratory tube from Elekta; (b) demo sketch of the proposed system; the circle indicates the 
schematic of the breath-hold control system driven by pneumatic power; (c-d) schematic of  
breath-hold control mechanism in detail 
6.1.2 Components  
The following components will be integrated to create the MRI-compatible in-room 
patient interactive respiratory motion management system: 
6.1.2.1 Dentistry Team 
The dentistry team will design, simulate, conduct 3D printing, polish, and 
test the physical/mechanical properties of the following: 
• Mouthpiece component as described in Section 6.1.1; a patient-
adaptive, stable, and tightly sealed thru-mouthpiece will be developed 
to replace the current clinical device from Elekta (Figure 5). 
• Non-metallic (ie, MR-safe) airflow control device which will be driven by 
pneumatic power. The air-chamber and piston will be simulated and 
3D-printed. Responding time will be tested with designated pneumatic 
power (pressure). 
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6.1.2.2 Radiation Oncology Team 
The radiation oncology team will design, simulate, assemble and test all of 
the devices: 
• Breathing control device (investigational device developed by the 
Sponsor-Investigator) 
• Motion monitoring device using an infrared camera to monitor the 
breathing motion 
• Safety device using optic fiber technique so that the patient can 
communicate with the clinical staff if the patient cannot tolerate the 
involuntary breath-hold control 
6.1.3 Research Assessments for Participants in Cohort A 
A total of 10-15 healthy participants will be enrolled in Cohort A. The procedures 
described below will be performed. 
• Participants will have photos taken and/or a video filmed of their dental 
structure and oral cavity. This oral assessment will take place in the VCU 
Radiation Oncology Department. (The participant’s face will not be included in 
the photographs or video images.) 
• Multiple preliminary prototypes with differences in size, shape, and function 
will be created through computer-aided design (CAD). These will be  
3D-printed using biocompatible resin. 
6.1.4 Research Assessments for Participants in Cohort B 
A total of 10-15 healthy participants will be enrolled, and the following procedures 
will be performed. 
• An optimized mouthpiece prototype will be selected for the participant based 
on mouth size (eg, small, medium, or large) or other criteria. 
• The novel non-metallic thru-mouth breathing airflow control system will be 
tested. This system (the “MRI-Compatible In-Room Patient Interactive 
Respiratory Motion Management System”) combines the selected optimized 
mouthpiece and an airflow control device that utilizes pneumatic power and 
electronic control. 
• Breathing traces with and without the MRI-Compatible In-Room Patient 
Interactive Respiratory Motion Management System will be recorded during 
assessments in the VCU Radiation Oncology Department to test the 
effectiveness of the MRI-Compatible In-Room Patient Interactive Respiratory 
Motion Management System. The data will be analyzed in terms of the RMSE 
of displacement and period for breathing motion regularity. (There will be no 
imaging acquisition during this process.) 
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6.2 Optimization of 4D MRI Acquisition Procedures 
Studies will be performed to achieve optimal 4D MR configurations with the AV-aided 
patient interactive motion management system described in Section 6.1.1. 
6.2.1 Procedure Optimization with the 4D Motion Phantom 
• MRI pulse sequence optimization to improve image quality and process 
compliance 
• Image reconstruction development in cooperation with pulse sequence to 
improve image quality and calculation time 
• 4D MRI pulse sequence optimization and image reconstruction development  
with the 4D motion phantom 
6.2.2 Research Assessments for Participants in Cohort C 
Upon completion of the procedure optimization using the 4D motion phantom, a total 
of 4-6 healthy participants will be enrolled and will have 2 research MRIs. The MRI 
scans performed as part of this study are for research purposes only. These scans 
are not diagnostic and cannot be used for any medical or diagnostic purposes. 
6.2.2.1 MRI Screening Process 
• An MRI safety survey will be completed to establish eligibility for having 
MRI scans at the CARI facility (Section 6.6) 
• A urine pregnancy test will be performed for WCBP prior to each MRI. 
6.2.2.2 MRI Scans 
4D MRI images of the torso will be acquired using the optimized 4D MRI 
pulse sequences with the AV-aided interactive motion management 
system. The MRIs will be performed at the CARI facility at the following 2 
time points: 
• Within 3 weeks following study registration 
• Within 1 to 4 weeks following the first study-required MRI 
6.2.2.3 Incidental Finding on Research MRI Scan 
As noted previously, the scans performed at the CARI facility are research, 
not diagnostic, scans and can only be used for research purposes. 
However, if an incidental finding is noted on the research images of a 
healthy participant in Cohort C, a VCU radiologist will be asked to review 
the research images to provide additional information, if possible. The 
finding will be communicated to the Cohort C participant by the study 
physician (ie, co-investigator), and recommendations for follow-up with the 
participant’s primary care physician (PCP) will also be discussed. If the 
participant is not in the care of a PCP or other physician, the study team 
will assist the participant in arranging for appropriate follow-up. 
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6.3 Optimization of DTI and MRE Acquisition Procedures 
Studies will be performed to achieve optimal DTI and MRE acquisition procedures with the 
AV-aided patient interactive motion management system for active breath-hold. These 
studies will be conducted in healthy participants (Cohort C) who will have MRI scans at 
CARI as described in Section 6.2.2. 
6.3.1 Procedure Optimization with the 4D Motion Phantom with Designated Diffusivity and 
Stiffness Properties 
• DTI and MRE pulse sequence optimization to improve image quality and 
process compliance eg, imaging parameters/the number of diffusion gradient 
directions (for DTI) and the frequency of the applied waves/motion-encoding 
gradient (for MRE) 
• ADC map and elastogram analysis development 
6.3.2 Feasibility Tests in Healthy Participants 
Upon completion of the DTI procedure optimization using the 4D Motion Phantom 
(with designated diffusivity and stiffness properties), the following feasibility tests will 
be performed: 
• DTI and MRE images will be acquired using the optimized pulse sequences with 
the AV-aided interactive motion management system for active breast-hold. 
• ADC map and elastogram analysis of the healthy participants will be evaluated 
and determined as the reference of healthy tissue. 
6.4 Development of the Purpose-Oriented Sampling Approach for the Supportive 4D 
MRI 
Studies will be performed to develop the PoSA for the supportive 4D MRI. A SAP-4D MRI 
will be conducted to obtain multidimensional statistical tumor motion information based on 
2 orthogonal 2D cine MRIs for confidence-weighted target definition. 
6.4.1 SAP-4D MR Imaging with the 4D Motion Phantom 
• Two orthogonal cine 2D MR images in multi-respiratory cycles (approximately 
one minute/plane) will be acquired with < 200ms sampling time/frame monitored 
with the patient interactive motion management system. Statistical tumor 
trajectory will be obtained using both internal position information from 2D MR 
images and external position information from the respiratory monitoring system. 
The target identified in the reference 4D MR images will be superimposed on the 
statistical tumor trajectory to define a confidence-weighted target. 
• In evaluation, the statistical target definition obtained from SAP-4D MRI will be 
compared with the target trajectory from the reference 4D MR images. 
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6.4.2 Research Assessments for Participants in Cohort D 
The feasibility of the method established in the phantom study will be evaluated with 
4-6 participants who have primary or metastatic cancer in the liver.  
The scans performed as part of this study will not be diagnostic scans and cannot 
be used for any medical or diagnostic purposes. These research scans will also not 
be used for SBRT treatment planning. Therefore, the imaging conducted will have 
no influence on patient treatment. 
6.4.2.1 MRI Screening Process 
• An MRI safety survey will be completed to establish eligibility for having 
MRI scans at the CARI facility (Section 6.6) 
• A urine pregnancy test will be performed for WCBP prior to each MRI. 
6.4.2.2 MRI Scan Time Points 
4D MRI images of the torso will be acquired using the optimized 4D MRI 
pulse sequences with the AV-aided interactive motion management 
system. The MRIs will be performed at the CARI facility at the following 2 
time points: 
• Within 3 weeks following study registration but must be before SBRT is 
initiated 
• Within 1 to 4 weeks following the last SBRT treatment 
6.4.2.3 MRI Acquisition Procedures 
• Patient simulation will be made under AV-aided patient interactive 
guidance. The reference 4D MR images will be acquired for target 
identification. Two orthogonal cine 2D MR images over multi-respiratory 
cycles will be acquired with < 200 ms sampling time/frame. The target 
identified in the reference 4D MR images will be superimposed on the 
statistical tumor trajectory to define a confidence-weighted target. 
• If the required image acquisition time for appropriate image quality is 
>200 ms, the internal respiratory position (eg, diaphragm) from 2D 
images will be determined based on the external position information 
from the respiratory monitoring system to obtain the entire 
range/probability of tumor motion. Regarding the internal-external 
respiratory motion correlation, our team reported the strong motion 
correlation between the diaphragm and the abdomen under AV 
guidance (mean Pearson’s R correlation = 0.96). 
• For evaluation of the method, 1 or 2 additional 4D MR image sets, 
depending on the participant’s condition, will be acquired for each 
participant with cancer in the liver. Tumor trajectories from 2 to 3 4D 
MR image sets will be compared with the statistical tumor trajectory 
obtained in the SAP-4D-MRI. 
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6.5 Establishment of Optimal DTI and MRE Acquisition with Participants Who Have 
Cancer in the Liver 
To establish DTI and MRE acquisition with 4-6 participants with cancer in the liver in 
addition to conventional MR tools, the following procedures will be conducted with Cohort 
D Participants (see Section 6.4.2 for additional information regarding Cohort D and 
Section 6.6 regarding MRI scans at CARI): 
• DTI and MRE procedure optimization with actual patients will be performed in addition 
to conventional MRI acquisition such as T1-weighted (T1w) and T2-weighted (T2w) 
MRI. 
• Optimizing ADC map and elastogram analysis will be performed in cooperation with 
imaging parameters and acquisition. 
• Diffusivity maps and elastrograms of the participants with cancer in the liver will be 
processed to compare to those of the healthy participants. 
• The regions of interest (ROIs) in healthy tissues and tumors identified in the reference 
3D MR images of the participants with cancer in the liver will be analyzed in terms of 
the diffusivity maps and the elastograms to determine the correlation of the diffusivity 
and elasticity with tissue types. 
6.6 MRI Scans at CARI for Participants in Cohorts C and D 
6.6.1 General Information  
• The research MRI scans in this study will be performed at the VCU CARI facility: 
VCU Collaborative Advanced Research Imaging (CARI) Program 
203 East Cary Street 
Richmond, VA 23219 
804-828-3639 
• The MRI scans performed in this study impart no ionizing radiation dose. 
• Contrast material will not be used. 
6.6.2 Contraindications for MRI  
• Participants in Cohorts C and D will be assessed prior to study registration for 
MRI contraindications using the VCU Health System MRI Safety Checklist. 
• After the cohort-specific consent form has been signed, the study team will 
assist the participant in completing the MRI Safety Checklist or, if a previously 
completed MRI Safety Checklist is available, the study team will review the 
checklist with the participant and update, as needed. The completed/updated 
checklist will be provided by the study team to the CARI facility staff for review to 
identify any contraindications that would prevent performing the MRI. 
Additionally, to screen for the presence of any contraindication since the 
previous checklist was completed, CARI facility staff will update or complete a 
new MRI Safety Checklist on site within 24 hours prior to each of the MRI scans. 
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• Examples of contraindications include: 
− Inability to independently move onto an MRI exam table 
− Need for sedation in order to proceed with the MRI 
Individuals who are known to experience claustrophobia-related anxiety 
to the extent that they require sedation in order to undergo the MRI 
procedure will be excluded from this trial. In the event that an enrolled 
participant experiences new significant anxiety due to claustrophobia 
during the initial MRI, the CARI facility staff will notify the study team to 
determine if the participant will be able to undergo the second scan. 
− Presence of ferromagnetic objects or materials 
The presence of some pacemakers, metal or electromechanical 
implants, and metallic foreign bodies including some tattoo ink can lead 
to injury during the MRI procedure. In some cases, the duration that the 
metallic material has resided in the body may impact whether its 
presence is a contraindication to the MRI. 
− Pregnancy 
The risks of MRI for the fetus are unknown. Pregnant women will be 
excluded from participation in Cohorts C and D of this study. For 
WCBP, a urine pregnancy test will be performed at CARI immediately 
prior to each MRI. 
6.7 Follow-Up 
There are no follow-up requirements in this study. Study participation will conclude when 
the cohort-specific requirements have been completed. 
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7 STUDY RISKS/REPORTING UNANTICIPATED ADVERSE DEVICE 
EFFECTS 
7.1 Unanticipated Adverse Device Effects 
7.1.1 Definition of Serious Injury 
A serious injury is an injury or illness that: 
• Is life-threatening; 
• Results in permanent impairment of a body function or permanent damage to a 
body structure; or 
• Necessitates medical or surgical intervention to preclude permanent impairment 
of a body function or permanent damage to a body structure. 
7.1.2 Definition of Unanticipated Adverse Device Effects 
Unanticipated adverse device effect (UADE) includes any incident, experience, or 
outcome that meets all of the following criteria: 
Serious adverse effect (see Section 7.1.1 for definition of serious injury) on 
health or safety or any life-threatening problem or death or any other 
unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of participants 
• Caused by or associated with a device 
• Not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan/application) 
7.2 Known Risks 
7.2.1 Dental Assessment (Cohort A) 
There are no anticipated risks associated with the dental assessment with a photo 
camera and/or a video camera (Section 6.1.3). The participant’s face will not be 
included in photographs/videos. 
7.2.2 Breathing Device Testing (Cohorts B, C, and D) 
There are no anticipated risks associated with testing the breath motion 
management system (Section 6.1.4) or with use of breath motion management 
system during the MRIs. 
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7.2.3 MRI Scans (Cohorts C and D) 
• Metal objects may pose a risk due to the high magnetic fields utilized. As 
described in Section 6.6.2, proper screening will be performed to omit 
individuals who are at risk due to: artificial joints, limbs, or valves, embedded 
bullet or shrapnel, implantable defibrillators, metal clips, pacemakers, and other 
metallic objects. 
• Potential participants who require medication to manage claustrophobia-related 
anxiety during MRI scans will be excluded from participation in Cohort C or 
Cohort D (Sections 4.6.2 and 4.8.2), but some participants may experience  
MRI-related claustrophobia. 
7.3 Time Period and Procedures for Reporting UADEs 
• The time period required for reporting UADEs begins with the initiation of cohort-
specific study procedures and ends 30 days after the final cohort-specific requirement. 
• All UADEs will be recorded in MCC’s OnCore Clinical Trials Management System in 
the OnCore Deviations domain. (Refer to Table 1 for expedited reporting requirements 
for UADEs.) 
7.4 Expedited Reporting Requirements for UADEs 
Expedited reporting is required for UADEs (defined in Section 7.1) as outlined on Table 1. 
Table 1. Expedited Reporting Requirements for UADEs 
Report Recipient Requirements 
Sponsor-Investigator 
Taeho Kim, MD 
Phone: 804-828-7418 
Email: taeho.kim@vcuhealth.org Report the UADE to the Sponsor-Investigator and 
Study Team within 1 business day of becoming 
aware of the occurrence. Study Team
 





Report any UADE that meets the criteria outlined in 
Section 7.1 to the IRB within 5 business days of 
becoming aware of the occurrence. 
FDA 
Using MedWatch Form 3500A, the Sponsor-
Investigator will report to the FDA any UADE that 
meets the criteria outlined in Section 7.1 within 
10 business days of the Sponsor-Investigator 
becoming aware of the occurrence. 
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8 STUDY CALENDARS 
The schedule of exams, assessments, and other requirements are listed on Table 2 for 
Cohort A, Table 3 for Cohort B, Table 4 for Cohort C, and Table 5 for Cohort D. 
 
Table 2. Study Calendar for Cohort A 
Required Assessments 
Within 21 Days  
Prior to Study Registration 
Within 21 Days  
After Study Registration 
Informed Consent (Cohort A) X  
Demographics X  
Performance Status  
(Appendix 2) 
X  
Height and Weight X 
Dental Assessment, 
Photographs, and Video 
Imaging* 
 X 




Table 3. Study Calendar for Cohort B 
Required Assessments 
Within 21 Days  
Prior to Study Registration 
Within 21 Days  
After Study Registration 
Informed Consent (Cohort 
B) 
X  
Demographics X  
Performance Status  
(Appendix 2) 
X  
Height and Weight X 
Respiratory AssessmentA X  
Breathing TestingB   X 
A. Limited to asking the potential participant to demonstrate breath hold for 20 seconds (see 
Section 4.3.3). 
B. See Section 6.1.4. 
152
Table 4. Study Calendar for Cohort C 
Required Tests and 
Assessments 
Prior to Study 
Registration 






21 Days  
Following Study 
Registration 
Within 7-28 Days 
Following First 
MRI at CARI 
Informed Consent (Cohort C) X    
Demographics X    
Performance Status  
(Appendix 2) 
X    
Height and Weight X  
Respiratory AssessmentA X    
Pregnancy TestB  X XC XC 
Assessment for MRI at CARID X  XE XE 
MRI of TorsoF   X X 
A. Limited to the patient demonstrating breath hold for 20 seconds (see Section 4.5.5). 
B. Only required for WCBP (see Section 4.5.6); if required, perform within 14 days prior to study 
registration; serum or urine pregnancy test is acceptable. 
C. Pregnancy test (urine test) at this time point will be performed at the CARI facility prior to the 
MRI. 
D. See Section 6.6.2 regarding MRI contraindications. 
E. Review of MRI contraindications at CARI. 




Table 5. Study Calendar for Cohort D 
Required Tests and 
Assessments 
Prior to Study 
Registration 
































7-28 Days  
After Last SBRT 
Treatment 
Informed Consent (Cohort D) X    
Demographics X    
Performance Status 
(Appendix 2) 
X    
Height and Weight X  
Respiratory AssessmentA X    
Pregnancy TestB  X XC XC 
Determination that Patient is 
Candidate for SBRT to Liver 
X    
Assessment for MRI at 
CARID 
X  XE XE 
MRI of TorsoF   X X 
A. Limited to the patient demonstrating breath hold for 20 seconds (see Section 4.7.7). 
B. Only required for WCBP (see Section 4.7.8); if required, perform within 14 days prior to study 
registration; serum or urine pregnancy test is acceptable. 
C. Pregnancy test (urine test) will be performed at the CARI facility prior to the MRI. 
D. See Section 6.6.2 regarding MRI contraindications. 
E. Review of MRI contraindications at CARI. 
F. Research MRI at the CARI facility with the Philips 3T MRI unit (see Sections 6.4.2 and 6.6). 
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9 STATISTICAL CONSIDERATIONS 
9.1 Study Design 
The primary goals of this pilot study are to develop a breathing motion management 
system, which includes an investigational device, and using this system to optimize MRI 
procedures needed for SBRT treatment planning for liver cancer. Phases of development 
and optimization will be conducted with 4 participant cohorts as defined in Section 3.3. 
9.2 Sample Size/Accrual Rates 
According to the preliminary results with 10 to 15 healthy participants, assuming a type I 
error rate of 5%, 80% power and a moderate effect size of 0.512σ for the paired 
differences between free breathing and respiratory motion management breathing, a 
sample size of 10 to 15 participants will be required. Therefore, 10 to 15 healthy 
participants will be recruited for the feasibility study of the motion management system. 
9.2.1 Sample Size for Developing an MR-Compatible AV-aided Patient Interactive 
Breathing Motion Management System 
The sample size for the primary objective of developing an MR-Compatible  
AV-aided patient interactive breathing motion management system will be 15-20 
healthy participants in Cohort A and 10-15 healthy participants in Cohort B. Accrual 
for these 2 cohorts is expected to take about 3 months. 
9.2.2 Sample Size for Developing Optimized MRI Procedures with the Assistance of an 
MR-Compatible AV-aided Patient Interactive Breathing Motion Management System 
The sample size for the primary objective of developing optimized MRI procedures 
will be 4-6 healthy participants in Cohort C and 4-6 participants with primary or 
metastatic cancer in the liver in Cohort D. Accrual for these 2 cohorts is expected to 
take about 6 months. 
9.3 Analysis of Primary Endpoints 
The information will be summarized in a clinical study report as a result of statistical 
analysis. For the primary objective in this application, internal organ motion reproducibility 
with the respiratory motion management system will be quantified. Results will be 
evaluated using the RMSE method and comparison of the data between the healthy 
participants and the participants with primary or metastatic cancer in the liver will be 
performed using statistical analysis methods such as the Student t-test. 
9.3.1 Cohort A 
Healthy volunteers will be used to develop the mouthpiece for the breath control 
device. Measurements from healthy volunteers will be summarized and used to 
guide the specifications of the new mouthpiece to be developed. 
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9.3.2 Cohort B 
The second phase of the study uses healthy participants to demonstrate the 
reproducibility of the motion management strategy. Each participant will have a 
positional marker on the abdominal area and the position of the subsequent breath-
holds will be recorded 3 more times. Displacement from the initial position will be 
measured. Because the data will be repeated measures within each participant, a 
mixed effects model for longitudinal data will be used to estimate the within 
participant variation. The model for variation will be a compound symmetric 
covariance matrix. We expect within participant variation to be less than 3 mm which 
will be an acceptable demonstration of reproducibility of our strategy. 
9.3.3 Cohorts C and D 
The goal of the pilot study with 4-6 healthy participants (Cohort C) and 4-6 
participants with primary or metastatic cancer in the liver (Cohort D) will be to 
optimize the MRI planning process and to develop goals for subsequent 
development of the treatment planning procedure. Imaging time, image outcomes, 
and other dosimetric parameters will be summarized and reported through their 
median and range of values. 
9.4 Analysis of Secondary Endpoints 
Results will be evaluated using the RMSE method and comparison of the data between the 
healthy participants and the participants with primary or metastatic cancer in the liver will 
be performed using statistical analysis methods such as the Student’s t-test. 
10 DATA AND SAFETY MONITORING 
10.1 Study Team 
The study team minimally consists of the Sponsor-Investigator, the research nurse, the 
clinical research associate, and the study biostatistician. The Sponsor-Investigator, the 
research nurse, and the clinical research associate will meet at least monthly to review 
study status; quarterly meetings will be held with the study biostatistician. This review will 
include, but not be limited to, reportable UADEs and an update of the ongoing study 
summary that describes study progress. All meetings, including attendance, are 
documented. 
10.2 Monitoring and Auditing 
Compliance specialists in the MCC Compliance Office will provide ongoing monitoring and 
auditing for this study. 
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11 REGULATORY COMPLIANCE AND ETHICS 
11.1 Ethical Standard 
This study will be conducted in conformance with the principles set forth in The Belmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research (US National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research, April 18, 1979). 
11.2 Regulatory Compliance 
This pilot study will be conducted in compliance with: 
• The protocol 
• Federal regulations, as applicable, including: 21 CFR Part 812, Investigational Device 
Exemptions; 21 CFR 50 (Protection of Human Subjects/Informed Consent); 21 CFR 56 
(Institutional Review Boards); and 45 CFR 46 Subparts A (Common Rule), B (Pregnant 
Women, Human Fetuses and Neonates), C (Prisoners), and D (Children) 
11.3 Institutional Review Board 
The VCU IRB will review and provide approval for the protocol, the associated informed 
consent documents, and recruitment materials. Any amendments to these materials must 
also be approved. 
11.4 Informed Consent Process 
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and continues throughout the individual’s study participation. 
Discussion of the risks and possible benefits of this pilot study will be provided to study 
participants and their families. Cohort-specific consent forms describing the study 
procedures and risks are given to the potential participant, and written documentation of 
informed consent is required prior to starting study participation. 
Cohort-specific consent forms will be IRB-approved and the participant will be asked to 
read and review the appropriate document for the cohort they are considering. Upon 
reviewing the document, the investigator will explain the study and answer any questions 
that may arise. The participant will sign the cohort-specific consent document prior to any 
procedures being done specifically for the study. Potential participants should have the 
opportunity to discuss the study with their surrogates or think about it prior to agreeing to 
participate. A copy of the informed consent document will be given to participants for their 
records. 
Participants may withdraw consent at any time throughout the course of the trial. The rights 
and welfare of participants in Cohort D will be protected by emphasizing to them that the 
quality of their medical care will not be adversely affected if they decline to participate in 
this study. 
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11.5 Participant Confidentiality and Access to Source Documents/Data 
Participant confidentiality is strictly held in trust by the participating investigators and their 
staff. This confidentiality includes the clinical information relating to participants. 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the Sponsor-Investigator. 
The Sponsor-Investigator will allow access to all source data and documents for the 
purposes of audits, IRB review, and regulatory inspections. Source documents provided for 
the purpose of auditing will be de-identified and labeled with the study number, participant 
ID, and participant initials. 
The study monitor or other authorized representatives of the Sponsor-Investigator may 
inspect all documents and records required to be maintained by the investigator, including 
but not limited to, medical records (office, clinic, or hospital) for the participants in this 
study. The clinical study site will permit access to such records. 
12 DATA HANDLING AND RECORD KEEPING 
12.1 Data Management Responsibilities 
The Sponsor-Investigator is responsible for: (i) the overall conduct of the investigation; (ii) 
ongoing review of trial data including all safety reports; and (iii) apprising participating 
investigators of any UADEs. 
The Sponsor-Investigator is responsible for: (i) the data management; and (ii) reviewing 
and, if required, reporting UADEs as described in Section 7.4. 
12.2 CRFs and Data Collection 
MCC OnCore data management will provide standard electronic CRFs (eCRFs) and create 
study-specific eCRFs to be able to capture all information required by the protocol. The 
eCRFs will be approved by the study team to ensure the most effective data acquisition. 
Data will be entered into MCC’s OnCore database on an ongoing basis. The Coordinating 
Study Team will review electronic data submissions periodically for data timeliness and 
accuracy. All eCRFs should be completed and available for collection within a timely 
manner, preferably no more than 14 days after the participant’s visit. 
The investigator(s) and study coordinator must maintain source documents for each 
participant in the study. All information on eCRFs will be traceable to these source 
documents, which are generally maintained in the participant’s file. 
12.3 Study Record Retention 
As applicable, study records will be maintained a minimum of 5 years beyond the 
publication of any abstract or manuscript reporting the results of the protocol. 
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APPENDIX 1. INVESTIGATIONAL DEVICE LABEL 
The investigational device, an integral part of the breathing motion management system, is 
illustrated in Figure 5 (Part B). This device will be labeled in accordance with CFR 812.5 which 
includes the information listed below. 
• Name and place of business of the manufacturer, packer, or distributor 
• Quantity of contents, if appropriate 
• The following statement: “CAUTION: Investigational device. Limited by Federal law to 
investigational use.” 
There are no contraindications, hazards, adverse effects, interfering substances or devices, 
warnings, or precautions included on the label because none have been identified to be 
associated with this device. 
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APPENDIX 2. PERFORMANCE STATUS CRITERIA 
ECOG Performance Status Scale 
 
Karnofsky Performance Scale 
 
Grade Description Percent Description 
0 
Normal activity. Fully active, able 
to carry on all pre-disease 
performance without restriction. 
100 
Normal, no complaints, no evidence of 
disease. 
90 
Able to carry on normal activity; minor 
signs or symptoms of disease. 
1 
Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (eg, light 
housework, office work). 
80 
Normal activity with effort; some signs 
or symptoms of disease. 
70 
Cares for self; unable to carry on 
normal activity or to do active work. 
2 
In bed < 50% of the time. 
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities. Up and about 
> 50% of waking hours. 
60 
Requires occasional assistance, but is 
able to care for most of his/her needs. 
50 
Requires considerable assistance and 
frequent medical care. 
3 
In bed > 50% of the time. 
Capable of only limited self-care, 
confined to bed or chair > 50% of 
waking hours. 
40 
Disabled; requires special care and 
assistance. 
30 
Severely disabled; hospitalization 
indicated. Death not imminent. 
4 
100% bedridden. Completely 
disabled. Cannot carry on any 
self-care. Totally confined to bed 
or chair. 
20 
Very sick, hospitalization indicated. 
Death not imminent. 
10 
Moribund, fatal processes progressing 
rapidly. 
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RESEARCH PARTICIPANT INFORMED CONSENT FORM 
TITLE: A Pilot Study to Develop A Clinical MRI Procedure and Application for Precise 
Stereotactic Body Radiation Therapy to Treat Primary or Metastatic Cancer in 
the Liver 
Group A Participants –Photographs and Videos of Mouth and Teeth in Healthy 
Volunteers 
PROTOCOL #: MCC-16-13073 
VCU IRB #: HM20010234 
SPONSOR-
INVESTIGATOR: 
Taeho Kim, PhD 
Virginia Commonwealth University 
Massey Cancer Center 
PO Box 980058 
Richmond, VA 23298 
804-828-7418 
INTRODUCTION 
This consent form will tell you about this research study. The researchers or study team will 
explain the research study to you. Research studies only include people who choose to take 
part. You have the option to not participate. You may take home an unsigned copy of this consent 
form so that you can discuss the study with your family or friends before making your decision. If 
you have any questions, ask Dr. Kim or a member of the study team for more explanation.  
WHY IS THIS STUDY BEING DONE? 
This study is being done to develop and test systems that may be able to improve the process 
of treatment planning for a type of radiation therapy called “stereotactic body radiation therapy” 
(SBRT) for patients with cancer. You are being asked to participate as a healthy volunteer by 
having a photographs and videos of your mouth and teeth to help improve the device used to 
manage breathing during SBRT planning.  
There will be about 15 to 20 healthy volunteers taking part in Group A of this study. 
WHAT WILL I BE ASKED TO DO IF I TAKE PART IN THIS STUDY? 
Participants in Group A will be asked to attend one 30-minute session, which will take place in 
the Radiation Oncology Department at Virginia Commonwealth University (VCU). A member of 
the study team will photograph and videotape your mouth and teeth. The images of your mouth 
and teeth will be used to develop a mouthpiece for a breathing motion management device 
which will be tested by other groups participating in this study 
Before or during your session, you will be weighed and have your height measured. Information 
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HOW LONG WILL I BE IN THIS STUDY? 
Your participation in Group A will take place on one day during a session lasting about  
30 minutes.  
WHAT POSSIBLE RISKS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
There are no anticipated risks or discomforts. 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You will not receive any benefit from taking part in this study. In the future, patients with cancer 
may benefit from the knowledge gained through your participation.  
CAN I STOP TAKING PART IN THIS STUDY? 
Yes. You can decide to stop at any time. If you decide to stop taking part in this study, the 
images of your mouth and teeth and the information collected about you up to the time that you 
stop taking part will be kept in the study records and will not be removed. 
The researchers will tell you about new information or changes in the study that may affect your 
willingness to take part in the study. If the study is stopped by the sponsor or the institutional 
review board (IRB), which is a group of people who review the research with the goal of 
protecting the people who take part in the study, the researchers may take you out of the study 
before you have your dental session. 
WHAT ARE MY RIGHTS IN THIS STUDY? 
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. Your decision will not affect your relationship 
with the researchers or with VCU. You will not lose any legal rights. 
WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY? 
You will not be billed for the photographs or video images taken of your mouth and teeth. 
You will not be paid for taking part in this study. 
WHO WILL SEE MY INFORMATION? 
Your privacy is very important to us. The researchers will make every effort to protect it but your 
information may be given out if required by law. However, the researchers will do their best to 
make sure that any information that is released will not identify you.  
Your face will not appear in the photographs and videos. Your photographs, videos, and 
personal identifying information will be kept private through the use of password-protected 
electronic files and locked research areas. Study identification numbers and your initials instead 
of your name will be used on any images and other study records. The results of this research 
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There are groups that may inspect your records. These groups are required to make sure your 
information is kept private, unless required by law to provide information. Some of these groups 
are: 
• Virginia Commonwealth University (VCU) 
• VCU IRB  
• National Cancer Institute (NCI) 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
You can talk to Dr. Kim about any questions or concerns you have about this study. You can 
also contact a study team member at 804-628-2334.  
The Office of Sponsored Research can answer your general questions or concerns about your 
rights as a participant in this or any other research. Also, if you would like to speak to a person 
who does not work directly with Dr. Kim and the study team or if you cannot reach the 
researchers or a member of the study team, you may contact the Office of Research. 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 3000 
PO Box 980568 
Richmond, VA 23298 
804-827-2157 
MY SIGNATURE AGREEING TO TAKE PART IN GROUP A OF THIS STUDY 
I have been given the opportunity to carefully read this consent form. All of the questions that I 
wish to raise concerning this study have been answered. 
By signing this consent form, I have not given up any of my legal rights or benefits. My signature 
indicates that I freely consent to participate in this research study. I will receive a copy of the 
signed consent form. 
________________________________________________  
Participant Name (Printed) 
________________________________________________  ________________ 
Participant Name (Signature)        Date   
________________________________________________  
Person Conducting Informed Consent Discussion (Printed Name)   
________________________________________________  ________________ 
Person Conducting Informed Consent Discussion (Signature)   Date 
________________________________________________  ________________ 
Signature of Investigator (If different than above)     Date 
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RESEARCH PARTICIPANT INFORMED CONSENT FORM 
TITLE: A Pilot Study to Develop A Clinical MRI Procedure and Application for Precise 
Stereotactic Body Radiation Therapy to Treat Primary or Metastatic Cancer in 
the Liver 
Group B Participants – Testing a Breathing Motion Management Device in 
Healthy Volunteers 
PROTOCOL #: MCC-16-13073 
VCU IRB #: HM20010234 
SPONSOR-
INVESTIGATOR: 
Taeho Kim, PhD 
Virginia Commonwealth University 
Massey Cancer Center 
PO Box 980058 
Richmond, VA 23298 
804-828-7418 
INTRODUCTION 
This consent form will tell you about this research study. The researchers or study team will 
explain the research study to you. Research studies only include people who choose to take 
part. You have the option to not participate. You may take home an unsigned copy of this consent 
form so that you can discuss the study with your family or friends before making your decision. If 
you have any questions, ask Dr. Kim or a member of the study team for more explanation. 
WHY IS THIS STUDY BEING DONE? 
This study is being done to develop and test systems that may be able to improve the process 
of treatment planning for a type of radiation therapy called “stereotactic body radiation therapy” 
(SBRT) for patients with cancer. Managing the normal breathing movement of the chest and 
abdomen can improve SBRT treatment planning. You are being asked to participate as a 
healthy volunteer by testing the device that will be used to manage breathing during treatment 
planning.  
There will be about 10 to 15 healthy volunteers taking part in Group B of this study. 
WHAT WILL I BE ASKED TO DO IF I TAKE PART IN THIS STUDY? 
Participants in Group B will be asked to attend one 60-minute session to test a breathing device. 
The session will take place in the Radiation Oncology Department at Virginia Commonwealth 
University (VCU). While lying on a couch, you will use the breathing device that has been 
developed for this study. Tracings will be made of your breathing and the movement of your 
chest and abdomen.  
Before or during your session, you will be weighed and have your height measured. Information 
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HOW LONG WILL I BE IN THIS STUDY? 
Your participation in Group B will take place on one day during a session lasting about one 
hour.  
WHAT POSSIBLE RISKS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
There are no anticipated risks or discomforts. 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You will not receive any benefit from taking part in this study. In the future, patients with cancer 
may benefit from the knowledge gained through your participation in this study.  
CAN I STOP TAKING PART IN THIS STUDY? 
Yes. You can decide to stop at any time. If you decide to stop taking part in this study, the 
information collected about you up to the time that you stop taking part in the study will be kept 
in the study and will not be removed. 
The researchers will tell you about new information or changes in the study that may affect your 
willingness to take part in the study. If the study is stopped by the sponsor or the institutional 
review board (IRB), which is a group of people who review the research with the goal of 
protecting the people who take part in the study, the researchers may take you out of the study. 
WHAT ARE MY RIGHTS IN THIS STUDY? 
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. Your decision will not affect your relationship 
with the researchers or with VCU. You will not lose any legal rights. 
WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY? 
You will not be billed for any of the research activities for this study. 
You will not be paid for taking part in this study. 
WHO WILL SEE MY INFORMATION? 
Your privacy is very important to us. The researchers will make every effort to protect it but your 
information may be given out if required by law. However, the researchers will do their best to 
make sure that any information that is released will not identify you.  
Your research records will be kept private through the use of password-protected electronic files 
and locked research areas. Study identification numbers and your initials instead of your name 
will be used on any study records. The results of this research may be presented at meetings or 
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There are groups that may inspect your records. These groups are required to make sure your 
information is kept private, unless required by law to provide information. Some of these groups 
are: 
• Virginia Commonwealth University (VCU) 
• VCU IRB  
• National Cancer Institute (NCI) 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
You can talk to Dr. Kim about any questions or concerns you have about this study. You can 
also contact a study team member at 804-628-2334.  
The Office of Sponsored Research can answer your general questions or concerns about your 
rights as a participant in this or any other research. Also, if you would like to speak to a person 
who does not work directly with Dr. Kim and the study team or if you cannot reach the 
researchers or a member of the study team, you may contact the Office of Research. 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 3000 
PO Box 980568 
Richmond, VA 23298 
804-827-2157 
MY SIGNATURE AGREEING TO TAKE PART IN GROUP B OF THIS STUDY 
I have been given the opportunity to carefully read this consent form. All of the questions that I 
wish to raise concerning this study have been answered. 
By signing this consent form, I have not given up any of my legal rights or benefits. My signature 
indicates that I freely consent to participate in this research study. I will receive a copy of the 
signed consent form. 
________________________________________________  
Participant Name (Printed) 
________________________________________________  ________________ 
Participant Name (Signature)        Date   
________________________________________________  
Person Conducting Informed Consent Discussion (Printed Name)   
________________________________________________  ________________ 
Person Conducting Informed Consent Discussion (Signature)   Date 
________________________________________________  ________________ 
Signature of Investigator (If different than above)     Date 
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RESEARCH PARTICIPANT INFORMED CONSENT FORM 
TITLE: A Pilot Study to Develop A Clinical MRI Procedure and Application for Precise 
Stereotactic Body Radiation Therapy to Treat Primary or Metastatic Cancer in 
the Liver 
Group C Participants – Magnetic Resonance Imaging (MRI) of the Chest and 
Abdomen Using the Breathing Motion Management System in Healthy 
Volunteers 
PROTOCOL #: MCC-16-13073 
VCU IRB #: HM20010234 
SPONSOR-
INVESTIGATOR: 
Taeho Kim, PhD 
Virginia Commonwealth University 
Massey Cancer Center 
PO Box 980058 
Richmond, VA 23298 
804-828-7418 
INTRODUCTION 
This consent form will tell you about this research study. The researchers or study team will 
explain the research study to you. Research studies only include people who choose to take 
part. You have the option to not participate. You may take home an unsigned copy of this consent 
form so that you can discuss the study with your family or friends before making your decision. If 
you have any questions, ask Dr. Kim or a member of the study team for more explanation.  
WHY IS THIS STUDY BEING DONE? 
This study is being done to develop and test systems that may be able to improve the process 
of treatment planning for a type of radiation therapy called “stereotactic body radiation therapy” 
(SBRT) for patients with cancer. You are being asked to participate as a healthy volunteer by 
having a magnetic resonance imaging (MRI) scan of your chest and abdomen while using the 
breathing motion management device developed for this study. An MRI is a type of scan that 
uses magnetic fields and radio waves to make a picture. In this study, the purpose of the MRI is 
to find out how managing the normal breathing movement of the chest and abdomen during the 
MRI affects the MRI pictures. 
There will be about 4 to 6 healthy participants in Group C of this study. 
WHAT WILL I BE ASKED TO DO IF I TAKE PART IN THIS STUDY? 
Participants in Group C will be asked to have MRI scans of the chest and abdomen while using 
the breathing motion management device that has been developed for this study. You will have 
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Before Study Enrollment  
• You will be asked to complete a standard MRI questionnaire to identify any reason you 
should not have an MRI scan, for example, the presence of metal objects in your body or 
implanted medical devices.  
• You will be weighed and have your height measured. Information about you including 
your age, sex, race, and ethnicity will be collected. 
After Study Enrollment 
• You will have two research MRI scans while using the breathing motion management 
device developed for this study. These research MRIs will be performed at a nearby 
imaging facility called “Collaborative Advanced Research Imaging (CARI)”. The CARI 
facility is located in Richmond, Virginia near the VCU campus. 
• You will have the MRIs at the following time points: 
− About 2 to 3 weeks after you are enrolled in the study  
− About 1 to 4 weeks after the first MRI 
• If you are able to become pregnant, you will have a urine pregnancy test at CARI before 
each scan. 
• Before the MRI, you will practice using the breathing management device so that you 
are able to breathe evenly and consistently over a short period of time. During the MRI, 
you will lie inside a small closed area inside a large magnetic tube. Each of the two 
sessions will take 1 to 2 hours including the breathing practice and MRI. 
Results of the MRI scans will not be provided to you because the type of research scan being 
performed are not for the purpose of detecting problems or diagnosing illnesses. However, in 
the unlikely event that an abnormality is noted on your research MRI images, the study doctor 
will talk with you about the abnormal finding and suggest follow-up steps. 
HOW LONG WILL I BE IN THIS STUDY? 
You will be in the study as a participant in Group C for about 1 to 2 months depending on when 
you have your MRI scans.  
WHAT POSSIBLE RISKS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You may be bothered by the MRI machine noise and by feelings of being closed in 
(claustrophobia). Using the breathing motion management device during the MRI may possibly 
increase your feeling of being closed in. 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You will not receive any benefit from taking part in this study. In the future, patients with cancer 
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CAN I STOP TAKING PART IN THIS STUDY? 
Yes. You can decide to stop at any time. If you decide to stop taking part in this study, the 
information collected about you up to the time that you stop taking part in the study will be kept 
in the study and will not be removed. 
The researchers will tell you about new information or changes in the study that may affect your 
willingness to take part in the study. If the study is stopped by the sponsor or the institutional 
review board (IRB), which is a group of people who review the research with the goal of 
protecting the people who take part in the study, the researchers may take you out of the study. 
WHAT ARE MY RIGHTS IN THIS STUDY? 
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. Your decision will not affect your relationship 
with the researchers or with VCU. You will not lose any legal rights. 
WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY? 
You will not be billed for any of the research activities for this study. 
You will not be paid for taking part in this study, but a small stipend ($50.00 for each MRI scan) 
will be provided. 
WHO WILL SEE MY INFORMATION? 
Your privacy is very important to us. The researchers will make every effort to protect it but your 
information may be given out if required by law. However, the researchers will do their best to 
make sure that any information that is released will not identify you. 
Your MRI images and research records will be kept private through the use of password-
protected electronic files and locked research areas. Study identification numbers and your 
initials instead of your name will be used on any study records. The results of this research may 
be presented at meetings or in publications, but you will not be identified by name. 
There are groups that may inspect your records. These groups are required to make sure your 
information is kept private, unless required by law to provide information. Some of these groups 
are: 
• Virginia Commonwealth University (VCU) 
• VCU IRB  
• National Cancer Institute (NCI) 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
You can talk to Dr. Kim about any questions or concerns you have about this study. You can 
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The Office of Sponsored Research can answer your general questions or concerns about your 
rights as a participant in this or any other research. Also, if you would like to speak to a person 
who does not work directly with Dr. Kim and the study team or if you cannot reach the 
researchers or a member of the study team, you may contact the Office of Research. 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 3000 
PO Box 980568 
Richmond, VA 23298 
804-827-2157 
MY SIGNATURE AGREEING TO TAKE PART IN GROUP C OF THIS STUDY 
I have been given the opportunity to carefully read this consent form. All of the questions that I 
wish to raise concerning this study have been answered. 
By signing this consent form, I have not given up any of my legal rights or benefits. My signature 
indicates that I freely consent to participate in this research study. I will receive a copy of the 
signed consent form. 
________________________________________________  
Participant Name (Printed) 
________________________________________________  ________________ 
Participant Name (Signature)        Date   
________________________________________________  
Person Conducting Informed Consent Discussion (Printed Name)   
________________________________________________  ________________ 
Person Conducting Informed Consent Discussion (Signature)   Date 
________________________________________________  ________________ 
Signature of Investigator (If different than above)     Date 
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RESEARCH PARTICIPANT INFORMED CONSENT FORM 
TITLE: A Pilot Study to Develop A Clinical MRI Procedure and Application for Precise 
Stereotactic Body Radiation Therapy to Treat Primary or Metastatic Cancer in 
the Liver 
Group D Participants – Magnetic Resonance Imaging (MRI) of the Chest and 
Abdomen Using the Breathing Motion Management System in Participants with 
Cancer in the Liver  
PROTOCOL #: MCC-16-13073 
VCU IRB #: HM20010234 
SPONSOR-
INVESTIGATOR: 
Taeho Kim, PhD 
Virginia Commonwealth University 
Massey Cancer Center 
PO Box 980058 
Richmond, VA 23298 
804-828-7418 
INTRODUCTION 
This consent form will tell you about this research study. The researchers or study team will 
explain the research study to you. Research studies only include people who choose to take 
part. You have the option to not participate. You may take home an unsigned copy of this consent 
form so that you can discuss the study with your family or friends before making your decision. If 
you have any questions, ask Dr. Kim or a member of the study team for more explanation.  
WHY IS THIS STUDY BEING DONE? 
This study is being done to develop and test systems that may be able to improve the process 
of treatment planning for a type of radiation therapy called “stereotactic body radiation therapy” 
(SBRT) for patients with cancer. You are being asked to participate by having a magnetic 
resonance imaging (MRI) scan of the chest and abdomen while using the breathing motion 
management device developed for this study. An MRI is a type of scan that uses magnetic fields 
and radio waves to make a picture. In this study, the purpose of the MRI is to find out how 
managing the normal breathing movement of the chest and abdomen during the MRI affects the 
MRI pictures. 
There will be about 4 to 6 participants with cancer in the liver taking part in Group D of this 
study. 
WHAT WILL I BE ASKED TO DO IF I TAKE PART IN THIS STUDY? 
All participants in Group D will be asked to have MRI scans of the chest and abdomen while 
using the breathing motion management device that has been developed for this study. Results 
of the MRI scans will not be used for planning your SBRT treatment because the methods used 
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You will have the following tests and procedures for the purposes of this research study: 
Before Study Enrollment 
• You will be asked to complete a standard MRI questionnaire to identify any reason you 
should not have an MRI scan, for example, the presence of metal objects in your body or 
implanted medical devices.  
• Information about you including your age, sex, race, ethnicity, height, and weight will be 
collected. 
After Study Enrollment 
• You will have two research MRI scans while using the breathing motion management 
device developed for this study. These research MRIs will be performed at a nearby 
imaging facility called “Collaborative Advanced Research Imaging (CARI)”. The CARI 
facility is located in Richmond, Virginia near the VCU campus. 
• You will have the MRIs at the following time points: 
− Before your first SBRT treatment (within 3 weeks after you are enrolled in the study)  
− Within 1 to 4 weeks after your SBRT treatments have been completed 
• If you are able to become pregnant, you will have a urine pregnancy test at CARI before 
each scan. 
• Before the MRI, you will practice using the breathing management device so that you 
are able to breathe evenly and consistently over a short period of time. During the MRI, 
you will lie inside a small closed area inside a large magnetic tube. Each of the two 
sessions will take 1 to 2 hours including the breathing practice and MRI. 
HOW LONG WILL I BE IN THIS STUDY? 
You will be in the study as a participant in Group D for about 1 to 2 months depending on when 
you have your MRI scans.  
WHAT POSSIBLE RISKS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You may be bothered by the MRI machine noise and by feelings of being closed in 
(claustrophobia). Using the breathing motion management device during the MRI may possibly 
increase your feeling of being closed in. 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS STUDY? 
You will not receive any benefit from taking part in this study. Future patients with cancer may 
benefit from the knowledge gained through your participation in this study.  
CAN I STOP TAKING PART IN THIS STUDY? 
Yes. You can decide to stop at any time. If you decide to stop taking part in this study, the 
information collected about you up to the time that you stop taking part in the study will be kept 
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The researchers will tell you about new information or changes in the study that may affect your 
willingness to have the MRI scans. If the study is stopped by the sponsor or the institutional 
review board (IRB), which is a group of people who review the research with the goal of 
protecting the people who take part in the study, the researchers may take you out of the study. 
WHAT ARE MY RIGHTS IN THIS STUDY? 
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. Your decision will not affect your medical care 
or your relationship with the researchers or with VCU. You will not lose any legal rights. 
WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY? 
You will not be billed for any of the research activities for this study. 
You will not be paid for taking part in this study, but a small stipend ($50.00 for each MRI scan) 
will be provided. 
WHO WILL SEE MY INFORMATION? 
Your privacy is very important to us. The researchers will make every effort to protect it but your 
information may be given out if required by law. However, the researchers will do their best to 
make sure that any information that is released will not identify you. 
Your research records will be kept private through the use of password-protected electronic files 
and locked research areas. Study identification numbers and your initials instead of your name 
will be used on any study records. The results of this research may be presented at meetings or 
in publications, but you will not be identified by name. 
There are groups that may inspect your records. These groups are required to make sure your 
information is kept private, unless required by law to provide information. Some of these groups 
are: 
• Virginia Commonwealth University (VCU) 
• VCU IRB  
• National Cancer Institute (NCI) 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
You can talk to Dr. Kim about any questions or concerns you have about this study. You can 
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The Office of Sponsored Research can answer your general questions or concerns about your 
rights as a participant in this or any other research. Also, if you would like to speak to a person 
who does not work directly with Dr. Kim and the study team or if you cannot reach the 
researchers or a member of the study team, you may contact the Office of Research. 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 3000 
PO Box 980568 
Richmond, VA 23298 
804-827-2157 
MY SIGNATURE AGREEING TO TAKE PART IN GROUP D OF THIS STUDY 
I have been given the opportunity to carefully read this consent form. All of the questions that I 
wish to raise concerning this study have been answered. 
By signing this consent form, I have not given up any of my legal rights or benefits. My signature 
indicates that I freely consent to participate in this research study. I will receive a copy of the 
signed consent form. 
________________________________________________  
Participant Name (Printed) 
________________________________________________  ________________ 
Participant Name (Signature)        Date   
________________________________________________  
Person Conducting Informed Consent Discussion (Printed Name)   
________________________________________________  ________________ 
Person Conducting Informed Consent Discussion (Signature)   Date 
________________________________________________  ________________ 





1 %S c r i p t to c r e a t e GUI f o r DICOM import , image r e g i s t r a t i o n ,
deno i s ing , and
2 %IVIM a n a l y s i s o f DW MRI a c q u i s i t i o n s .
3 %% Run IVIM GUI app to get user s e l e c t e d opt ions
4 c l e a r
5
6 run IVIM GUI v1 . mlapp
7
8 w a i t f o r ( IVIM GUI v1 )
9
10 %Pr int s s e l e c t e d parameters to command window .
11 f p r i n t f ( ’%s\n\n ’ , ’ S e l e c t ed parameters ’ ) ; f p r i n t f ( ’Number o f
f o l d e r s : ’ ) ;
12 f p r i n t f ( num fo lde r s va lue ) ; f p r i n t f ( ’\nImage r e g i s t r a t i o n : ’ )
; f p r i n t f ( r e g i s t r a t i o n v a l u e ) ;
13 f p r i n t f ( ’\nDenois ing : ’ ) ; f p r i n t f ( d e n o i s i n g v a l u e ) ; f p r i n t f ( ’
\nROI p r e f e r e n c e : ’ ) ;
14 f p r i n t f ( ROI value ) ; f p r i n t f ( ’\nADC: ’ ) ; f p r i n t f ( mat2str (
ADC calc value ) ) ;
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15 f p r i n t f ( ’\nIVIM c a l c u l a t i o n type : ’ ) ; f p r i n t f ( IVIM calc va lue
) ; f p r i n t f ( ’\n ’ ) ;
16 f p r i n t f ( ’\nTA c a l c : ’ ) ; f p r i n t f ( mat2str ( TA calc va lue ) ) ;
17
18 i f ADC calc value == 0
19 ADC calc = ’No ADC c a l c u l a t i o n ’ ;
20 end
21
22 i f ADC calc value == 1




27 %Open s e l e c t e d f o l d e r s and save DICOM f i l e s in f o l d e r s to
matrix , and
28 %e x t r a c t image matrix , b values , and number o f b va lue s .
29
30 i f num fo lde r s va lue == ’One f o l d e r ’
31 f o lder one name = u i g e t d i r ( ’ ’ , ’ S e l e c t f o l d e r conta in ing
d i f f u s i o n weighted image s e t f o r a n a l y s i s ’ )
32
33 i f i s e q u a l ( fo lder one name , 0 )
34 di sp ( ’ User pre s s ed cance l ’ )




38 [ f u l l m a t r i x num b vals un ique b va l s image s i z e ] =
DICOM to matrix one ( fo lder one name ) ;
39 end
40
41 i f num fo lde r s va lue == ’Two f o l d e r s ’
42 f o lder one name = u i g e t d i r ( ’ ’ , ’ S e l e c t f i r s t f o l d e r
conta in ing d i f f u s i o n weighted image s e t f o r a n a l y s i s ’ )
43 fo lder two name = u i g e t d i r ( ’ ’ , ’ S e l e c t second f o l d e r
conta in ing d i f f u s i o n weighted image s e t f o r a n a l y s i s ’ )
44
45 i f i s e q u a l ( fo lder one name , 0 ) | i s e q u a l ( fo lder two name , 0 )
46 di sp ( ’ User pre s s ed cance l ’ )
47 r e turn
48 end
49
50 [ f u l l m a t r i x num b vals un ique b va l s image s i z e ] =
DICOM to matrix two ( fo lder one name , fo lder two name ) ;
51 end
52
53 o r i g i n a l i m a g e = f u l l m a t r i x ;
54
55 %%
56 %Perform image r e g i s t r a t i o n us ing MI based r i g i d r e g i s t r a t i o n
57
183
58 i f r e g i s t r a t i o n v a l u e == ’ Mutual in fo rmat ion based r i g i d
r e g i s t r a t i o n ’
59 [ f u l l m a t r i x ] = MI reg ( f u l l m a t r i x ) ;
60 r e g i s t e r e d i m a g e = f u l l m a t r i x ;
61 end
62
63 i f r e g i s t r a t i o n v a l u e == ’No image r e g i s t r a t i o n ’






70 %Perform deno i s ing us ing d e s i r e d deno i s i ng method
71
72 i f d e n o i s i n g v a l u e == ’Non−l o c a l means f i l t e r i n g ’
73 [ f u l l m a t r i x ] = MRI denoised ( f u l l m a t r i x ) ;
74 denoised image = f u l l m a t r i x ;
75 end
76
77 i f d e n o i s i n g v a l u e == ’No deno i s ing ’
78 denoised image = [ ]
79 end
80
81 image s i z e = s i z e ( f u l l m a t r i x ) ;
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82 %%
83 %Prompts user to draw ROI f o r d e s i r e d c a l c u l a t i o n volume
84
85 i f ROI value == ’Draw custom ROI ’
86 [ ro i mask ] = ROI contour ( f u l l m a t r i x ) ;
87 end
88
89 i f ROI value == ’ Load ROI from . mat f i l e ’
90 [ f i l e , path ] = u i g e t f i l e ;
91 f u l l f i l e = f u l l f i l e ( path , f i l e ) ;
92 ro i mask = load ( f u l l f i l e ) ;
93 end
94
95 i f ROI value == ’No ROI ’




100 %Perform ADC c a l c f o r volume i f d e s i r e d
101
102 i f ADC calc value == 1
103 [ ADC full ] = ADC calc ( f u l l m a t r i x , un ique b va lue s ) ;
104 end
105
106 i f ADC calc value == 0
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111 %Perform d e s i r e d IVIM c a l c u l a t i o n method
112
113 i f IVIM method == ’ Biexponent ia l method ’
114 [ D map D star map PF map ] = Biexponentia l IVIM (
f u l l m a t r i x ro i mask un ique b va lue s ) ;
115 D star map = [ ] ;
116 end
117
118 i f IVIM method == ’ Monoexponential method ’
119 [ D map PF map ] = Monoexponential IVIM ( f u l l m a t r i x ADC map
roi mask un ique b va lue s ) ;
120 D star map = [ ] ;
121 end
122
123 i f IVIM method == ’ LeBihan method ’
124 [ D map PF map ] = LeBihan IVIM ( f u l l m a t r i x ro i mask
un ique b va lue s ) ;





129 %Perform Texture a n a l y s i s i f d e s i r e d
130
131 i f TA calc va lue == 1
132 [ TA values ] = TA calc ( f u l l m a t r i x ) ;
133 end
134
135 i f TA calc va lue == 0
136 TA values = [ ] ;
137 end
138 %%
139 %Generate c e l l array conta in ing Or i g i na l image ,
140
141 Output values = c e l l ( 1 , 9 )
142 Output values ( 1 , : ) = o r i g i n a l i m a g e ;
143 Output values ( 2 , : ) = denoised image ;
144 Output values ( 3 , : ) = r e g i s t e r e d i m a g e ;
145 Output values ( 4 , : ) = roi mask ;
146 Output values ( 5 , : ) = ADC map;
147 Output values ( 6 , : ) = D map ;
148 Output values ( 7 , : ) = D star map ;
149 Output values ( 8 , : ) = PF map ;
150 Output values ( 9 , : ) = TA values ;
B.2 GUI main code
1 c l a s s d e f IVIM GUI v1 exported < matlab . apps . AppBase
2
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3 % P ro p e r t i e s that correspond to app components
4 p r o p e r t i e s ( Access = pub l i c )
5 UIFigure matlab . u i . Figure
6 Performdenois ingwithselectedmethodButtonGroup matlab
. u i . c on ta ine r . ButtonGroup
7 NodenoisingButton matlab . u i . c o n t r o l .
RadioButton
8 Nonloca lmeans f i l t e r ingButton matlab . u i . c o n t r o l .
RadioButton
9 DrawROItodefinecalculationvolumeButtonGroup matlab .
u i . c on ta ine r . ButtonGroup
10 NoROIButton matlab . u i . c o n t r o l .
RadioButton
11 LoadROIfrommatfileButton matlab . u i . c o n t r o l .
RadioButton
12 DrawcustomROIButton matlab . u i . c o n t r o l .
RadioButton
13 SelectIVIMcalculationmethodButtonGroup matlab . u i .
c on ta ine r . ButtonGroup
14 LeBihanmethodnoDatleast3bvaluesButton matlab . u i .
c o n t r o l . RadioButton
15 MonoexponentialmethodNoDrequires2bvaluesButton
matlab . u i . c o n t r o l . RadioButton
16 BiexponentialmethodButton matlab . u i . c o n t r o l .
RadioButton
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17 PerformADCcalculationCheckBox matlab . u i . c o n t r o l .
CheckBox
18 NumberoffolderscontainingDWimagesetsButtonGroup
matlab . u i . c on ta ine r . ButtonGroup
19 OnefolderButton matlab . u i . c o n t r o l .
RadioButton
20 TwofoldersButton matlab . u i . c o n t r o l .
RadioButton
21 Performimageregistrat ionButtonGroup matlab . u i .
c on ta ine r . ButtonGroup
22 Noimagereg i s t rat ionButton matlab . u i . c o n t r o l .
RadioButton
23 Mutua l in f o rmat i onbased r i g id r eg i s t r a t i onBut ton matlab
. u i . c o n t r o l . RadioButton
24 OptionsforIVIMandTextureAnalys isCalculat ionToolboxLabel
matlab . u i . c o n t r o l . Label
25 DoneButton matlab . u i . c o n t r o l .
Button




29 methods ( Access = pr i va t e )
30
31 % Button pushed func t i on : DoneButton
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32 f unc t i on DoneButtonPushed ( app , event )
33 ADC calc button = app .
PerformADCcalculationCheckBox . Value ;
34 deno i s ing but ton = app .
Performdenois ingwithselectedmethodButtonGroup .
Se l e c t edObjec t ;
35 IVIM calc button = app .
SelectIVIMcalculationmethodButtonGroup .
Se l e c t edObjec t ;
36 num fo lders button = app .
NumberoffolderscontainingDWimagesetsButtonGroup
. Se l e c t edObjec t ;
37 r e g i s t r a t i o n b u t t o n = app .
Per formimageregistrat ionButtonGroup .
Se l e c t edObjec t ;
38 ROI button = app .
DrawROItodefinecalculationvolumeButtonGroup .
Se l e c t edObjec t ;
39 TA calc button = app .
PerformTextureAnalysisCheckBox . Value ;
40
41 ADC calc value = ADC calc button ;
42 d e n o i s i n g v a l u e = deno i s ing but ton . Text ;
43 IVIM calc va lue = IVIM calc button . Text ;
44 num fo lde r s va lue = num fo lders button . Text ;
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45 r e g i s t r a t i o n v a l u e = r e g i s t r a t i o n b u t t o n . Text ;
46 ROI value = ROI button . Text ;
47 TA calc va lue = TA calc button
48
49 a s s i g n i n ( ’ base ’ , ’ ADC calc value ’ , ADC calc value ) ;
50 a s s i g n i n ( ’ base ’ , ’ d e n o i s i n g v a l u e ’ , d e n o i s i n g v a l u e
) ;
51 a s s i g n i n ( ’ base ’ , ’ IVIM calc va lue ’ , IVIM calc va lue
) ;
52 a s s i g n i n ( ’ base ’ , ’ num fo lde r s va lue ’ ,
num fo lde r s va lue ) ;
53 a s s i g n i n ( ’ base ’ , ’ r e g i s t r a t i o n v a l u e ’ ,
r e g i s t r a t i o n v a l u e ) ;
54 a s s i g n i n ( ’ base ’ , ’ ROI value ’ , ROI value ) ;
55 a s s i g n i n ( ’ base ’ , ’ TA calc va lue ’ , TA calc va lue ) ;
56




61 % App i n i t i a l i z a t i o n and con s t ru c t i on
62 methods ( Access = pr i va t e )
63
64 % Create UIFigure and components
65 f unc t i on createComponents ( app )
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66
67 % Create UIFigure
68 app . UIFigure = u i f i g u r e ;
69 app . UIFigure . Po s i t i on = [100 100 640 4 8 0 ] ;




73 app . Performdenois ingwithselectedmethodButtonGroup
= uibuttongroup ( app . UIFigure ) ;
74 app . Performdenois ingwithselectedmethodButtonGroup
. T i t l e = ’ Perform deno i s ing with s e l e c t e d
method ’ ;
75 app . Performdenois ingwithselectedmethodButtonGroup
. Pos i t i on = [24 211 258 8 0 ] ;
76
77 % Create NodenoisingButton
78 app . NodenoisingButton = ui rad iobut ton ( app .
Performdenois ingwithselectedmethodButtonGroup )
;
79 app . NodenoisingButton . Text = ’No deno i s ing ’ ;
80 app . NodenoisingButton . Pos i t i on = [11 37 92 2 2 ] ;
81 app . NodenoisingButton . Value = true ;
82
83 % Create Non loca lmeans f i l t e r ingButton
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85 app . Non loca lmeans f i l t e r ingButton . Text = ’Non−
l o c a l means f i l t e r i n g ’ ;
86 app . Non loca lmeans f i l t e r ingButton . Pos i t i on = [11




89 app . DrawROItodefinecalculationvolumeButtonGroup =
uibuttongroup ( app . UIFigure ) ;
90 app . DrawROItodefinecalculationvolumeButtonGroup .
T i t l e = ’Draw ROI to d e f i n e c a l c u l a t i o n volume
’ ;
91 app . DrawROItodefinecalculationvolumeButtonGroup .
Pos i t i on = [371 300 229 1 0 6 ] ;
92
93 % Create NoROIButton
94 app . NoROIButton = ui rad iobut ton ( app .
DrawROItodefinecalculationvolumeButtonGroup ) ;
95 app . NoROIButton . Text = ’No ROI ’ ;
96 app . NoROIButton . Pos i t i on = [11 60 62 2 2 ] ;
97 app . NoROIButton . Value = true ;
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98
99 % Create LoadROIfrommatfileButton
100 app . LoadROIfrommatfileButton = ui rad iobut ton ( app .
DrawROItodefinecalculationvolumeButtonGroup ) ;
101 app . LoadROIfrommatfileButton . Text = ’ Load ROI
from . mat f i l e ’ ;
102 app . LoadROIfrommatfileButton . Pos i t i on = [11 38
146 2 2 ] ;
103
104 % Create DrawcustomROIButton
105 app . DrawcustomROIButton = ui rad iobut ton ( app .
DrawROItodefinecalculationvolumeButtonGroup ) ;
106 app . DrawcustomROIButton . Text = ’Draw custom ROI ’ ;
107 app . DrawcustomROIButton . Pos i t i on = [11 16 117
2 2 ] ;
108
109 % Create SelectIVIMcalculationmethodButtonGroup
110 app . SelectIVIMcalculationmethodButtonGroup =
uibuttongroup ( app . UIFigure ) ;
111 app . SelectIVIMcalculationmethodButtonGroup . T i t l e
= ’ S e l e c t IVIM c a l c u l a t i o n method ’ ;
112 app . SelectIVIMcalculationmethodButtonGroup .
Pos i t i on = [371 60 229 1 3 6 ] ;
113
114 % Create LeBihanmethodnoDatleast3bvaluesButton
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115 app . LeBihanmethodnoDatleast3bvaluesButton =
ui rad iobut ton ( app .
SelectIVIMcalculationmethodButtonGroup ) ;
116 app . LeBihanmethodnoDatleast3bvaluesButton . Text =
{ ’ LeBihan method ( no D∗ ’ ; ’ at l e a s t 3 b−
va lues ) ’ } ;
117 app . LeBihanmethodnoDatleast3bvaluesButton .
Pos i t i on = [11 40 147 2 8 ] ;











. Text = { ’ Monoexponential method (No D∗ ’ ; ’
r e q u i r e s 2 b−va lue s ) ’ } ;
123 app .
MonoexponentialmethodNoDrequires2bvaluesButton
. Pos i t i on = [11 77 194 2 8 ] ;
124
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125 % Create BiexponentialmethodButton
126 app . BiexponentialmethodButton = ui rad iobut ton ( app
. SelectIVIMcalculationmethodButtonGroup ) ;
127 app . BiexponentialmethodButton . Text = ’
Biexponent ia l method ’ ;
128 app . BiexponentialmethodButton . Pos i t i on = [11 10
137 2 2 ] ;
129
130 % Create PerformADCcalculationCheckBox
131 app . PerformADCcalculationCheckBox = uicheckbox (
app . UIFigure ) ;
132 app . PerformADCcalculationCheckBox . Text = ’ Perform
ADC c a l c u l a t i o n ’ ;
133 app . PerformADCcalculationCheckBox . Pos i t i on = [382






= uibuttongroup ( app . UIFigure ) ;
137 app .
NumberoffolderscontainingDWimagesetsButtonGroup
. T i t l e = ’Number o f f o l d e r s conta in ing DW
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image s e t s ’ ;
138 app .
NumberoffolderscontainingDWimagesetsButtonGroup
. Pos i t i on = [24 337 258 6 9 ] ;
139
140 % Create OnefolderButton
141 app . OnefolderButton = ui rad iobut ton ( app .
NumberoffolderscontainingDWimagesetsButtonGroup
) ;
142 app . OnefolderButton . Text = ’One f o l d e r ’ ;
143 app . OnefolderButton . Pos i t i on = [11 23 78 2 2 ] ;
144 app . OnefolderButton . Value = true ;
145
146 % Create TwofoldersButton
147 app . TwofoldersButton = ui rad iobut ton ( app .
NumberoffolderscontainingDWimagesetsButtonGroup
) ;
148 app . TwofoldersButton . Text = ’Two f o l d e r s ’ ;
149 app . TwofoldersButton . Pos i t i on = [11 1 83 2 2 ] ;
150
151 % Create Performimageregistrat ionButtonGroup
152 app . Performimageregistrat ionButtonGroup =
uibuttongroup ( app . UIFigure ) ;
153 app . Performimageregistrat ionButtonGroup . T i t l e = ’
Perform image r e g i s t r a t i o n ’ ;
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154 app . Performimageregistrat ionButtonGroup . Pos i t i on
= [24 91 258 8 7 ] ;
155
156 % Create Noimagereg i s t rat ionButton
157 app . Noimagereg i s t rat ionButton = ui rad iobut ton ( app
. Per formimageregistrat ionButtonGroup ) ;
158 app . Noimagereg i s t rat ionButton . Text = ’No image
r e g i s t r a t i o n ’ ;
159 app . Noimagereg i s t rat ionButton . Pos i t i on = [11 45
136 2 2 ] ;
160 app . Noimagereg i s t rat ionButton . Value = true ;
161
162 % Create
Mutua l in f o rmat i onbased r i g id r eg i s t r a t i onBut ton
163 app . Mutua l i n f o rmat i onbased r i g id r eg i s t r a t i onBut ton
= ui rad iobut ton ( app .
Per formimageregistrat ionButtonGroup ) ;
164 app . Mutua l i n f o rmat i onbased r i g id r eg i s t r a t i onBut ton
. Text = ’ Mutual in fo rmat ion based r i g i d
r e g i s t r a t i o n ’ ;
165 app . Mutua l i n f o rmat i onbased r i g id r eg i s t r a t i onBut ton







= u i l a b e l ( app . UIFigure ) ;
169 app .
OptionsforIVIMandTextureAnalys isCalculat ionToolboxLabel
. Hor izontalAl ignment = ’ cen te r ’ ;
170 app .
OptionsforIVIMandTextureAnalys isCalculat ionToolboxLabel
. FontSize = 20 ;
171 app .
OptionsforIVIMandTextureAnalys isCalculat ionToolboxLabel
. Po s i t i on = [58 440 529 2 4 ] ;
172 app .
OptionsforIVIMandTextureAnalys isCalculat ionToolboxLabel
. Text = ’ Options f o r IVIM and Texture Ana lys i s
Ca l cu l a t i on Toolbox ’ ;
173
174 % Create DoneButton
175 app . DoneButton = uibutton ( app . UIFigure , ’ push ’ ) ;
176 app . DoneButton . ButtonPushedFcn =
createCal lbackFcn ( app , @DoneButtonPushed , t rue
) ;
177 app . DoneButton . Pos i t i on = [271 22 100 2 2 ] ;
178 app . DoneButton . Text = ’Done ’ ;
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179
180 % Create PerformTextureAnalysisCheckBox
181 app . PerformTextureAnalysisCheckBox = uicheckbox (
app . UIFigure ) ;
182 app . PerformTextureAnalysisCheckBox . Text = ’
Perform Texture Ana lys i s ’ ;
183 app . PerformTextureAnalysisCheckBox . Pos i t i on =




187 methods ( Access = pub l i c )
188
189 % Construct app
190 f unc t i on app = IVIM GUI v1 exported
191
192 % Create and c o n f i g u r e components
193 createComponents ( app )
194
195 % Reg i s t e r the app with App Des igner
196 r eg i s t e rApp ( app , app . UIFigure )
197
198 i f nargout == 0





203 % Code that execute s be f o r e app d e l e t i o n
204 f unc t i on d e l e t e ( app )
205
206 % Delete UIFigure when app i s de l e t ed





1 f unc t i on [ f u l l m a t r i x num b vals un ique b va l s image s i z e ] =
DICOM to matrix one ( fo lder one name )
2 %DICOM to matrix one
3 % Takes in the d i r e c t o r y o f a s i n g l e f o l d e r with a
d i f f u s i o n weighted
4 % image s e t and conver t s the DICOM f i l e s to an array with
the
5 % dimmensions : [ x y b−va lue s s l i c e s ]
6
7 %%MRI Read in DICOM data f o r IVIM scan
8
9
10 cd fo lder one name
11 i m a g e f i l e s = d i r ( fo lder one name )
201
12 num images = s i z e ( i m a g e f i l e s , 1 ) %Counts the number o f f i l e s
in the s e l e c t e d f o l d e r
13
14 b va lue s1 = ze ro s (1 , num images ) ;
15 p o s i t i o n = ze ro s (1 , num images ) ;
16





22 %%Generate 4D Matrix o f 2D images in a and b , by b−value in c
, and s l i c e in
23 %d , matrix form [ a , b , c , d ]
24
25 f i r s t n a m e = g e t f i e l d ( i m a g e f i l e s ,{3 , 1} , ’name ’ ) ;
26 f i r s t i m a g e = dicomread ( f i r s t n a m e ) ;
27 image s i z e = s i z e ( f i r s t i m a g e )
28
29
30 %% Find a l l b−va lues and number o f b va lue s
31
32 f o r i = 1 : num images
33 name = g e t f i e l d ( i m a g e f i l e s , { ( i +2) ,1} , ’name ’ ) ;
34 i n f o = dicominfo (name) ;
202
35 b va lue s ( ( i ) ) = g e t f i e l d ( in fo , ’ Di f fus ionBValue ’ ) ;
36 end
37
38 un ique b va lue s = unique ( b va lue s ) ;
39
40 num b values = length ( un ique b va lue s ) ;
41
42 num s l i c e s = num images/ num b values ;
43
44 image matrix = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , num b values
, num s l i c e s ) ;
45
46 j = 0 ;
47
48 f o r s = 1 : num s l i c e s
49 f o r b = 1 : num b values
50 j = j +1;
51 name = g e t f i e l d ( i m a g e f i l e s , { ( j +2) ,1} , ’name ’ ) ;
52 image = dicomread (name) ;




57 f u l l m a t r i x = image matrix ;
58
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59 f u l l m a t r i x ( f u l l m a t r i x == 0) = eps ;
60
61 image s i z e = s i z e ( f u l l m a t r i x ) ;
62
63 end
1 f unc t i on [ f u l l m a t r i x num b vals un ique b va l s image s i z e ] =
DICOM to matrix two ( fo lder one name , fo lder two name )
2 %DICOM to matrix one
3 % Takes in the d i r e c t o r y o f a s i n g l e f o l d e r with a
d i f f u s i o n weighted
4 % image s e t and conver t s the DICOM f i l e s to an array with
the
5 % dimmensions : [ x y b−va lue s s l i c e s ]
6
7 %%MRI Read in DICOM data f o r IVIM scan
8
9
10 cd fo lder one name
11 i m a g e f i l e s = d i r ( fo lder one name )
12 num images1 = s i z e ( i m a g e f i l e s , 1 ) %Counts the number o f
f i l e s in the s e l e c t e d f o l d e r
13
14 b va lue s1 = ze ro s (1 , num images1 ) ;
15 p o s i t i o n = ze ro s (1 , num images1 ) ;
16
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21 %%Generate 4D Matrix o f 2D images in a and b , by b−value in c
, and s l i c e in
22 %d , matrix form [ a , b , c , d ]
23
24 f i r s t name1 = g e t f i e l d ( i m a g e f i l e s ,{3 , 1} , ’name ’ ) ;
25 f i r s t i m a g e 1 = dicomread ( f i r s t name1 ) ;
26 image s i z e = s i z e ( f i r s t i m a g e 1 )
27
28
29 %% Find a l l b−va lues and number o f b va lue s
30
31 f o r i = 1 : num images1
32 name = g e t f i e l d ( i m a g e f i l e s , { ( i +2) ,1} , ’name ’ ) ;
33 i n f o = dicominfo (name) ;
34 b va lue s1 ( ( i ) ) = g e t f i e l d ( in fo , ’ Di f fus ionBValue ’ ) ;
35 end
36
37 un ique b va lue s1 = unique ( b va lue s1 ) ;
38
39 num b values1 = length ( un ique b va lue s1 ) ;
40
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41 num s l i c e s1 = num images/ num b values1 ;
42
43 image matrix1 = ze ro s ( image s i z e (1 ) , image s i z e (2 ) ,
num b values1 , num s l i c e s1 ) ;
44
45 j = 0 ;
46
47 f o r s = 1 : num s l i c e s1
48 f o r b = 1 : num b values1
49 j = j +1;
50 name = g e t f i e l d ( i m a g e f i l e s , { ( j +2) ,1} , ’name ’ ) ;
51 iv im image = dicomread (name) ;




56 image matrix1 ( image matrix1 == 0) = eps ;
57
58 %% Cal l dicom images from 2nd image s e t
59 cd fo lder two name
60 i m a g e f i l e s = d i r ( fo lder one name )
61 num images2 = s i z e ( i m a g e f i l e s , 1 ) %Counts the number o f
f i l e s in the s e l e c t e d f o l d e r
62
63 b va lue s1 = ze ro s (1 , num images1 ) ;
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64 p o s i t i o n = ze ro s (1 , num images1 ) ;
65




70 %%Generate 4D Matrix o f 2D images in a and b , by b−value in c
, and s l i c e in
71 %d , matrix form [ a , b , c , d ]
72
73 f i r s t name2 = g e t f i e l d ( i m a g e f i l e s ,{3 , 1} , ’name ’ ) ;
74 f i r s t i m a g e 2 = dicomread ( f i r s t name2 ) ;
75 image s i z e = s i z e ( f i r s t i m a g e 2 )
76
77
78 %% Find a l l b−va lues and number o f b va lue s
79
80 f o r i = 1 : num images2
81 name = g e t f i e l d ( i m a g e f i l e s , { ( i +2) ,1} , ’name ’ ) ;
82 i n f o = dicominfo (name) ;
83 b va lue s2 ( ( i ) ) = g e t f i e l d ( in fo , ’ Di f fus ionBValue ’ ) ;
84 end
85
86 un ique b va lue s2 = unique ( b va lue s2 ) ;
87
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88 num b values2 = length ( un ique b va lue s2 ) ;
89
90 num s l i c e s2 = num images/ num b values2 ;
91
92 image matrix2 = ze ro s ( image s i z e (1 ) , image s i z e (2 ) ,
num b values2 , num s l i c e s2 ) ;
93
94 j = 0 ;
95
96 f o r s = 1 : num s l i c e s2
97 f o r b = 1 : num b values2
98 j = j +1;
99 name = g e t f i e l d ( i m a g e f i l e s , { ( j +2) ,1} , ’name ’ ) ;
100 iv im image = dicomread (name) ;




105 image matrix2 ( image matrix2 == 0) = eps ;
106
107 t o t a l b v a l u e s = num b values1+num b values2−1
108 un ique b va lue s = ze ro s (1 , t o t a l b v a l u e s ) ;
109 un ique b va lue s ( 1 , 1 : num b values1 ) = un ique b va lue s1 ;
110 un ique b va lue s ( 1 , ( num b values1+1) : end ) = un ique b va lue s2
( 2 : end ) ;
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111
112 f u l l m a t r i x = ze ro s ( image s i z e (1 ) , image s i z e (2 ) ,
t o t a l b v a l u e s , num s l i c e s1 ) ;
113
114 f u l l m a t r i x ( : , : , 1 : num b values1 , : ) = image matrix1 ;
115 f u l l m a t r i x ( : , : , ( num b values1+1) : ( t o t a l b v a l u e s ) , : ) =
image matrix2 ( : , : , 2 : end , : ) ;
116
117
118 f u l l m a t r i x ( f u l l m a t r i x == 0) = eps ;
B.4 Image registration
1 f unc t i on [ f u l l m a t r i x ] = MI reg ( f u l l m a t r i x ) ;
2
3 image s i z e = s i z e ( f u l l m a t r i x ) ;
4
5 num s l i c e s = image s i z e (4 ) ;
6 t o t a l b v a l u e s = image s i z e (3 ) ;
7
8 %%Rigid r e g i s t r a t i o n o f images
9
10 [ opt imizer , metr ic ] = imregcon f i g ( ’ multimodal ’ ) ;
11
12 opt imize r . I n i t i a l R a d i u s = 0 . 0 0 9 ;
13 opt imize r . Eps i lon = 1 .5 e−4;
14 opt imize r . GrowthFactor = 1 . 0 1 ;
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15 opt imize r . MaximumIterations = 300 ;
16
17
18 movingRegistered = ze ro s ( image s i z e (1 ) , image s i z e (2 ) ,
t o t a l b v a l u e s , num s l i c e s1 ) ;
19 %di f f e r ence map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) ,1 ,
t o t a l b v a l u e s ) ;
20 movingRegistered ( : , : , 1 , : ) = f u l l m a t r i x ( : , : , 1 , : ) ;
21
22 f o r k = 1 : num s l i c e s
23 f o r i = 2 : t o t a l b v a l u e s
24 f i x e d = f u l l m a t r i x ( : , : , 1 , k ) ;
25 moving = f u l l m a t r i x ( : , : , i , k ) ;
26 movingRegistered ( : , : , i , k ) = i m r e g i s t e r ( moving , f i xed , ’






1 f unc t i on [ f i l t e r e d m a t r i x ] = MRI denoised ( f u l l m a t r i x )
2
3 image matrix = f u l l m a t r i x ;
4
5 image s i z e = s i z e ( image matrix ) ;
210
6
7 num s l i c e s = image s i z e (4 ) ;
8 num b values = image s i z e (3 ) ;
9
10 %% Ca l l s the s imple nlm func t i on
11
12 s l i c e max = ze ro s ( num b values , num s l i c e s ) ;
13
14 [ n x ] = h i s t ( image matrix ( : ) ) ;
15
16 c u t o f f = x (8) ;
17
18 image matrix ( image matrix > c u t o f f ) = c u t o f f ;
19
20 f o r s = 1 : num s l i c e s
21 f o r b = 1 : num b values
22 s l i c e = image matrix ( : , : , b , s ) ;
23 s l i c e max (b , s ) = max( s l i c e ( : ) ) ;
24 f i l t e r e d m a t r i x ( : , : , b , s ) = simple nlm ( ( image matrix
( : , : , b , s ) / s l i c e max (b , s ) ∗100) , 1 , 0 , 1 , 1 , 0 ) ;
25 f i l t e r e d m a t r i x ( : , : , b , s ) = f i l t e r e d m a t r i x ( : , : , b , s )∗





29 f i l t e r e d m a t r i x ( f i l t e r e d m a t r i x <= 0) = eps ;
30
31 f unc t i on [ output ]= simple nlm ( input , t , f , h1 , h2 , s e l f s i m )
32
33 % For d e t a i l s s e e :
34 % A. Buades , B. Co l l and J .M. Morel , ”A non−l o c a l
a lgor i thm f o r image deno i s i ng ”
35
36 [m n]= s i z e ( input ) ;
37 p i x e l s = input ( : ) ;
38
39 s = m∗n ;
40
41 p s i z e = 2∗ f +1;
42 n s i z e = 2∗ t +1;
43
44 % Compute patches
45 padInput = padarray ( input , [ f f ] , ’ symmetric ’ ) ;
46 f i l t e r = f s p e c i a l ( ’ gauss ian ’ , ps i z e , h1 ) ;
47 patches = repmat ( s q r t ( f i l t e r ( : ) ) ’ , [ s 1 ] ) .∗ im2col (
padInput , [ p s i z e p s i z e ] , ’ s l i d i n g ’ ) ’ ;
48
49 % Compute l i s t o f edges ( p i x e l p a i r s with in the same
search window )
50 indexes = reshape ( 1 : s , m, n) ;
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51 padIndexes = padarray ( indexes , [ t t ] ) ;
52 ne ighbors = im2col ( padIndexes , [ n s i ze , n s i z e ] , ’ s l i d i n g ’ )
;
53 TT = repmat ( 1 : s , [ n s i z e ˆ2 1 ] ) ;
54 edges = [TT( : ) ne ighbors ( : ) ] ;
55 RR = f i n d (TT( : ) >= neighbors ( : ) ) ;
56 edges (RR, : ) = [ ] ;
57
58 % Compute weight matrix ( us ing weighted Eucl idean
d i s t ance )
59 d i f f = patches ( edges ( : , 1 ) , : ) − patches ( edges ( : , 2 ) , : ) ;
60 V = exp(−sum( d i f f .∗ d i f f , 2 ) /h2 ˆ2) ;
61 W = spar s e ( edges ( : , 1 ) , edges ( : , 2 ) , V, s , s ) ;
62
63 % Make matrix symetr i c and s e t d iagona l e lements
64 i f s e l f s i m > 0
65 W = W + W’ + s e l f s i m ∗ speye ( s ) ;
66 e l s e
67 maxv = max(W, [ ] , 2 ) ;
68 W = W + W’ + spd iags (maxv , 0 , s , s ) ;
69 end
70
71 % Normalize weights
72 W = spdiags ( 1 . / sum(W, 2 ) , 0 , s , s )∗W;
73
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74 % Compute deno i sed image
75 output = W∗ p i x e l s ;






1 f unc t i on [ ro i mask ] = ROI contour ( f u l l m a t r i x )
2 %Generate a binary ROI mask us ing the r o i p o l y func t i on in
matlab
3
4 image s i z e = s i z e ( f u l l m a t r i x ) ;
5
6 ro i mask = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) ) ;
7
8 f o r k = 1 : num s l i c e s1
9 s l i c e = f u l l m a t r i x ( : , : , 1 , k ) ;
10 im max = max( s l i c e ( : ) ) ;
11 ro i mask ( : , : , k ) = r o i p o l y ( ( 4∗ ( f u l l m a t r i x ( : , : , 1 , k ) /im max







1 f unc t i on [ ADC full ] = ADC calc ( f u l l m a t r i x , un ique b va lue s )
2
3 %Cal cu l a t e s ADC map us ing the s m a l l e s t and l a r g e s t b value
images
4
5 image s i z e = s i z e ( f u l l m a t r i x ) ;
6
7 ADC map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , num s l i c e s1 ) ;
8
9 ind = length ( un ique b va lue s ) ;
10
11
12 f o r k = 1 : image s i z e (4 )
13 f o r l = 1 : image s i z e (1 )
14 f o r m = 1 : image s i z e (2 )
15 ADC map( l ,m, k ) = ( log ( movingRegistered ( l ,m,
ind , k ) / movingRegistered ( l ,m, 1 , k ) ) /(







B.8 IVIM parameter calculatin
B.8.1 LeBihan’s method
1 f unc t i on [ D map PF map ] = LeBihan IVIM ( f u l l m a t r i x ro i mask
un ique b va lue s )
2
3 %Calcu lated D and f maps us ing LeBihan ’ s method and l e a s t
squares f i t t i n g
4
5 D map = ze ro s ( ( b o x s i z e +1) , ( b o x s i z e +1) ) ;
6 PF map = ze ro s ( ( b o x s i z e +1) , ( b o x s i z e +1) ) ;
7
8 ind = f i n d ( un ique b va lue s > 150 , 1) ;
9
10 xdata = [ un ique b va lue s ] ;
11 x0 = [ 0 0 ] ;
12
13 f = @(x , xdata ) exp(−xdata∗x (1 )+log (1−x (2 ) ) ) ;
14
15
16 f o r s = 1 : image s i z e (4 )
17 f o r k = 1 : image s i z e (1 )
18 f o r l = 1 : image s i z e (2 )
19 i f ro i mask (k , l , s ) == 1
20 f o r b = ind : image s i z e (3 )
21 r a t i o (b−ind+1) = f u l l m a t r i x (k , l , b , s ) /
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f u l l m a t r i x (k , l , ind , s ) ;
22 end
23
24 a = l s q c u r v e f i t ( f , x0 , xdata , r a t i o ) ;
25
26 D map(k , l ) = a (1 ) ;







34 D map(D map <= 0) = eps ;




1 f unc t i on [ D map PF map ] = Monoexponential IVIM ( f u l l m a t r i x
ADC map roi mask un ique b va lue s )
2
3 %% Calcu la te D slow LB us ing Le Bihan Model
4
5 image s i z e = s i z e ( f u l l m a t r i x )
6
217
7 ind = f i n d ( un ique b va lue s > 90 , 1) ;
8
9 D map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) ) ;
10
11 f o r k = 1 : image s i z e (4 )
12 f o r l = 1 : image s i z e (1 )
13 f o r m = 1 : image s i z e (2 )
14 D map( l ,m, k ) = log ( movingRegistered ( l ,m, end , k ) /
movingRegistered ( l ,m, ind , k ) ) /( un ique b va lue s (





19 %% Calcu la te f map us ing s i m p l i f i e d Lebihan Model .
20
21 f map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) ) ; %
Map o f pseudo−d i f f u s i o n f r a c t i o n X(1)
22
23 f o r k = 1 : image s i z e (4 )
24 f o r l = 1 : image s i z e (1 )
25 f o r m = 1 : image s i z e (2 )
26 f map ( l ,m, k ) = 1−exp(−un ique b va lue s ( end ) ∗(






31 f map ( f map <= 0) = eps ;




1 f unc t i on [ D map D star map PF map ] = Biexponentia l IVIM (
f u l l m a t r i x ro i mask un ique b va lue s )
2 %%Calcu l a t i on o f IVIM parameters us ing the b i exponen t i a l
model
3
4 image s i z e = s i z e ( f u l l m a t r i x ) ;
5
6 f map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) ) ; %
Map o f pseudo−d i f f u s i o n f r a c t i o n X(1)
7 D map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) ) ; %
Map o f t rue d i f f u s i o n c o e f f i c i e n t s X(2)
8 D star map = ze ro s ( image s i z e (1 ) , image s i z e (2 ) , image s i z e (4 ) )
; %Map o f p e r f u s i o n c o e f f i c i e n t s X(3)
9




12 x0 = [ . 2 10ˆ−3 7∗10ˆ−2]; %[PF D D∗ ]
13 LB = [ 0 . 0 2 5 0.4∗10ˆ−3 5∗10ˆ−3];
14 UB = [ 0 . 5 0 .003 0 . 1 4 ] ;
15
16
17 r a t i o = ze ro s ( 1 , ( t o t a l b v a l u e s ) ) ;
18
19 b va lue s = ze ro s ( 1 , ( t o t a l b v a l u e s ) ) ;
20 b va lue s ( 1 : t o t a l b v a l u e s ) = un ique b va lue s ;
21
22
23 opts = opt imset ( ’ Algorithm ’ , ’ l evenberg−marquardt ’ ) ;
24
25
26 f o r k = 1 : image s i z e (4 )
27 f o r l = 1 : image s i z e (1 )
28 f o r m = 1 : image s i z e (2 )
29 i f ro i mask ( l ,m, k ) == 1
30 f o r b = 1 : t o t a l b v a l u e s
31 r a t i o (b) = movingRegistered ( l ,m, b , k ) /
movingRegistered ( l ,m, 1 , k ) ;
32 end
33
34 f o r b = ( t o t a l b v a l u e s +6) : l ength ( r a t i o )
35 r a t i o (b) = movingRegistered ( l ,m,
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t o t a l b v a l u e s , k ) / movingRegistered ( l ,m
, 1 , k ) ;
36 end
37
38 X = l s q c u r v e f i t (F , x0 , b va lues , r a t i o ,LB,UB,
opts ) ;
39 f map ( l ,m, k ) = X(1) ;
40 D map( l ,m, k ) = X(2) ;
41 D star map ( l ,m, k ) = X(3) ;
42 e l s e
43 f map ( l ,m, k ) = NaN;
44 D map( l ,m, k ) = NaN;







1 f unc t i on [ TA values ] = TA calc ( f u l l m a t r i x )
2 %Cal cu l a t e s t ex tu re a n a l y s i s f e a t u r e s by s l i c e f o r the volume
3 image s i z e = s i z e ( f u l l m a t r i x ) ;
4
5
6 f o r s = 1 : image s i z e (4 )
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7 i m s l i c e = f u l l m a t r i x ( : , : , : , s ) ;
8
9 f o r b = 1 : image s i z e (3 )
10 a r o i e n t r o p y (b , s ) = mean(mean( entropy ( i m s l i c e ( : , : , b
) ) ) ) ;
11 a r o i e n t r o p y f i l t (b , s ) = mean(mean( e n t r o p y f i l t (
i m s l i c e ( : , : , b ) ) ) ) ;
12 a r o i r a n g e f i l t (b , s ) = mean(mean( r a n g e f i l t ( i m s l i c e
( : , : , b ) ) ) ) ;
13 a r o i s t d f i l t (b , s ) = mean(mean( s t d f i l t ( i m s l i c e ( : , : , b
) ) ) ) ;
14 ca l c ed graycomatr ix ( : , : , b , s ) = graycomatr ix ( i m s l i c e
( : , : , b ) ) ;
15 a g l c m s t a t s (b , s ) = graycoprops ( ca l c ed graycomatr ix
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